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Abstract 
 
Polycystic ovary syndrome (PCOS) is a common condition characterised by hyperandrogenism, 
oligo/anovulation and defects in insulin secretion and sensitivity. PCOS patients also have an 
increased prevalence of hypertension, dyslipidaemia and endothelial dysfunction, a state 
associated with decreased nitric oxide bioavailability and increased oxidative stress. Using 
women with PCOS as a model of predisposition to cardiovascular disease (CVD), the aim of 
this thesis was to provide a clearer understanding of mechanisms that may predispose 
individuals to endothelial dysfunction, and ultimately CVD.  
 
PCOS patients were compared to healthy controls in an observational study, which involved a 
comprehensive assessment of biochemical nitro-oxidative stress indices and a detailed 
characterisation of circulating microparticles (MPs). There was little evidence to suggest that 
women with PCOS have an increased oxidative stress compared to age/BMI-matched controls. 
However, PCOS patients did display elevated levels of annexin V positive MPs that were 
predominantly derived from platelets.  
 
In vitro studies investigated the effect of several metabolic stressors akin to those found in 
PCOS on endothelial-derived MP characteristics and function. Human endothelial (HECV) cells 
were exposed to oxidative, hypoxic, hyperandrogenic and metabolic stressors. Each metabolic 
stressor affected MP generation uniquely, suggesting MP characteristics and function reflect 
parental cell conditions.  
 
In order to determine whether circulating MP levels could be modulated in a clinical cohort, the 
effect of apheresis on circulating MP levels was investigated in patients with established CVD 
(familial hypercholesterolaemia). Apheresis decreased circulating levels of MPs and was 
associated with a decreased thrombin generation capacity in these patients.  
The data in this thesis thus provide evidence that young women with PCOS have an elevated 
concentration of annexin V positive MPs, even though there is little biochemical evidence for 
nitro-oxidative stress. Further studies are needed to assess the effect of this increase in 
circulating MPs on cardiovascular clinical end-points. In vitro experiments showed that the 
cellular stress condition is reflected in the MP characteristics, whereby each pathological 
stressor resulted in a unique MP phenotype. Furthermore, in patients with established CVD, 
apheresis reduced circulating levels of MPs.  
 
In conclusion, an elevated annexin V positive MP population may represent a novel mechanism 
by which cardiovascular risk is increased in patients with PCOS. These findings could have 
future implications for use as biomarkers, in diagnosis and therapeutics. 
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1. GENERAL INTRODUCTION 
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1.1 Cardiovascular disease 
Cardiovascular disease (CVD) or disease of the blood vessels and heart, comprise many 
pathological conditions that vary in manifestation, prevalence and public health importance. 
CVD is the leading cause of morbidity and mortality across the globe (1). Since the initial 
description of heart disease, there has been a burgeoning awareness in the concept of CVD risk 
factors and an ever-increasing understanding of its pathophysiology.  
 
Preceding a generic overview of CVD, associated entities and its global burden, it would be 
useful to define CVD. Terminology and definitions vary amongst published studies, as CVD 
may also refer to cerebrovascular disease; coronary heart disease (CHD); peripheral artery 
disease (PAD); cardiometabolic disease; coronary artery disease (CAD) and ischaemic heart 
disease (IHD). Furthermore the definition of CVD has evolved/expanded with increasing 
awareness and understanding. In essence, the generic term CVD will be employed throughout 
this thesis, or the terminology utilised will reflect the original manuscript quoted. The present 
focus is chiefly on CVD entities that predispose individuals to endothelial dysfunction and 
atherosclerotic diseases. 
 
1.1.1 Epidemiology: The global burden of 
cardiovascular disease 
The World Health Organisation (WHO) declared that CVD kills in excess of 17 million people 
a year, representing ~30% of total global deaths (1). This trend is set to worsen in the near 
future, with in excess of 23 million CVD attributed deaths a year are expected by 2030 (2). Of 
these, ~50% of deaths are from myocardial infarction (MI) and a further 23% from stroke, 
affecting both men and women equally (2).  
 
Although CVD is a global problem, epidemiological studies have shown mortality rates vary 
considerably on a geographic and demographic basis. Broadly, the lowest age-adjusted 
mortality rates are in the developed industrialised countries and parts of Latin America, whereas 
the worst rates are found in Eastern Europe and several low/middle income countries (3). 
Specifically, age-standardised mortality rates for CVD are >500 per 100,000 individuals in 
Russia and Egypt; between 400 and 450 in countries such as South Africa and India and around 
300 for Brazil and China. In comparison, Australia, Japan and France have between 100 and 
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200 CVD attributed deaths per 100,000 individuals. Interestingly, Japan has a three-four fold 
lower rate of CVD mortality rate than the USA (4). The discrepancies in inter-population CVD 
morbidity and mortality rates are intrinsically related to CVD risk factors (table 1.1). 
 
Table 1.1 Cardiovascular disease risk factors 
1. Smoking 
2. Dyslipidaemia (characterised by elevated LDL-cholesterol and low HDL-cholesterol) 
3. Diet  
4. Hypertension 
5. Diabetes mellitus 
6. Physical inactivity 
7. Obesity  
8. Low socioeconomic status 
9. Elevated prothrombotic/inflammatory markers 
10. Genetic susceptibility 
LDL, low density lipoprotein; HDL, high density lipoprotein. Adapted from (3). 
 
Collectively, the spectrum of CVD risk factors are coupled with environmental, geographic and 
demographic dyanmics which contribute to the global variation in prevalence of CVD (3). In 
addition to this, the epidemiology of CVD within each specific geographic region differs, in 
terms of male-female and ethnic risk. For example, Cubbin et al, (5) noted higher rates of 
hypertension and diabetes amongst African American women living in deprived (low 
socioeconomic) areas compared to female African Americans living in more affluent areas.  
 
Of all CVD entities, the American Heart Association noted CHD was the largest cause of death 
accounting for 48.2 % of total CVD deaths. Other causes of CVD death included stroke (16.4 
%), heart failure (7.3 %), disease of the arteries (3.4%) and hypertension (8 %) (6). In Wales, 
CVD accounts for 10,341 deaths, out of a total of 31,197 deaths per year, where adult males 
appear modestly more prone to CVD than their female counterparts (7). Although, CVD still 
represents the leading cause of death in Wales and the rest of the UK, mortality rates have been 
steadily declining. The majority of countries in Europe, except Eastern European countries, 
have all experienced a similar decreased trend in CVD mortality rates over recent decades (4). 
However, CVD remains the leading cause of death globally and represents a great global health 
burden.  
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1.2 Vascular endothelium 
1.2.1 Structure and function 
The vascular endothelium occupies a unique interface between circulating blood and 
extravascular tissues. It is a dynamic autocrine and paracrine organ that maintains vascular 
homeostasis by modulating vascular tone, governing local cellular growth, possessing critical 
secretory, metabolic and immunological functions whilst regulating inflammatory responses (8, 
9). The endothelium is a continuous cellular monolayer that retains a selectively permeable 
membrane and possesses an array of membrane-associated receptors for numerous molecules 
including lipid transport particles (such as low-density lipoprotein (LDL)-cholesterol), 
metabolites (serotonin), proteins (such as growth factors, coagulant/anticoagulant proteins) and 
hormones (including endothelin-1 (ET1)). Moreover, the endothelial cell (EC) is equipped with 
specific junction proteins that aid cell-cell matrix interactions (9).  
 
Structurally, a network of adhesive proteins link ECs together to form the endothelium. 
Functionally, three junctions have been described, tight, gap and adheren junctions. Tight 
junctions form close seals between ECs and are often associated with cytosolic proteins such as 
cingulin. Adheren junctions are formed by cadherins (adhesion molecules with vascular 
endothelial (VE)-cadherin being the most abundant). These adhesive structures (junctions) are 
involved in the regulation of membrane permeability. EC permeability is associated with 
changes/redistribution of surface cadherins in an attempt to meet the functional requirements of 
the perfused organ. Under physiological conditions, EC permeability permits the transport of 
plasma molecules (such as drugs, glucose and hormones) via non-specific and receptor 
mediated endocytosis or transcytosis.  
 
The endothelium plays an integral role in the regulation of vascular tone. ECs regulate vascular 
tonicity by the release of a spectrum of vasodilatory molecules such as nitric oxide (NO), 
endothelial-derived hyperpolarising factor (EDHF) and prostacyclin (PGI2). Conversely, the 
endothelium is able to secrete vasoconstrictive factors (such as platelet activating factor (PAF), 
angiotensin-II (Ang-II) and ET1, (figure 1.1) (10). In addition to their direct effects on vascular 
tonicity, these vasoactive mediators also influence EC interactions with circulating leukocytes 
and platelets, playing an important role in EC permeability and vascular homeostasis. 
Furthermore, the endothelium plays a pivotal role in angiogenesis, a process that is 
predominantly governed by growth factors, particularly vascular endothelial growth factor 
(VEGF, figure 1.2) (11, 12). However, the mechanisms governing such modes of action are 
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complex and the overall vascular responsiveness varies between endothelial ‘beds’ and the 
differing pathophysiological circumstances. A summary of the principal regulatory compounds 
synthesised by the vascular endothelium are described in table 1.2. 
 
 
Figure 1.1. Vasoactive agents regulate vascular tone of a blood vessel. Vasoactive 
substances synergistically regulate vascular tone, (vasodilatation and vasoconstriction). Arrow 
direction indicates the principle effect of the vasoactive agent (vasoconstriction or 
vasodilatation). ECs, endothelial cells; SMCs, smooth muscle cells; EDHF, endothelial derived 
hyperpolarising factor; NO, nitric oxide; PGI1, prostacyclin; PAF, platelet activating factor; ET-
1, endothelin-1; Ang-II, angiotensin-II. Adapted from (12). 
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Figure 1.2 Schematic diagram representing key characteristics in vascular endothelial homeostasis. Endothelial cells (ECs) regulate the transport 
between blood and tissues via the caveolae/vesicle system and the intracellular junctions. The endothelium regulates the vascular tone and blood 
coagulation by the secretion of vasoactive substances. The endothelium plays an important role in inflammation by facilitating the migration of 
leukocytes into the sites of vascular injury. ECs can initiate angiogenesis, which is essential for tissue growth and wound repair. Described in detail in 
text. Adapted from (9). 
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Table 1.2 Summary of the principal regulatory compounds synthesised by the vascular endothelium 
Substance Principle effect Other effects Stimulation Compound 
NO Vasodilatation Maintains basal tone of vessels, inhibits leukocyte 
adhesion, inhibits platelet adhesion / activation / 
aggregation and inhibits SMC migration and 
proliferation. 
Bradykinin, substance P, 
muscarinic agonists, shear 
stress, thrombin, ADP. 
Diatomic 
radical 
PGI2 Vasodilatation Inhibits platelet aggregation and deposition Induced at sites of vascular 
perturbation 
Eicosanoid 
EDHF Vasodilatation - - - 
PAF Vasoconstriction Promotes leukocyte adhesion at cell surface 
Inducement of platelet activation and aggregation 
- Phospholipid 
ET1 Vasoconstriction Mitosis of SMC. Activation of ACE. Induced by hypoxia, shear 
stress, and ischemia 
Peptide 
VEGF Angiogenesis Increases EC migration, mitosis and MMP activity. 
Vasodilation (indirectly by NO release). 
Hypoxia Peptide 
Ang-II Vasodilatation Vasoconstriction (via AT1 receptor), Vasodilatation (via 
AT2 receptor and by stimulation of NO release). 
Angiogenesis. 
- Peptide 
NO, nitric oxide; PGI2, prostacyclin; EDHF, endothelial derived-hyperpolarising factor; PAF, platelet activating factor; ET1, endothelin-1; VEGF, 
vascular endothelial growth factor; Ang-II, angiotensin-II; SMCs, smooth muscle cells; ADP, adenosine diphosphate AT receptor, angiotensin receptor; 
ACE, angiotensin-converting enzyme; EC, endothelial cell. A muscarinic receptor agonist is a substance that activates the muscarinic acetylcholine 
receptor. The chemical identity of the EDHF has not been determined. Adapted from (13, 14). 
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1.2.2 Endothelial dysfunction  
Endothelial dysfunction refers to the impaired ability of the endothelium to regulate and 
maintain vascular homeostasis (15). Under physiological conditions the vascular endothelium 
maintains an antithrombotic surface. In contrast, under pathological stresses, alterations in the 
vascular endothelium may shift the pattern towards a prothrombotic state. EC activation is 
associated with a reduction in anticoagulant surface molecules such as thrombomodulin (TM) 
and a concomitant elevation in prothrombotic components such as tissue factor (TF) or 
increased binding of coagulation factors (15). Cellular activation can also promote EC 
interactions with circulating cells by elevated expression of surface adhesion molecules, 
including VE-cadherin, intercellular cell adhesion molecule (ICAM)-1, vascular cell adhesion 
molecule-1 (VCAM-1), platelet endothelial cell adhesion molecule-1 (PECAM-1), endoglin, E-
selectin and P-selectin (16). Accordingly, abnormalities in the endothelium (endothelial 
dysfunction) is characteristically observed in the initial stages of CVD and is often evident 
before CVD phenotypically manifests itself (17). Of note, the endothelium observes a shift, 
from NO mediated signalling towards EC activation by altered redox signalling. 
 
There are many cumulative and synergistic causes of endothelial dysfunction. Although 
decreased NO production, L-arginine depletion and SMC stiffening are known to be important 
in endothelial dysfunction, NO bioavailability, reactive oxygen species (ROS) and antioxidant 
levels are considered central to many mechanisms that predispose individuals to endothelial 
dysfunction (16, 18).  
 
1.2.3 Nitric oxide 
1.2.3.1 Nitric oxide synthase 
Although there are alternative mechanisms that can generate NO (for example the acidification 
or reduction of nitrite (NO2-)), the majority of mammalian NO is derived enzymatically from 
NO synthase (NOS) (19). NOS enzymes convert L-arginine to L-citruline and NO in an oxygen 
(O2) and NADPH dependent manner. There are three NOS isoforms that have been described, 
including nNOS (neuronal, NOS-1), iNOS (inducible, NOS-2) and eNOS (endothelial, NOS-3). 
iNOS and nNOS are found mainly in the cytosol whilst eNOS is predominantly membrane 
associated. Two of these isoforms are constitutive (eNOS and nNOS) whereas the other is 
inducible (iNOS) (19). The activity of all NOS isoforms is also dependent on the presence of 
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several critical co-factors including tetrahydrobiopterin (BH4), nicotinamide adenine 
dinucleotide phosphate (NADPH), as well as an optimum supply of the substrates O2 and L-
arginine. A reduction in these cofactors or substrates will limit NO production proportionately.  
Of the three NOS isoforms, eNOS is the primary signal generator in the control of vascular 
tone. The endothelial isoform is activated in response to shear stress and several key 
endogenous agonists. For example bradykinin and acetylcholine act via endothelial receptors 
that modulate intracellular calcium (Ca2+), interaction with substrate and protein 
phosphorylation. Dysregulation of these processes alters eNOS activity and may reduce NO 
output, a characteristic feature of several pathological disorders including diabetes and 
atherosclerosis (20).  
Several pharmacological agents can inhibit NO production by disrupting eNOS. For example, 
arginine-derived analogues such as NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-
arginine methyl ester (L-NAME) inhibit eNOS derived-NO production. Interestingly, the effect 
of L-NMMA in vivo is primarily dependent on the route of administration, whereby Clark and 
co-workers found that a single intrapleural injection of L-NMMA in a rodent model of 
inflammation (carrageenin-induced pleurisy) exacerbated the inflammatory status (21). In 
contrast, administering L-NMMA systemically ameliorated the severity of inflammation (22), 
exemplifying the complexity of NO biochemistry in vivo and demonstrating the route of 
administration is vital to the clinical outcome.  
 
1.2.3.2 Nitric oxide metabolites 
NO is an important signalling molecule that plays an important role in a range of biological 
activities, including vascular tonicity and vasodilation. NO can rapidly diffuse to smooth muscle 
(3200 µm2s-1, diffusion coefficient) where it activates soluble guanylate cyclase (sGC) and 
initiates a downstream signalling cascade resulting in K+ channel activation and subsequent Ca2+ 
channel inhibition, reducing intracellular Ca2+ concentration and inducing vascular relaxation 
(23). This highly diffusible diatomic radical gives rise to a complex biochemistry. Scavenging 
reactions with antioxidants, free radicals and haemoglobin limit the diffusion rate and influence 
NO metabolite formation. NO can be stabilised in blood, most notably in the form of NO2- and 
nitrate (NO3-). These metabolites are now considered bioactive endocrine molecules. Other 
research groups have shown NO can also be stabilised in the form of nitrated fatty acids and S-
nitrosothiols (RSNO). However, in vivo detection and measurement of these metabolites is 
difficult, and as such their physiological concentration is highly debated. Traditionally, NO2- 
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and NO3- were viewed as undesirable inert end products of NO metabolism. More recently NO2- 
and NO3- reduction has been shown to complement the traditional NO/sGC/cGMP pathway, 
playing a key role in vasodilatation (24) (figure 1.3). 
 
Figure 1.3 Endothelial nitric oxide production. Endothelial derived- nitric oxide (NO) is 
enzymatically generated via a reaction between endothelial NO synthase (eNOS), L-arginine 
and molecular oxygen to yield NO and L-citruline. NO can rapidly diffuse to smooth muscle 
cells (SMCs) where it activates soluble guanylate cyclase (sGC) and initiates a downstream 
signalling cascade resulting in K+ channel activation and subsequent Ca2+ channel inhibition, 
reducing intracellular Ca2+ concentration ([Ca2+]i) and inducing vascular relaxation. NO in the 
blood is readily oxidised to nitrite (NO2-) and nitrate (NO3-). S-nitrosothiols (RSNO) are 
produced when NO binds to thiols. RBC refers to red blood cell. Adapted from (23). 
 
1.2.3.3 Nitrite 
NO2- is an ionic compound that represents a bioactive reservoir for NO. In vivo, NO2- is formed 
in the body through the oxidation of NO or through the reduction of NO3-. Interestingly, L-
arginine–NOS generation of NO is O2 dependent, whereas the NO2-–NO pathway is 
implemented when the O2 concentration decreases. Thus, the NOS-independent generation of 
NO (i.e. NO2- – NO pathway) may be viewed as a back-up mechanism to ensure that there is 
copious NO levels when O2 supply is limited (25). However, the precise physiological O2 
concentration at which NOS dependent NO generation fails is unclear. Previous studies have 
shown that at low O2 conditions (ischaemia/reperfusion studies), NO generation in tissues is 
independent of NOS activity and dependent on NO2- (26). The vasoactive properties of NO2- at 
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supra-physiological levels have been known for decades, where Furchgott and Bhadrakom 
found that NaNO2 induced relaxation of rabbit aortic strips, however the micromolar 
concentration range used did not reflect endogenous NO2- levels (27). A number or research 
groups (including ours) have shown that the typical plasma NO2- range from healthy subjects is 
between 100 – 500 nM (28, 29). Previous research in our laboratory has shown that intravenous 
infusion of NaNO₂ (1.5 μmol/min for 20 min) protects against vascular ischemia-reperfusion 
injury only when it is given before the onset of ischemia (30). Furthermore, ex vivo studies have 
shown that the efficacy of NO2- (in terms of vasodilatation) is enhanced at lower buffer pH 
levels in isolated vessel (myography) experiments (31). Moreover, Gladwin and coworkers 
found that artery-to-vein gradients in NO2- across the human forearm (with venous blood 
exhibiting reduced NO2- levels in a study involving 5 healthy subjects), suggesting that NO2- is 
metabolised across the peripheral circulation (32). 
 
1.2.3.4 Nitrate 
Several research groups (including ours) have shown that plasma NO3- concentration ranges 
between 20 – 40 μM in healthy subjects (29, 33). In vivo, NO3- originates from two potential 
sources: (i) the oxidative metabolism of NO, or (ii) dietary NO3-. Foodstuffs contain varying 
concentrations of NO3-, where leafy vegetables and beetroot are a relatively rich source (34). 
Kapil and coworkers noted that ~66% of the absorbed NO3- is excreted (unaltered) in the urine 
(35). The remaining bioavailable NO3- is believed to enter the entero-salivary circulation for 
subsequent metabolism where NO3- is converted to NO2- by bacteria in the oral cavity. Located 
at the posterior, dorsal area of the tongue, several bacterial species (including lactobacillus, 
micrococcous, corynebacterium and propionibacterium) have been shown to convert NO3- to 
NO2- (24). Importantly, several studies have shown that the destruction of the oral micro-flora 
by antibacterial mouthwashes prevents the conversion of NO3- to NO2- (36). Furthermore, in a 
rodent model, Sobko and coworkers showed that the gut micro-flora also participates in the 
conversion of NO3- to NO2- (37). Wylie and co-workers showed that NO3- administration (4 – 
24 mM) elevated plasma NO2- in a dose dependent manner (38). There is an increasing 
awareness of the potential therapeutic applications of the NO3- - NO2- - NO pathway. Larsen and 
co-workers showed that NaNO3 (0.1 mmol/kg body weight) administration reduces blood 
pressure (39). Webb et al, (40) showed that a bolus dietary NO3- load attenuated endothelial 
dysfunction caused by an acute ischaemic insult in the human forearm, as well as reduced ex 
vivo platelet aggregation.  
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1.2.3.5 Nitric oxide bioavailability 
A reduction in bioactive NO metabolites (NOx) is recognised to reflect an overall decreased NO 
bioavailability. Such pathological environments may lead to abnormalities in endothelial 
function (41). Moreover, such conditions are an established feature of atherosclerotic vascular 
disease, where decreased NO bioavailability and a concomitant increase in reactive oxygen 
species (ROS) may synergistically contribute to endothelial impairment. There are several 
possible defects that could account for reduced NO bioavailability. These include depletion of 
NO as a consequence of its reaction with superoxide (∙O2-), diminished NO production due to 
changes in eNOS activity (i.e. eNOS uncoupling, depletion of L-arginine or other co-factors 
such as BH4), or decreased dietary consumption of NOx (20, 42, 43).  
 
Altered NO production, often coupled with accelerated NO removal (through poorly understood 
mechanisms) may have detrimental consequences on secondary NO species and overall NO 
bioavailability. Rubbo et al, (44) suggested that the powerful radical peroxynitrite (OONO-) 
accounts for the major part of accelerated NO removal. Interestingly, OONO- dissociation yields 
a hydroxyl radical (OH∙) and nitrogen dioxide (NO2), which participate in secondary 
oxidative/nitrative actions (as mentioned in section 1.2.4). 
 
With a short half-life and potent tendency for reactivity, NO is difficult to directly detect in vivo. 
Thus, studies have relied on plasma NOx levels (in particular plasma NO2- and NO3-) to reflect 
NO bioavailability. On assessment of 351 healthy volunteers, Kleinbongard et al, (41) found 
that plasma NO2- concentration is a direct measurement of endothelial function. Inhibition of 
endothelial NO production by L-NMMA infusion can impair endothelial function. Virdis and 
colleagues showed that L-NMMA decreased endothelial-dependent vasodilatation, as assessed 
by flow-mediated dilatation (FMD) (45). However in this particular study NOx levels were not 
assessed. Interestingly, Rogers et al, (46) explored the effect of L-NMMA on cross heart NOx 
metabolism. They found that infusion of L-NMMA increased diastolic and systolic blood 
pressure coupled with the constriction of coronary artery diameter. However, no change in net 
NOx concentration was observed. This trend was also observed in control subjects not receiving 
L-NMMA. Thus, it can be concluded that although NOx metabolites have been shown to be a 
biomarker for endothelial dysfunction in the chronic setting, because NO redox chemistry is 
complex in vivo these measures can only reflect the net effects of NO production, NO 
utilisation, and NO inactivation. This also questions whether measurement of venous NOx can 
accurately reflect endothelial NO production in the acute setting, a parameter that will be 
influenced by the changes in flow and O2 saturation per se. Using physiological parameters to 
assess endothelial function is practically challenging, is operator dependent, and has relatively 
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poor repeatability. Often, loosely defined terms for flow and velocity are interchanged, coupled 
with singular measurement parameters used as physiological/clinical endpoints without 
considering the synergistic relationship between cardiac output, heart rate, pressure, velocity, 
flow and function of the vessel.  
 
1.2.3.6 Clinical assessment 
Assessment of endothelial function is employed as a diagnostic and prognostic tool in regards to 
CVD risk. With a diverse pathogenesis endothelial dysfunction can be assessed at a molecular / 
biochemical and physiological level, where numerous in vitro, ex vivo and in vivo 
methodologies are routinely employed in research, as highlighted in table 1.3.  
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Table 1.3 Common measures / indicators of endothelial dysfunction 
Measure Type Interpretation  
FMD Physiological 
Impaired responsiveness of NO 
vasodilatation. 
NO metabolites Biochemical 
Decreased NO metabolite levels (accelerated 
NO removal and/or reduced NO production). 
Inflammatory markers / 
cytokines: inc’ (VCAM-1, 
sICAM-1, E-selectin, 
TNFα, IL-8) 
Biochemical 
Enhanced leukocyte adhesion/inflammatory 
activation / EC activation. 
ROS production and up regulation of 
inflammatory genes 
PWV Physiological 
Arterial stiffness / impaired responsiveness of 
NO vasodilation. 
Angiogenic growth factors: 
VEGF 
Biochemical 
Indication of membrane permeability, 
migration and angiogenesis. 
Nitro-oxidative stress (inc’ 
TBARS, TAC, lipid 
radicals) 
Biochemical Reflects systemic nitro-oxidative stress. 
MPs Biochemical 
Elevated levels are associated with 
endothelial dysfunction. 
FMD, flow mediated dilatation; NO, nitric oxide; sVCAM-1, soluble vascular cell adhesion 
molecule-1; sICAM-1, soluble intercellular cell adhesion molecule-1; E-selectin, endothelial 
selectin; TNFα, tumour necrosis factor alpha; IL-8, interleukin 8; PWV, pulse wave velocity; 
VEGF, vascular endothelial growth factor; TBARS, thiobarbituric acid reactive substances; 
MPs, microparticles; EC, endothelial cell. Adapted from (47). 
15 
 
1.2.4 Reactive oxygen species  
Reactive oxygen species (ROS) play a central role in modulating endothelial function. ROS are 
produced via numerous oxidase enzymes, including NADPH oxidase, xanthine oxidase, 
uncoupling of eNOS and mitochondrial electron transport. Common ROS include ∙O2-, 
hydrogen peroxide (H2O2), OH∙, ONOO– and NO. ROS are generated from numerous cell types, 
including vascular smooth muscle cells (VSMCs), ECs and mononuclear cells, by a variety of 
cellular processes. ∙O2- is a common bi-product of the electron transport system in mitochondria.  
 
Notably, ∙O2- rapidly reacts with NO to yield ONOO– (44). ONOO– is an established mediator of 
lipid peroxidation and protein nitration, both of which have downstream proatherogenic 
capabilities. During vascular homeostasis, ∙O2- is commonly metabolised by superoxide 
dismutase (SOD) to H2O2. H2O2 may then be converted to H2O and O2 by glutathione 
peroxidase or catalase (48). Oxidative stress is defined as an imbalance between the production 
of ROS and their removal by naturally occurring antioxidant defences of cells including the 
enzymatic catalase and SOD, as well as direct actions of antioxidants like glutathione, vitamin 
E, β-carotene and ascorbate. Increased cellular production of ∙O2- and H2O2 can facilitate the 
formation of OH∙ in the presence of metal ions such as iron (Fenton reaction) or copper (figure 
1.4). As OH∙ has a very short half-life (T½) and is highly reactive, it can rapidly damage 
surrounding macromolecules, including amino acids (potentially leading to protein 
inactivation/denaturation), carbohydrates (causing degradation), lipids (by interaction with 
polyunsaturated fatty acids (PUFAs) of membrane phospholipids, leading to lipid peroxidation) 
and nucleic acids (resulting in possible mutations) (48). In addition to mitochondrial ROS 
generation, NADPH oxidases (NOX) a multi-subunit complex composed of cytosolic 
components (p47phox, p67phox and Rac 1) and membrane-spanning components (p22phox and 
gp91phox) are also considered an important source of ROS (49). 
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Figure 1.4. Generation and inactivation of reactive oxygen species. Superoxide (O2-) is 
converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD). Fenton style reactions 
propagate the conversion of H2O2 to hydroxyl radicals (OH-). H2O2 can be detoxified by 
glutathione peroxidase or catalase to H2O. Adapted from (50). 
 
Numerous studies have shown that cardiovascular risk factors increase the expression / activity 
of NOX in the vasculature, and consequently elevate levels of ROS. Evidence for NOX 
activation has been provided in animal models of diabetes mellitus, hypercholesterolaemia and 
hypertension. In isolated atherosclerotic arteries, Xu and colleagues showed an elevated 
expression of NOX2 and NOX4 (51). Additionally, Ushio-Fukai et al, (52) were the first to 
report that inhibition of p22phox (NOX subunit) messenger ribonucleic acid (mRNA) (achieved 
by antisense transfection in VSMCs) resulted in decreased Ang-II-stimulated NADPH 
dependent ∙O2– production and subsequent H2O2 production. 
 
NOX attenuate a plethora of signalling pathways that regulate gene expression. Kunsch and 
colleagues noted that ROS may influence cell proliferation, apoptosis and inflammation through 
the activation of redox-sensitive transcriptional factors and signalling cascades which may result 
in overexpression of redox genes, intracellular calcium overload and DNA fragmentation in ECs 
(53). Moreover Lu et al, (54) found that ROS regulate EC gene expression, including surface 
adhesion molecules, antioxidant enzymes and vasoactive mediators. Increased expression of 
adhesion molecules (including VCAM-1 and ICAM-1) by redox reactions may also contribute 
to endothelial dysfunction. These surface adhesion molecules promote adhesion and migration 
of leukocytes to the endothelium (54). Conversely, NO has been shown to inhibit the 
transcriptional induction of surface adhesion molecules by cytokines in a cGMP-independent 
manner (54). 
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1.2.4.1 Xanthine oxidase 
Xanthine oxidase (XO) is an enzyme that catalyses the oxidation of hypoxanthine to xanthine 
and ultimately the oxidation of xanthine to uric acid. XO also plays a role in the catabolism of 
purines and caffeine. XO is also a potential source of ROS generation in states of endothelial 
dysfunction whereby XO readily donates electrons to O2, consequently producing ∙O2− and 
H2O2. Previous studies showed that pharmacological inhibition of XO (using XO inhibitor 
oxypurinol), improved endothelial function in patients with hypercholesterolaemia (55) and 
diabetes (56). This is supported by in vitro studies showing reduced ∙O2− production and 
improved endothelium-dependent vasorelaxation in isolated hypercholesterolaemia animal 
vessels (57). In contrast, other studies have reported no improvement in endothelial function 
with another XO inhibitor, allopurinol (58). 
 
1.2.4.2 Antioxidant defence 
The influence of ROS (such as ∙O2−and H2O2) on the vascular endothelium is regulated by the 
capacity of the antioxidant defence system. An array of enzymes typically constitute key 
antioxidant systems, these include SOD, catalase, glutathione peroxidase and glutathione 
reductase coupled with water and lipid soluble antioxidants, such as ascorbate, glutathione, α-
tocopherol and carotenoids (table 1.4).  
 
Table 1.4 Summary of antioxidant defenses in biological systems 
System Remarks 
Non-enzymatic   
α-tocopherol Radical chain breaker 
β-carotene Singlet O2 quencher 
Lycopene Singlet O2 quencher 
Ubiquinol-10 Radical scavenger 
Ascorbate Diverse functions 
GSH  Diverse functions 
Urate Radical scavenger 
Flavonoids Plasma antioxidant 
Plasma proteins Plant antioxidant 
Chemical  Food/drugs 
Enzymatic  
Superoxide dismutase Converts ∙O2− into either O2 or H2O2. 
GSH peroxidase Reduces lipid hydroperoxides  
Catalase Decomposition of H2O2 
GSH, glutathione; ∙O2−, superoxide radical; Hydrogen peroxide, H2O2. Adapted from (59). 
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Numerous clinical studies/trials have studied the effects of antioxidants on CVD. Engler et al, 
(60) demonstrated that antioxidant therapy (vitamin C and E supplementation) improved 
endothelial function (assessed via flow-mediated dilatation) in hyperlipidaemic children. 
Conversely, in a meta-analysis, Vivekananthan and colleagues assessed the effect of vitamin E 
or β carotene on long-term cardiovascular mortality. Vitamin E supplementation did not 
significantly decrease risk of cardiovascular death (>81,000 patients across 7 randomised 
studies) (61). Also, β carotene supplementation was associated with a modest increase in 
cardiovascular death. However, supplementation dose did vary across studies. Clinical trial 
results investigating antioxidant therapy in the setting of preventive CVD, have been, to date, 
mostly negative. Although there are a number of hypotheses for this, the exact reason remains 
unknown. Steinhubl et al, 2008 speculated that perhaps the single vitamin regimen was not what 
was needed (i.e. a multi-vitamin supplement would provide a broader range of antioxidants) 
(62). Additional reasons could include the wrong dosage range, inadequate durations and the 
wrong subject populations (i.e. testing antioxidant therapy on subjects with depleted antioxidant 
levels or increased oxidative stress rather than healthy subjects).  
 
Although it is well established ROS may damage proteins, nucleic acids and membrane 
phospholipids, ROS may also be important in maintaining normal cell function (such as signal 
transduction, cell proliferation, transcription regulation and phagocytosis) (63).  
 
Interestingly, physical exercise (specifically 200 eccentric muscle actions of the rectus femoris) 
has been shown to elevate systemic nitro-oxidative stress, oxidatively modify proteins and 
initiate damage to DNA in skeletal muscle in human and animal models (64). In order to 
tolerate this exposure to ROS during exercise, previous studies have shown that antioxidant 
enzymes are up regulated by exercise (65). Thus, exercise-induced oxidative stress appears to be 
counter balanced by a concomitant increase in endogenous antioxidants, including glutathione.  
 
Although exercise (i.e. cycling until volitional exhaustion) is known to increase ROS 
production, a known risk for endothelial dysfunction, there is a wealth of evidence supporting 
the notion that exercise improves endothelial dysfunction and reduces the risk of CVD. 
Antioxidant supplementation prior to exercise has been reported to blunt exercise induced 
(interleukin) IL-6 release from contracting human skeletal muscle. However, Ristow et al, (66) 
noted that the additional health benefits of physical exercise such as up regulation of glucose 
transporter type-4 (GLUT4), plasma adiponectin level and antioxidant enzymes in human 
skeletal muscle are abolished by administration of vitamin C and E. Therefore, whilst 
antioxidant supplementation may reduce ROS damage, this protective quenching of ROS may 
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subsequently inhibit the body’s natural antioxidant systems and neutralise any potential 
benefits.  
 
1.2.5 Clinical significance of endothelial dysfunction - 
implications in atherosclerosis 
Homeostatic alterations in the endothelium can result from a chemical insult (for example, ROS 
damage). Endothelial dysfunction resulting from insult can often shift the vessel into a 
prothrombotic state, whereby the endothelium attempts to repair the damage by increasing 
leukocyte recruitment. Additionally, endothelial injury initiates the secretion of procoagulant 
factors (including cytokines and growth factors). If this inflammatory cascade is not neutralised 
back to a non-procoagulant state, it may continue indefinitely, leading to migration and 
proliferation of lipid and SMCs to the site of damage. If these responses continue unrestricted, 
they can thicken and stiffen the arterial wall.  
 
Continued inflammation results in increased recruitment of leukocytes (macrophages and 
lymphocytes), which migrate to the lesion. Activation of these cells results in the release of 
cytokines, chemokines, and growth factors, which further induce vascular damage and 
eventually lead to focal necrosis. Fatty streaks are initiated by the adherence of circulating 
monocytes to activated ECs. Subsequently, adhered monocytes may migrate to the 
subendothelial space where they differentiate into macrophages, a process governed by 
chemoattractant molecules (67). Monocyte differentiation is coupled with a substantial up 
regulation of ‘scavenger’ receptors. Typically, scavenger receptors are involved in the 
recognition and internalisation of pathogens however, scavenger receptors also recognise 
modified low-density-lipoprotein and mediate the formation of lipid peroxides and 
accumulation of cholesterol in the macrophage to form foam cells (67). Accumulation of 
mononuclear cells, migration and proliferation of SMCs, and formation of fibrous tissue results 
in the further enlargement of the lesion. The fibrous cap encapsulates the necrotic tissue and 
accumulated lipid, to become an advanced atherosclerotic lesion (67).  
 
Concomitantly, endothelial dysfunction has been proposed to be of immense pathophysiological 
importance in the development of atherosclerosis. The imbalance in NO bioavailability coupled 
with a concomitant increase in ROS is referred to as nitro-oxidative stress. The pathological 
mechanisms that oversee endothelial dysfunction are complex. For example, decreased NO 
bioavailability is associated with increased VCAM-1 expression in ECs. In parallel, elevated 
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ROS may directly or indirectly (via oxidised LDL) up-regulate EC surface adhesion molecule 
expression. Consequently, with a decreased NO bioavailability, VCAM-1 binds to leukocytes 
and initiates their subsequent invasion of the vessel wall. Following foam cell formation 
oxidised LDL attenuate the damage by reducing eNOS expression and further stimulating 
surface adhesion molecule expression in ECs (67). 
 
Eventually, compensatory mechanisms (such as vascular dilatation) become exhausted, and 
consequently atherosclerotic lesions may rupture, intrude into the lumen and alter the flow of 
blood. The vicious spiral of nitro-oxidative stress may also activate matrix metalloproteinases 
(MMP, including MMP-2 and MMP-9), which weaken the fibrous cap of atherosclerotic lesions 
causing plaque ruptures and acute coronary syndrome (67). Summarised in figure 1.5. 
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Figure 1.5. The pathology of atherosclerosis. (A) Endothelial dysfunction. Endothelial 
dysfunction is the earliest manifestation of atherosclerosis to precede the formation of 
atherosclerotic lesions. (B) Fatty streak formation. The fatty streak involves the recruitment of 
monocytes, macrophages and T-lymphocytes to initiate foam cell formation. Foam cell 
formation is accompanied by SMC migration (stimulated by platelet-derived growth factor, 
fibroblast growth factor 2, and transforming growth factor β). Additionally, T-cell activation is 
mediated by tumour necrosis factor alpha (TNFα), interleukin-2, and granulocyte–macrophage 
colony-stimulating factor. Macrophages engulf modified LDL (especially oxLDL) by 
endocytosis via scavenger receptors to initiate the formation of foam cells. Foam cell formation 
is associated with oxidised low-density lipoprotein (LDL), macrophage colony-stimulating 
factor, TNFα, and interleukin-1 (IL-1) and platelet adhesion and aggregation (itself stimulated 
by integrins, P-selectin, fibrin, thromboxane A2, tissue factor (TF)). (C) Advanced 
atherosclerosis. A fatty streak can progress to an advanced atherosclerotic lesion. These 
advanced lesions often form a fibrous cap that walls off the lesion from the lumen (as a healthy 
blood vessel would respond to a vascular injury). The fibrous cap encapsulates an array of 
leukocytes, lipid deposits and debris, which in turn form a necrotic core. Lesions may expand 
via continued leukocyte adhesion and entry. ECs, endothelial cells; SMCs, smooth muscle cells. 
Adapted from (67). 
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1.3 Polycystic ovary syndrome 
In my thesis, I chose to use patients with Polycystic Ovary Syndrome (PCOS) as a clinical 
model of early CVD. PCOS is a common endocrine disorder affecting 5-10% of women in 
reproductive age (68). The syndrome is a complex disorder with environmental and epigenetic 
factors playing a key role in the phenotypical expression of disease symptoms, of which 
cardiovascular disease is prevalent. The clinical characteristics of PCOS are highlighted in table 
1.5. 
 
Whilst the aetiology of PCOS is largely unknown, studies in families have shown it appears to 
be heritable in nature, at least in part. In a study looking at 93 patients with PCOS, Kashar-
Miller et al, (69) found that 35% of patients’ mothers and 40% of their sisters also had PCOS, a 
proportion which is markedly higher than the 5-10% anticipated in the general population. To 
date, numerous efforts have been made to find candidate genes that influence PCOS pathology. 
Several possible genes have been suggested including hexose-6-phosphate dehydrogenase 
(H6PD) (70), a pivotal gene in glucocorticoid and cortisone regulation.  
 
Major endocrine disruption includes enhanced androgen activity coupled with the impaired 
action of insulin. Endocrine abnormalities affect a variety of physiological processes, resulting 
in several common health complications, including menstrual dysfunction and infertility, acne, 
hirsutism, obesity and metabolic syndrome (71).  
 
Table 1.5 Clinical characteristics of polycystic ovary syndrome 
1. Oligomenorrhea / amenorrhea 
2. Infertility 
3. Hirustism 
4. Male pattern baldness 
5. Acne  
6. Obesity 
7. Impaired actions of insulin 
Adapted from (71). 
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1.3.1 Diagnosis 
The diagnostic traits for PCOS include hyperandrogenism, oligomenorrhea / anovulation, and 
polycystic ovaries. The disorder was first described by Stein and Leventhal in 1935, reporting a 
case of several women that presented with amenorrhea, hirsutism and polycystic ovaries, which 
has now come to be known as PCOS. However, despite the high prevalence of PCOS, diagnosis 
remains controversial (72). Additionally, since the first description of PCOS in 1935, the 
importance of different clinical features to the diagnosis of the syndrome has undergone 
multiple revisions (table 1.6).   
 
Firstly, the National Institute of Health (NIH, 1990) defined PCOS as chronic anovulation with 
clinical and/or biochemical hyperandrogenism (73). Following this, the European Society for 
Human Reproduction/American Society of Reproductive Medicine proposed the Rotterdam 
criteria for diagnosis. This includes any two of the following three criteria: oligomenorrhea 
and/or anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries 
(assessed via bilateral ultrasound). The Rotterdam criteria is still used in current clinical 
practice. With the additional diagnostic tool (polycystic ovaries) suggested by the Rotterdam 
criteria, it expanded the diagnosis of PCOS to women with oligomenorrhea / anovulation and 
polycystic ovaries (nonhyperandrogenic), as well as women with hyperandrogenism and 
polycystic ovaries (74). This diagnostic criteria has multiple phenotypes which when coupled to 
the spectrum of environmental factors, contributes to the diverse pathophysiology and 
phenotypical manifestations of the syndrome. More recently, the Androgen Excess and PCOS 
Society reported that PCOS is predominantly a hyperandrogenic disorder and suggested that the 
criteria should encompass hyperandrogenism and abnormal ovarian function (oligomennorrhea 
/anovulation and/or polycystic ovaries) (75). This definition makes hyperandrogenism a 
prerequisite for diagnosis. To date, the Rotterdam criteria is the most widely used. All revisions 
of the syndrome acknowledge the importance of correct diagnosis with the exclusion of other 
mimicking etiologies such as Cushing’s syndrome, thyroid and adrenal pathologies.  
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Table 1.6 Diagnostic criteria for polycystic ovary syndrome 
Criteria  Hyperandrogenism 
Oligomenorrhea / 
amenorrhea 
Polycystic ovaries 
NIH 1990 + + +/- 
Rotterdam 2003    
phenotype 1 + + - 
phenotype 2 + - + 
phenotype 3 - + + 
phenotype 4 + + + 
AE-PCOS 2006    
phenotype 1 + + - 
phenotype 2 + - + 
phenotype 3 + + + 
NIH, National Institute of Health; AE, androgen excess; PCOS, polycystic ovary syndrome. 
Adapted from (76). 
 
1.3.2 Cardiovascular disease in PCOS 
In addition to the well-established reproductive complications, the complexity of the syndrome 
has widened to encompass an array of cardiovascular health problems including obesity (77), 
hypertension (78) and dyslipidaemia (79). Reduced insulin sensitivity and impaired insulin 
secretion are considered the key metabolic deficits within PCOS, subsequently leading to an 
increased risk of type 2 diabetes (80, 81). Thus, there are a plethora of cardiometabolic 
derangements, synergistically contributing to the development of CVD risk in PCOS patients.  
 
1.3.3 Hypertension in PCOS 
The cardiovascular risk factors associated with PCOS may indeed be responsible for the 
promotion of hypertension in these patients. Numerous studies have reported an increased 
occurrence of hypertension in PCOS patients compared to control populations (81, 82). In a 
study investigating hypertension in 346 Dutch PCOS patients, Elting et al, (83) declared women 
with PCOS had a 2.5 fold greater prevalence of hypertension than women in the corresponding 
age-matched Dutch female population. However, this study was not adjusted for BMI, thus the 
additional complication of obesity related hypertension may confound this association. Holte et 
al, (82) found that compared to controls, women with PCOS had higher day-time ambulatory 
systolic blood pressure and mean arterial blood pressure measurements compared to their non-
PCOS counterparts. Groups did not differ in day-time diastolic blood pressure or in night-time 
measurements. This indication of pre-clinical hypertension was independent of BMI.  
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In contrast, another study involving small participant numbers (14 PCOS patients and 18 obese 
controls) found no relationship between PCOS and hypertension (84). Interestingly, Wild et al, 
(85) undertook a long-term (31 year) retrospective analysis of patients with PCOS, finding that 
women with PCOS had an increased prevalence of hypertension. However, BMI was again not 
considered, hence the effects of the syndrome, independent of obesity on BP, are yet to be fully 
established. 
 
Numerous mechanisms are potentially responsible for the development of hypertension in 
women with PCOS, including obesity, insulin resistance and androgen excess. In a study 
looking at 40 PCOS patients and 20 age/BMI matched controls, Luque-Ramirez et al, (86) 
found that androgen excess was associated with an increase in carotid intima media thickness 
(cIMT) in patients with PCOS. Furthermore, increased cIMT has been shown to reflect 
preclinical atherosclerosis, an established culprit in the development of hypertension (87). 
Conversely, a study employing the anti-androgen drug cyproterone acetate (2 mg/day) found 
that it increased systolic, diastolic ambulatory blood pressure measurements in PCOS patients 
(81).  
 
1.3.4 Dyslipidaemia in PCOS 
Dyslipidaemia in PCOS (and metabolic syndrome in general) is typically characterised by high 
LDL-cholesterol, low HDL- cholesterol levels and raised triglyceride (TG) levels, however 
various dyslipidaemia patterns have been described. Dyslipidaemia in PCOS appears to be 
common, yet the pattern and prevalence in PCOS is variable. Notably, the National Cholesterol 
Education Program reported ~70% of the PCOS population present with abnormal lipid levels 
(88).  
 
In a recent meta-analysis of dyslipidaemia in PCOS patients (diagnosed against Rotterdam (and 
NIH criteria) found that on average women with PCOS have a higher TG and lower HDL- 
cholesterol than their respective counterparts. Moreover, the meta-analysis found that PCOS 
patients have elevated LDL- cholesterol levels even when matching subjects for age/BMI (89). 
 
An array of dietary, ethnic, genetic and lifestyle factors might play a key role in the pathology 
of PCOS dyslipidaemia. For example, a small proportion of PCOS patients from the 
Mediterranean (Italy, n = 20) presented with an altered lipid profile compared to their American 
counterparts (n = 20), with USA patients exhibiting significantly higher TG and lower HDL- 
cholesterol levels, even after adjustment for BMI (90). In addition, Carmina and colleagues also 
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found USA patients presented with an increased saturated fat intake, hyper-caloric diets and 
significantly higher BMI compared to Italian PCOS patients (91). 
 
Akin to all other cardiometabolic abnormalities in PCOS, the pathogenesis of dyslipidaemia is 
multifactorial. Several mechanisms may influence this, with obesity, IR and hyperandrogenism 
likely playing key roles. For example, within adipocytes, IR and hyperandrogenism result in 
elevated catecholamine induced lipolysis and subsequent increased free fatty acids (FFAs) in the 
bloodstream. Elevated FFA flux to the liver may stimulate VLDL assembly and secretion 
resulting in hypertriglyceridemia. Testosterone has been associated with the regulation of 
hepatic lipase and scavenger receptor B1 (SR-B1) activity, both of which have been shown to 
reduce HDL levels in animal models. Moreover, testosterone (via androgen receptor interaction) 
has been shown to limit the removal of LDL by increasing the oestrogen receptor-mediated 
inhibition of the LDL-receptor, resulting in elevated LDL levels in the circulation. However the 
exact mechanism of how this occurs remains unclear (92).  
 
1.3.5 Insulin resistance in PCOS 
IR appears to be of paramount importance, not only for PCOS pathology, but for several CVD 
entities, as evidenced by the finding that IR and atherosclerosis frequently coexist in common 
proatherogenic disorders. By definition, IR is a common pathologic state where target cells fail 
to efficiently respond to endogenous insulin and is subsequently linked to the development of 
type 2 diabetes (93).  
 
In 1980, Burghen and coworkers first described the association of PCOS and IR (94). They 
found that obese PCOS women had elevated glucose levels and an increased glucose area-
under-curve (AUC) following an oral glucose tolerance test (OGTT) compared with age/BMI-
matched control women. However, in this study no difference was found between non-obese 
PCOS patients and their respective counterparts. Apter et al, (95) found the prevalence of IR in 
adolescent PCOS patients was ~20-40%, which was markedly higher than the prevalence rates 
reported in population-based studies for women of the same age (10.3% by WHO criteria in 
women aged 20–44 year). Additionally, in a recent cross-sectional study in our own research 
group involving 84 PCOS patients (diagnosed using Rotterdam criteria) and 95 healthy 
volunteers, Rees and colleagues found that PCOS subjects had an elevated insulin response 
(insulin AUC) following a 75g OGTT (96). In another study, Dunaif et al, (97) found that 
PCOS patients showed subnormal insulin action coupled with a reduced glucose effectiveness 
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(i.e. the ability of glucose per se to stimulate glucose uptake and suppress hepatic glucose 
production, independently of insulin), compared to controls. 
 
Carmina et al, (98) investigated the prevalence of IR in 3 geographically and genetically 
different populations (PCOS patients from the United States, Italy, and Japan, 25 patients per 
group). In this study fasting insulin was elevated in all groups when compared to age/BMI 
matched controls, but was greatest within patients from the United States and Italy compared to 
Japanese PCOS patients. The study also noted that the prevalence of IR, estimated from the 
results of an insulin tolerance test, ranged from 68 - 76%, across all ethnic groups. 
 
Although IR is a common feature of PCOS and confers a substantial burden, not all women with 
PCOS present with IR. As many as 50% of obese women with PCOS may not have documented 
insulin resistance by intensive testing and this prevalence has been shown to be even lower in 
non-obese PCOS patients (99-101). On balance, PCOS is a heterogeneous disorder, reflected by 
the different phenotypes which may or may not present with IR. In a recent review, Christakou 
and Diamanti-Kandarkis concluded that the reported prevalence of IR in PCOS within the 
literature was 44-70%, a rate higher than the prevalence for IR in the expected general 
population (102). It has been suggested that different diagnostic criteria used in the array of 
studies looking at IR in PCOS may account for some of the discrepancies in the prevalence and 
severity of IR. With the Rotterdam criteria giving a spectrum of possible phenotypes (four), 
with each phenotype harbouring differing degrees of IR. It has been suggested that those 
patients presenting with all three symptoms on the Rotterdam criteria present with the most 
severe IR (103).  
 
Insulin is a potent endocrine hormone that acts upon insulin sensitive tissues, including adipose 
tissue, skeletal muscle and the endothelium. Upon binding to its receptor, insulin initiates the 
phosphorylation of insulin receptor substrate (IRS), which subsequently activates 
phosphoinositide 3-kinase (PI3K) and mitogen-activated pathway kinase (MAPK) pathways. As 
IR is a tissue selective complication, the body will compensate for an impaired insulin 
responsiveness by producing excess insulin (hyperinsulinaemia). Hyperinsulinaemia in 
unaffected insulin-sensitive tissues will cause an imbalance in P13K mediated insulin 
signalling. IR in PCOS has been characterised in adipocytes by a post-binding defect in the 
insulin receptor-mediated signal transduction, which has also been confirmed in clinical studies 
of skeletal muscle action. In studies taking skeletal muscle biopsies from PCOS patients 
undergoing a hyperinsulinaemic euglycemic clamp, investigators have shown that women with 
PCOS have a decreased insulin-induced peroxisome proliferator agonist receptor-γ (PPARγ) co-
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activator 1α (PGC-1α) and enhanced IRS-2 expression when compared to controls (104). From 
subcutaneous adipocytes derived from 9 obese and 7 lean PCOS patients (with BMI matched 
controls), Rosenbaum et al, (105) noted that GLUT-4 expression was decreased in PCOS 
patients by 36%, independent of obesity. Collectively, these molecular abnormalities may lead 
to selective resistance to the actions of insulin. 
 
In addition to IR, β-cell dysfunction is a frequent feature in women with PCOS. It is this dual 
combination of these two metabolic derailments that synergistically contribute to the 
development of T2DM. Moreover, impaired glucose tolerance (IGT) and type 2 diabetes are 
both increased in women with PCOS compared to women of similar BMI with regular menses. 
In fact, in a large study of glucose intolerance among women with PCOS, 38.6% of the PCOS 
women had either IGT (31.1%) or diabetes (7.5%) by WHO criteria (99).  
 
1.3.5.1 Insulin resistance and PCOS pathology 
In patients with PCOS, excess insulin disrupts metabolic homeostasis. Such effects include 
androgen secretion by the ovarian theca; acanthosis nigricans and abnormal hepatic and 
peripheral lipid metabolism (103). Specifically, elevated insulin levels directly increase 
luteinizing hormone (LH)-stimulated androgen secretion from the ovary. Furthermore, in a 
study looking at 6 obese PCOS patients, elevated insulin levels were shown to decrease 
circulating sex hormone-binding globulin (SHBG) levels, subsequently yielding higher levels of 
free androgens (106). 
 
There are a number of studies linking IR with a spectrum of CVD aberrations. Notably, there is 
a striking association between IR and endothelial dysfunction. Kelly et al, (107) demonstrated 
an elevated pulse wave velocity (PWV, (increased vascular stiffness) and a functional defect in 
the vascular action of insulin in patients with PCOS (measured via micro-myography ex vivo). 
Several studies have also demonstrated an association between IR and increased carotid IMT 
and FMD of the brachial artery in women with PCOS, independent of age and obesity (108).  
 
During endothelial homeostasis, insulin binds to IRS and activates downstream MAPK and 
PI3K pathways. In IR states, as in PCOS, imbalances in these pathways occur, as a result of 
hyperinsulinaemia, impairment of PI3K pathway leading to decreased eNOS and subsequently 
NO levels (103). Also, hyperinsulinaemia associated MAPK activation promotes ET1 
expression coupled with increased expression of surface adhesion molecules such as VCAM-1 
29 
 
and E-selectin. Thus, IR is associated with endothelial dysfunction and may contribute to the 
development of accelerated atherosclerosis (103).  
 
The effects of insulin sensitisers on CVD pathology in PCOS are discussed in sections 1.3.7 and 
1.3.8.  
 
1.3.6 Inflammation in PCOS 
In an observational study looking at 8 lean and 8 obese PCOS patients and age/BMI matched 
healthy controls, Gonzalez et al, (109) declared that women with PCOS exhibited higher 
inerleukin-6 (IL-6), sICAM-1, C-reactive protein (CRP) and plasminogen activator inhibitor-1 
(PAI-1) levels compared to controls. In agreement, Diamanti-Kandarakis et al, (110) found that 
plasma hsCRP, sICAM-1 and sE-selectin levels were higher in the PCOS group compared to 
age/BMI matched controls. Interestingly, although soluble (s)VCAM-1 did not differ between 
the groups at baseline, a significant reduction in hsCRP and sVCAM-1 was noted in PCOS 
patients following 6 months of metformin administration. Thus, several studies have suggested 
that PCOS patients suffer from low-grade chronic inflammation which may play a role in 
atherogenesis and may be intrinsically linked to the development of IR (111).  
 
1.3.7 Obesity in PCOS 
With a spectrum of cardiometabolic abnormalities noted in PCOS, obesity is a major aggravator 
and often presents as a confounder in the interpretation of clinical studies. Clinically, a BMI of 
25–29 kg/m2 is classified as overweight whilst subjects with BMIs ≥30 kg/m2 are regarded as 
obese. Obesity prevalence in PCOS varies between studies (38-88% of patients). In a large 
observational study looking at 1741 PCOS patients, 38.4% were classified as obese, however 
this was based upon BMI >25 kg/m2 (112). With multiple studies demonstrating symptomatic 
improvements in PCOS following even modest weight loss, the marriage between obesity and 
PCOS appears to be an integral feature in PCOS pathophysiology.  
 
Independent of PCOS per se, obesity is an established risk factor and prerequisite for the array 
of cardiometabolic abnormalities seen within the syndrome, including hypertension, 
dyslipidaemia and accelerated atherosclerosis. Adipose tissue is an important endocrine organ 
that synthesises and secretes a variety of compounds into the bloodstream, playing a key 
immunomodulatory role. For example, adipocytes are a significant source of TNFα, IL-6, PAI-
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1, lipoprotein lipase, oestrogens (through P450 aromatase activity), leptin, adiponectin, insulin-
like growth factor-I (IGF-I) and insulin-binding protein 3 (IGFBP3). In addition to mature 
adipocytes, adipose tissue contains a network of pre-adipocytes, macrophages and vascular 
constituents. There is growing evidence to suggest that an increased adipose tissue mass directly 
elevates systemic inflammation. Numerous studies have found that BMI positively correlates 
with increases in systemic proinflammatory indices, including C-reactice protein (CRP), IL-6, 
plasminogen activator inhibitor-1 (PAI-1), P-selectin and VCAM-1 (113, 114).  
 
BMI is the most widely used measure of obesity in clinical practice. However, like other 
anthropometric measures, it is only a surrogate measure of obesity and is fraught with numerous 
limitations which are often overlooked when considering the associated benefits of BMI. 
Although BMI is of fundamental importance in predicting numerous pathological conditions 
including MI, type 2 diabetes, stroke, hypertension and even CVD mortality (115), BMI offers 
little information in regards to fat distribution or total body fat percentage. However a 
comprehensive assessment of total body fat distribution can be achieved using more sensitive 
methodology (for example computerised tomography (CT) scans).  
 
There is much evidence to suggest that the regional distribution of body fat is an important 
factor in the relationship between obesity, metabolism and the development of CVD. Broadly, 
visceral adipose tissue appears to show a much stronger association than subcutaneous adipose 
tissue with CVD risk and mortality (116).   
 
Rosito et al, (117) studied the CVD burden attributed by differing regional fat deposits in >1100 
subjects, and concluded that visceral and pericardial fat are correlated with CVD mortality. 
Interestingly, in comparison to subcutaneous or pericardial adipose tissue, visceral fat has the 
richest accumulation of infiltrated macrophages. In turn, visceral fat is a source of several 
cytokines which may invoke a proinflammatory state and initiate oxidative damage leading to 
the propagation of atherosclerosis (118). 
 
In a study investigating 200 overweight PCOS patients and 100 age/BMI matched controls, 
Cascella et al, (119) demonstrated that visceral fat amount (assessed by CT scan) associated 
with subclinical CVD in PCOS patients. In this study carotid IMT was positively correlated 
with visceral fat area, whereas an inverse relationship was found between FMD and visceral fat. 
In contrast, several studies have shown that visceral obesity is positively associated with 
endothelial dysfunction and premature atherosclerosis (120, 121). 
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Therapeutically, even modest weight loss achieved via diet and/or physical activity has been 
shown to improve an array of obesity-related factors. Additionally, weight loss (to achieve a 
healthy BMI) has been shown to improve PCOS symptoms including ovulatory function (122).  
 
IR may be one of the most important factors linking abdominal visceral adiposity to 
cardiovascular risk. Impaired suppression of adipocyte lipolysis and elevated fatty acid levels 
are also associated with excess visceral adiposity, potentially contributing to the impairment of 
endothelial function (123). Visceral fat is also associated with increased levels of the pro-
coagulant PAI-1 and low-grade inflammation (123). Besides these metabolic disorders, visceral 
fat accumulation is associated with elevated systolic blood pressure in postmenopausal women, 
and visceral fat reduction was directly associated with lowering of blood pressure. 
 
1.3.8 Endothelial dysfunction in PCOS 
Numerous studies have challenged the existence of endothelial dysfunction in PCOS at a 
physiological (Table 1.7) and biochemical level (Table 1.8). 
Several studies have shown that PCOS patients have impaired endothelium-dependent and 
independent vasodilator responses in the brachial artery (108, 124). However, other studies have 
failed to detect changes in endothelium-dependent vascular function but have shown that 
women with PCOS appear to exhibit an impaired endothelium-independent vasodilator response 
(125). Whereas impaired endothelium-dependent vasodilatation is indicative of eNOS 
dysfunction endothelium-independent vasodilatation is more complex and may be indicative of 
smooth muscle dysfunction. In addition, obese women with PCOS show similar basal leg blood 
flow (LBF), but an impaired metacholine-induced LBF in comparison to age/BMI matched 
controls (126). Conversely, in a slightly larger study population employing FMD, no vaso-
responsive difference was observed between PCOS and healthy controls (125). 
On balance, endothelial dysfunction within PCOS remains unclear. Of interest, several studies 
have noted key relationships between endothelial dysfunction and with metabolic variables in 
PCOS. Studies have found that endothelium-dependent responses were positively correlated 
with free testosterone (124, 126) and BMI (126). However Worboys et al, (127) found that 
testosterone implants in post-menopausal women receiving hormone replacement therapy 
improved both endothelial-dependent and independent brachial artery vasodilation. Tarkun et al, 
(111) found that endothelium-dependent vasodilatation was inversely associated with CRP 
levels in PCOS patients. In this study, PCOS patients presented with severe endothelial 
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dysfunction in comparison to age/BMI matched controls. Additionally IR, total testosterone and 
total cholesterol were all independent predictors of reduced FMD. IR may play a pivotal role in 
the development of endothelial dysfunction in PCOS patients. In a study involving 10 obese 
PCOS and 13 age/BMI matched controls, Paradisi et al, (128), found that after 3 months of 
troglitazone therapy (600 mg/day), PCOS patients had improved metacholine induced LBF 
responses which was similar to their non-PCOS counterparts. Similar results were noted in 
studies involving metformin (1700 mg/day for 6 months) and rosiglitazone (4 mg /day for 12 
months), where PCOS patients showed improved FMD (129, 130) and reduced plasma ET1 
levels (130). Also, in a randomised, placebo-control, cross over trial, previous work in our 
research group has found that metformin improves aortic and brachial PWV, central blood 
pressure and both endothelium-dependent and endothelium-independent vascular response in 
PCOS patients (131). 
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Table 1.7 Summary of endothelial dysfunction in patients with polycystic ovary syndrome 
Reference Methodology Population Interpretation 
Carmina et al, 
(108) 
FMD 
50 PCOS patients 
50 controls age/BMI matched 
PCOS patients showed an impaired endothelial-dependent 
response and greater carotid ITM compared to controls. 
Paradisi et al, 
(126) 
LBF 
12 obese PCOS patients 
13 controls age/BMI matched 
PCOS subjects showed a normal endothelial independent but 
diminished endothelial-dependent vasodilatation compared to 
controls. 
Tarkun et al, 
(111) 
FMD 
37 PCOS patients 
25 controls age/BMI matched 
Women with PCOS showed a decreased endothelial 
independent and endothelial-dependent vasodilatation 
response compared to controls. 
Orio et al, (11) FMD 
30 PCOS patients 
30 controls age/BMI matched 
PCOS patients showed an impaired endothelial-dependent 
response and greater carotid ITM compared to controls. 
Kravariti et al, 
(132) 
FMD 
62 PCOS patients 
17 controls age/BMI matched 
PCOS presented with a decreased endothelial independent 
and endothelial-dependent vasodilatation response compared 
to controls. 
Rajendran et al, 
(133) 
PWV 
24 PCOS patients: lean (n = 12), obese (n 
= 12) lean controls (n = 12) age matched 
Women with PCOS displayed a greater PWV than controls 
PCOS patients demonstrated an impaired endothelial-
dependent vascular response compared to controls. 
Sorensen et al, 
(134) 
FMD 
44 PCOS patients 
13 controls age/BMI matched 
PCOS patients showed an impaired endothelial-dependent 
vasodilatation response compared to controls.  
Sprung et al, 
(124) 
FMD 
19 PCOS patients 
16 controls age/BMI matched 
PCOS patients showed an impaired endothelial-dependent 
response compared to controls. 
Mather et al, 
(125) 
FMD 
18 PCOS patients 
19 controls age/matched 
PCOS patients presented with similar endothelial-dependent 
and independent vascular response compared to the control 
group. 
Meyer et al, 
(135) 
FMD and 
PWV 
100 OW PCOS 
20 controls age/BMI matched 
Subjects with PCOS showed increased arterial stiffness and 
an impaired endothelial-dependent vasodilatation response 
compared to controls. 
Diamanti-
Kandarakis et 
al, (136) 
FMD 
25 PCOS patients 
25 Controls age/BMI matched 
PCOS patients presented with a normal endothelial 
independent but diminished endothelial-dependent 
vasodilatation compared to controls. 
FMD; flow mediated dilatation; LBF; leg blood flow; PWV, pulse wave velocity; OW, over weight; ITM, intima thickness media. 
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In addition to physiological indices of endothelial dysfunction, determining NO bioavailability 
within PCOS patients may reflect preclinical endothelial dysfunction. To date, studies assessing 
plasma NO bioavailability employed the Griess methodology for NOx quantification. Several 
studies have found no difference in total NO bioavailability between PCOS patients and 
controls. In contrast, Bayram et al, and Mohamadin et al, (137) both demonstrated that women 
with PCOS exhibit decreased NO bioavailability. However a caveat of the studies to date is the 
methodology employed to detect plasma NOx. In comparison to more sensitive techniques 
currently available and employed (such as ozone-based chemiluminescence), the Griess reaction 
is limited to detecting primarily NO3-, with NO2- detection limited by the poor sensitivity of the 
assay to measuring baseline plasma levels even in healthy individuals. Furthermore, NO3- is 
>70% derived from dietary sources and unless participants are maintained on a relatively 
nitrate-free diet prior to measurement, the plasma values are unlikely to reflect vascular NO 
availability. More recently, with improvements in detection and advances in recognising factors 
influencing NOx measurement in blood, a more comprehensive understanding of blood NOx in 
PCOS is possible.  
 
Table 1.8 Nitric oxide measurements in women with polycystic ovary syndrome 
Study Methodology Population Interpretation 
Nacul et al, 
(138) 
Griess method 
31 PCOS patients 
20 controls age matched 
NO levels were similar 
between groups 
Kuşçu et al, 
(139) 
Griess method 
38 PCOS patients 
23 controls age/BMI 
matched 
NO levels were similar 
between groups 
Mohamadin 
et al, (137) 
Griess method 
50 PCOS patients 
30 Controls age-matched 
Decreased total NOx in Saudi 
PCOS patients compared to 
controls 
Dursun et al, 
(140) 
Griess method 
25 lean PCOS patients 
27 Controls age/BMI 
matched 
NO levels were similar 
between groups 
Turkcuoglu 
et al, (141) 
Griess method 
22 obese and 11 lean PCOS 
patients 
11 obese and 24 lean 
controls 
NO levels were similar 
between groups 
Baskol et al, 
(142) 
Griess method 
30 PCOS 
20 Controls age matched 
NO levels were similar 
between groups 
Bayram et 
al, (143) 
Griess method 
45 PCOS patients 
17 Controls 
Decreased total NOx in 
PCOS patients compared to 
controls 
NO, nitric oxide; NOx, nitric oxide metabolites. 
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1.3.9 Oxidative stress in PCOS 
Theoretically, elevated indices of oxidative damage would be expected in women with PCOS if 
oxidative stress had a significant contribution to pathophysiology. However, studies to date 
have shown conflicting results. Direct detection of ROS is challenging due to their potent 
reactivity. Thus, most previous studies relied upon more stable indices as biomarkers of 
oxidative damage to lipids and proteins. However, such oxidative stress biomarkers are 
associated with a complex biochemistry where the different thermodynamic and kinetic 
properties may contribute to the over estimation and inconsistent results (144). 
 
Numerous studies have shown that PCOS patients present with an increased oxidative burden in 
comparison to their non-PCOS counterparts (145). Malondialdehyde (MDA) levels, an end 
product of polyunsaturated fatty acid (PUFA) oxidation, were commonly employed as an 
indication of oxidative damage in these studies.  
 
Sabuncu et al, (146) found that plasma MDA levels were related to visceral fat, blood pressure 
and IR. In contrast, Gonzalez and colleagues found that basal plasma MDA levels were similar 
between women with PCOS and control subjects (147). However, in response to a 75g OGTT, 
the percent change in plasma thiobarbituric acid reactive substances (TBARS) as a consequence 
of hyperglycemia was higher in obese women with PCOS compared with lean and obese 
controls. Mononucelar cells such as macrophages are ubiquitous in adipose tissue and pose a 
significant threat to an injured endothelium. Mononucelar cells derived from PCOS patients 
were found to over-produce ROS in response to a 75g OGTT, ex vivo. The glucose challenge 
also increased p47phox expression (a key protein component of NADPH oxidase), in women with 
PCOS. Moreover, p47phox expression was negatively associated with insulin sensitivity and 
positively correlated with visceral fat percentage, whilst ROS generation (MDA levels) was 
positively associated with androgen levels (147).  
 
Of note, Macut et al, (148) found that lean women with PCOS showed an increased level of 
plasma nitro-tyrosine (assessed by enzyme immunoassay). Elevated nitro-tyrosine levels are 
indicative of nitro-oxidative stress, formed most notably from the reaction between NO and O2- 
and specifically from ONOO-. 
 
A recent systematic meta-analysis assessing oxidative stress in PCOS (68 studies, involving 
4,933 PCOS patients and 3,671 controls), found that compared to their non-PCOS counterparts, 
patients with PCOS presented with higher circulating concentrations of homocysteine, MDA, 
and asymmetric dimethylarginine (145). The magnitude of change in these markers was only 
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modest and the studies that underpinned the meta-analysis were generally limited to 
measurement of oxidant or antioxidant molecules in isolation and/or measurement of reaction 
end-products as surrogates of oxidative stress.  
 
1.3.10 Antioxidant status in PCOS 
With a growing awareness of oxidative stress in women with PCOS, many studies have also 
investigated the antioxidant status in these patients. In a study of 27 women with PCOS and 18 
age/BMI-matched controls, Sabuncu et al, (146) found that PCOS patients had an increased 
oxidative burden and reduced glutathione peroxidase activity. Similarly, a decrease was noted in 
SOD activity in PCOS patients when compared to healthy controls. Plasma and erythrocyte 
vitamin C and vitamin E levels were lower in PCOS patients compared to controls. However, no 
difference was observed in vitamin A and β-carotene levels between groups (149, 150). 
 
Several studies have shown, measures of antioxidants in isolation yield conflicting results. Total 
antioxidant capacity (TAC) is used to assess the net effect on antioxidant defences. Fenki and 
colleagues found that women with PCOS exhibit a decreased total antioxidant capacity (TAC) 
(151). However, on assessment of 7 studies (260 PCOS patients and 210 controls), a meta-
analysis found that TAC was similar between women with PCOS and respective controls, 
independent of age and BMI (145).  
 
1.3.11 PCOS and cardiovascular disease: ‘the 
uncertainties’ 
Since the early diagnoses of PCOS, a number of studies have highlighted the potential 
relationship between PCOS and CVD. There is considerable literature identifying established 
CVD risk factors (such as IR, hyperinsulinaemia, dyslipidaemia, hypertension and chronic low-
grade inflammation) in patients with PCOS. However, the prevalence of the reported 
cardiometabolic abnormalities is difficult to predict. Not all PCOS patients present with IR. 
Furthermore, the clinical quantification of IR is determined by various methods which may 
further complicate inter-study comparisons. In addition, dyslipidaemia has been reported as a 
common metabolic abnormality within the syndrome, yet the pattern (type of dyslipidaemia) 
and prevalence is highly variable (92).  
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Notably, the various PCOS phenotypes also make inter-study comparisons challenging. Thus, it 
is not surprising, with such diversity in diagnostic criteria and subsequent PCOS phenotypes 
that studies yield conflicting results whereby PCOS patients present with differing 
cardiometabolic severity. The syndrome suffers from an unknown aetiology and has no clear 
genetic signature. Therefore, ethnic, geographic and demographic differences need to be 
considered when interpreting studies.  
 
CVD risk in general, regardless of PCOS status is known to increase with age and BMI. Yet, 
not all studies assessing CVD in patients with PCOS use an appropriately age/BMI matched 
control group. Furthermore, many studies have used small sample sizes with limited long-term 
follow up. 
 
The assessment of nitro-oxidative stress in PCOS has produced conflicting results, which may 
be due to numerous limitations in the methodology. Previous studies assessing NO 
bioavailability used methodology that fails to distinguish between NOx metabolites and thus 
cannot detect any subtle changes in NO2- levels. Interpretation of previous results is made 
difficult by use of non-specific methods coupled with components of this complex biochemistry 
measured in isolation. This may have heavily influenced prior interpretation.  
 
There is a lack of adequately powered prospective, long-term studies looking at CVD outcome 
in PCOS cohorts. Wild et al, (85) undertook a retrospective study looking at 678 patients 
diagnosed with PCOS before 1979. They found that women with PCOS had higher levels of 
hypertension, diabetes, a greater waist-to-hip ratio and hypercholesterolaemia compared to age-
matched controls. However, after adjustment for BMI, despite the increased prevalence of 
several CHD risk factors, there was no difference found between groups with respect to CHD 
morbidity or mortality in middle aged-women with PCOS. In a 14 yr prospective follow-up 
study involving 82,439 females, Solomon and colleagues compared women with a regular 
menstrual cycle to women reporting irregular/very irregular cycles (between 1982-1996). They 
found that women with irregular/very irregular menstrual cycles had an increased risk of 
nonfatal or fatal cardiac events, even after adjusting for age and BMI (152). Furthermore, in a 
retrospective study looking at 21,740 PCOS patients, previous data from our research group 
showed that women with PCOS were not at increased risk of large-vessel-disease, cancer, or 
death, but they had increased risk of type 2 diabetes (data extracted from the General Practice 
Research Database in the United Kingdom, assessing patients with a diagnosis of PCOS 
between 1990 and 2010 (153)). 
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1.3.12 Treatment and management of PCOS 
The main issues which arise in the management of PCOS include menstrual cycle regulation, 
control of hirsutism, fertility management and the treatment of cardiometabolic abnormalities. 
Recently, an expert panel from the Androgen Excess – Polycystic Ovary Syndrome Society 
published a consensus statement on the assessment and prevention of CVD in women with 
PCOS (76). With many possible phenotypes, the medical management of PCOS needs to be 
personalised to the patient. The expert panel stated that the medical community should be made 
fully aware that PCOS patients with obesity, dyslipidaemia, hypertension and subclinical 
vascular disease are at increased risk of CHD with those patients presenting with metabolic 
syndrome and/or type 2 diabetes at the highest risk. BMI, waist circumference, serum 
lipid/glucose, and blood pressure determinations are recommended for all women with PCOS, 
as is OGTT in those with obesity, advanced age, personal history of gestational diabetes, or 
family history of type 2 diabetes. Importantly, lifestyle management is of paramount importance 
for primary CVD prevention, whilst drugs targeting abnormal lipid profiles and hypertension 
should be prescribed if symptoms persist. Moreover, the panel also recommended insulin-
sensitising drugs if risk factors persist, in agreement with the numerous studies that have 
highlighted the integral role IR plays in the development of endothelial dysfunction in PCOS 
(76). 
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1.4 Microparticles: Mediators of cardiovascular 
disease 
Microparticle (MP) production is a curious and intriguing feature of eukaryotic cells. MPs are 
small, spherical extracellular vesicles enclosed by a phospholipid bilayer that typically occupy a 
diameter of ~30-1000 nm. In vitro studies have demonstrated that platelets, adipocytes, ECs, 
leukocytes and erythrocytes release MPs, some of which have been detected in biological fluids 
in vivo (154). Recently, MPs have received increasing attention, where they are not only 
believed to play a pivotal role in health and disease but are key research themes for potential 
diagnostic, prognostics and therapeutic applications across multiple disciplines. 
 
1.4.1 History 
The first suggestion of MPs was provided by Chargaff and West in 1946 (155). They noted that 
plasma-clotting time was prolonged if plasma underwent high-speed centrifugation or shortened 
if the centrifugation pellet was added back to plasma. However the cause of this remained 
unclear. Following this, in 1967 Wolf and colleagues detected a sub-cellular fraction using 
electron microscopy, finding small spherical vesicles (20 – 50 nm in diameter) derived from 
platelets and accordingly termed the discovery as ‘platelet dust’ (156). There were few 
observations of vesicles in biological fluids over the next couple of decades. More recently, the 
isolation of vesicles from cell culture medium gave rise to the terminology exosomes, 
microvesicles (MVs) and MPs (154). 
 
1.4.2 Nomenclature 
As a relatively new and multi-disciplinary research community, the nomenclature, clarification 
and detection of these vesicles remains abstract. Although the International Society for 
Extracellular Vesicles (ISEV) are making attempts to clarify these uncertainties, traditionally, 
cell-derived vesicles have been named according to their cellular origin. For example, 
dexosomes originated from dendritic cells; adiposomes derived from adipocytes and 
cardiosomes derived from cardiomyocytes (table 1.9).   
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More recently, these extracellular vesicles have been categorised into several classes (including 
exosomes, MVs, shedding MVs, apoptotic bodies/vesicles and MPs). These sub-classes of 
vesicles were named based on their physiochemical properties, such as size, density, lipid 
composition, sub-cellular origin (i.e. membrane derived or intracellular) and predominant 
protein markers. With such a diverse and heterogeneous nature, practically it is increasingly 
difficult to uphold one terminology over another. Also, despite recent advances, terminology 
such as exosomes, MVs and MPs have been interchanged in many published studies (154).  
 
Arguably the most common term used in the published literature is MPs. In this thesis, the term 
MP will be used unless otherwise stated. For clarification, MP is a generic term that 
encompasses all extracellular vesicles (including exosomes and MVs), which are 30 – 1000 nm 
in diameter. However, for MP biogenesis, nomenclature will reflect the terminology used in 
original manuscripts. 
 
Table 1.9 Overview of vesicle nomenclature 
 
Previously, MP classification was often based upon the MPs cellular origin. Alternatively, 
MPs are now categorised on the basis of their biogenesis pathways.  
 
Cellular origin nomenclature: 
 Ectosomes: neutrophil derived MPs 
 Cardiosomes: cardiomyocytes derived MPs 
 Adiposomes: adipocyte derived MPs 
 
More recently, different biogenesis pathways have driven changes in nomenclature. MP 
definitions based solely on MP size are not conclusive. Thus, more generalised (‘umbrella’) 
terminology such as MPs and/or extracellular vesicles is often used.  
 
Terminology Size  Sub-cellular origin  Markers 
Microparticles 
(MPs) 
30 nm – 1 µm 
Both intracellular and 
membrane derived 
- 
Exosomes 30 – 100 nm 
Exosomal classical 
pathway  
(intracellular derived) 
TSG101, CD9, Alix, 
CD81, CD63 
Microvesicles 
(MVs) 
100 nm – 1 µm 
Cell surface  
(membrane derived) 
PS exposure on surface 
Apoptotic 
bodies 
1 – 5 µm 
Cell surface  
(membrane derived) 
- 
TSG 101, tumour susceptibility gene 101; CD, cluster of differentiation; Alix, ALG-2-
interacting protein X. Adapted from (154). 
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1.4.3 Microparticle biogenesis 
MPs are released from both eukaryotic and prokaryotic cells. MP production is a natural 
phenomenon where the precise cytoskeletal events involved in the formation and release of MPs 
remain relatively unclear. Two cellular processes appear to promote this; cellular activation and 
apoptosis. Several mechanistic pathways have been implied in the biogenesis of MPs such as 
the classical exosomal pathway and membrane shedding (figure 1.6) (157).  
 
1.4.3.1 Biogenesis: classical exosomal pathway  
Exosomes are a homogeneous class of MPs that are believed to be of endosomal origin. To 
unravel the mechanisms which govern their formation, several studies have pharmacologically 
inhibited MP release in vitro by using sphingomyelinase, Na+/H+ and Na+/ Ca2+ channel 
inhibitors (158). However, this type of cellular inhibition invokes a spectrum of pleiotropic 
effects, which makes it difficult to decipher the exact mechanism that governs MP formation. 
Arguably, the classic exosomal pathway is the most widely studied mechanism for MP 
formation. It involves the formation of intraluminal vesicles within multivesicular bodies 
(MVB). MVB are formed by the invagination (reverse – budding) of the membrane. In 
comparison to other intracellular budding events (i.e. intracellular transport vesicles for the 
transport of cargo between intracellular compartments), this reverse budding is unique to 
exosomes and apoptotic bodies (154). However, it remains unclear if all the MPs formed via 
reverse budding events use common intracellular machinery. 
 
During the formation of the MVB, internalised membrane receptors/proteins are often silenced 
and degraded, a process which often requires the ubquitination of the receptor/protein. This 
post-translational modification leads to the subsequent interaction with the endosomal sorting 
complex required for transport (ESCRT) machinery. Core components of this protein complex 
include Alix (ALG-2-interacting protein X)/vacuolar protein sorting-31 (Vps31) and tumor 
susceptibility gene 101 (Tsg101) (154, 159). It is hypothesised that the presence of these 
proteins in exosomes suggests that exosome secretion could be dependent on the ESCRTs. Few 
studies have addressed the function of ESCRTs in the biogenesis/secretion of exosomes: one 
report proposed that HRS (hepatocyte growth factor-regulated tyrosine kinase substrate, an 
ESCRT-0 member) promotes exosome secretion by dentric cells (159), whereas other studies 
did not find any role for Tsg101, Alix or Vps4 in exosome formation in oligodendroglial cells 
(160). Paradoxically, Bobrie and colleagues noted that inhibition of Vps4B increases secretion 
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of exosomes (but also of soluble proteins) by major histocompatibility complex (MHC) class-II 
expressing HeLa cells (161).   
 
Buschow et al, (162) have shown that dendritic cell derived exosomes express MHC class-II 
molecules, which do not require ubiquitination (or any ubiquitinated chaperones) and 
subsequently does not rely on the ESCRT machinery. Instead, targeting of MHC class II to 
dendritic cell derived exosomes may require their sequestration in lipid domains enriched in the 
tetraspanin (CD9). Additionally, Trajkovic and colleagues demonstrated the secretion of 
proteolipid protein within exosomes derived from oligodendroglial cells, a processes which 
required sphingomyelinase-derived ceramide (160).  
 
On balance, it is fair to suggest that several proteins may play an influential role in MP 
biogenesis via the classical exosomal pathway. The formation of the intraluminal vesicles 
within MVBs has been shown to require ESCRT proteins, tetraspanins and ceramide, but the 
role and importance of all these molecules in exosome biogenesis is unclear and may vary 
depending on cell. However, the biogenesis of exosomes has been examined in different cell 
lines of differing maturity.  
Mature MVBs fuse with the plasma membrane to release their content / secrete exosomes to the 
extracellular environment. Intracellular trafficking and fusion of compartments classically 
involve small GTPases of the Rab family. Different molecules have been described in different 
cells: Rab11 is required for Ca2+ induced exosome secretion by the K562 erythroleukemia cell 
line (163), Rab35 is involved in secretion of proteolipid protein-enriched exosomes by 
oligodendroglial cells (160), and Buschow et al, (162) have shown that Rab27A and Rab27B 
play complementary roles in spontaneous secretion of MHC class-II bearing exosomes by 
HeLa-CIITA cells. 
The final step of exosome release involves the fusion of MVBs with the plasma membrane and 
expulsion of exosomes. This process is likely to involve a specific combination of soluble 
attachment protein receptor (SNARE) proteins (a membrane bound, multi subunit protein 
complex) (161, 164). However, the exact SNARE machinery involved remains unclear. 
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Figure 1.6. Microparticle biogenesis.  Cells release microparticles (MPs) via two mechanisms. 
(i) The classic exosomal pathway involves the formation of intraluminal vesicles (ILVs) within 
multivesicular bodies (MVBs). In turn, the membrane of MVB fuses with the plasma 
membrane, resulting in the release of ILVs. When secreted, ILVs are called exosomes or MPs. 
(ii) The direct (membrane budding) pathway involves the release of vesicles directly from the 
plasma membrane. Adapted from (161). 
 
1.4.3.2 Biogenesis: membrane budding  
Plasma membranes consist of numerous proteins embedded in a double layer of phospholipids. 
During normal physiological conditions, phospholipids take up an asymmetrical distribution in 
eukaryotic cells, whereby the outer leaflet is enriched in phosphatidylcholine (PC) and 
sphingomyelin and the inner leaflet predominantly consists of phosphatidylserine (PS) and 
phosphatidylethanolamine (PE). Taken together, this serves as a semi-selective permeable 
membrane. 
This alignment of membrane phospholipids is the result of active regulation of phospholipid 
asymmetry. Floppase, an adenosine triphosphate (ATP)-dependent membrane associated 
protein, specifically mediates the rapid preclusion of PS to the outer membrane leaflet and is 
directly responsible for the disruption of membrane asymmetry when cells are activated (165). 
Concomitantly, flippase, also an ATP-dependent membrane associated protein, mediates the 
translocation of amino-phospholipids from the outer to the inner plasma membrane leaflet 
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(166). In addition, scramblase plays an important role in the maintenance of lipid randomisation 
across the plasma membrane. Scramblase activation results in non-specific, bidirectional 
movement of membrane phospholipids. In turn, phospholipids on the inner leaflet are readily 
transferred to the outer plasma membrane leaflet and vice versa (154, 167, 168).  
MVs (80-1000 nm) are another sub-class of MPs that are released directly from the plasma 
membrane during cellular stress. It is assumed that MVs form when the asymmetrical 
distribution of lipids between the inner and outer plasma membrane leaflets is compromised. 
When cells are activated or undergo apoptosis, the preclusion of PS to the outer leaflet is one of 
the first indicators of these processes. The externalisation of PS to outer leaflet of the membrane 
is the initial event that subsequently leads to the shedding of MVs. The cytoskeletal events that 
permit MP formation and detachment from the plasma membrane remain uncertain. Although 
likely to be cell specific, many studies to date have explored mechanisms governing MV 
biogenesis (membrane shedding) and show cells may share common cellular machinery (169).  
 
The activation of a cell, often initiated by a variety of extracellular stimuli/agonists, is known to 
promote the formation of MPs. Monocytes, ECs and platelets have been shown to release MPs 
upon activation from stimuli such as TNFα and lipopolysaccharides (LPS). Cellular activation 
involves a rapid increase in cytosolic Ca2+ concentration, specifically at the membrane shedding 
microenvironment. This release of activated-cell associated MPs has been shown to be Ca2+ 
dependent. Mechanistically, elevated cytosolic Ca2+ activates kinases, inhibits phosphatases and 
induces calpain activation. Calpain, a Ca2+-dependent thiol protease, is known to play an 
integral role in platelet MV formation. Ex vivo studies show that thrombin-induced platelet MV 
formation was inhibited when platelets were treated with calpeptin (a known calpain inhibitor) 
(170). Conversely Wiedmer et al, (171) did not see any inhibition of platelet MVs when 
inhibiting calpain, however this experiment used a different calpain inhibitor (leupeptin) which 
has been reported to poorly penetrate membrane bilayers. In addition, it has been suggested that 
MV formation in platelets in a resting state involves glycoprotein IIb/IIIa signalling, 
subsequently leading to destabilisation of actin filaments and MVs budding off the cellular 
membrane (172). Once the cellular cytoskeletal structure is destabilised and the budding 
sequence is initiated, caspases (cytoplasmic proteases) and calpain are responsible for the 
proteolytic cleavage of the MP from the cytoskeletal proteins (including filamin-1, talin and 
myosin).  
 
In vitro studies involving a T-lymphocyte cell line have demonstrated that caspase 3 mediates 
the cleavage of ROCK I, a Rho Kinase protein subunit that induces cell membrane contraction 
by myosin light chain phosphorylation (168, 173). Moreover, Sapet et al (174) have identified 
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that several cytoskeletal proteins are related to thrombin induced MP release in ECs. These 
proteins include the Rho kinase subunits; ROCK I and II. These findings are in accordance with 
previous reports such by Tramontano and co-workers who stated that Rho activation was pivotal 
in the generation of endothelial MPs (EMPs) during inflammation. Inhibition of Rho kinase 
activity by lovastatin and the Rho-kinase inhibitor Y26732 also decreased MP formation in ECs 
(173, 175). Collectively, although the exact mechanism governing MP formation (via 
membrane budding/shedding) is not fully clear, several proteins are known to play a crucial role 
in their development.  
 
1.4.4 Annexin V positivity  
Most studies support the principle that cells release MPs following the collapse of the plasma 
membrane asymmetry and subsequent preclusion of PS to outer leaflet of the membrane bilayer. 
However, the presence of this externalisation of PS on the surface of MPs is a matter of much 
debate.  
 
Numerous in vivo studies have shown that the MPs in the circulation are both PS positive and 
PS negative. This is commonly measured by the extent of annexin V binding, which indicates 
PS exposure and to a much lesser extent PE exposure. Connor et al, (176) found that, 80% of 
MPs derived from resting platelets (obtained from healthy subjects) failed to bind annexin V. 
Furthermore, altering the assay constituents (such as buffer, calcium and annexin V 
concentration) did not affect the degree of annexin V binding. Interestingly, this study did show 
that the proportion of annexin V positive MPs was dependent upon the agonist/stimuli, with 
physiological stimuli such as collagen resulting in fewer annexin V binding MPs than non-
physiological stimuli such as Ca2+ ionophore. Conversely, other studies have shown that 
annexin V MPs occupy the vast majority of circulating MPs (>70%) (177).  
 
Uncertainty also exists as to whether MPs formed via the classical exosomal pathway exhibit PS 
on their surface. Using immunogold labelling electron microscopy (EM), Heijen et al, (178) 
found that annexin V was not detected on the isolated platelet exosomes. In contrast, other 
studies have shown that exosomes expose PS and fuse with target cells in a PS-dependent 
manner, a process that was inhibited when exosomes were pretreated with annexin V (179).  
 
Functionally, the extent of annexin V positivity may be great importance in multiple 
pathological conditions. Of note, Sinauridze and colleagues found that the surface of a platelet 
derived-MP (PMP) is ~50 - 100-fold more procoagulant than the surface of an activated platelet. 
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Moreover, other studies have shown circulating annexin V positive MPs is associated with 
endothelial dysfunction and cardiovascular events (180).   
 
The nature of annexin V negative MP release is poorly understood. It is hypothesised that they 
represent basal tissue homeostasis. The difference between activated cell derived MPs and MPs 
derived from resting cells are not only differences in the external phospholipid profiles, but the 
array of bioactive cargo that is transported in the MPs. However, the methodological approach 
and pre-analytical protocols may play a crucial role in such discrepancies between studies and 
may partly account for the confusion as to the extent of annexin V positivity in MPs.  
 
1.4.5 Microparticle isolation and characterisation 
Accurate qualitative and quantitative analysis of MPs is of great value, but the current 
methodologies employed for the isolation, characterisation and quantification of MPs are far 
from standardised and contain a number of technical hurdles that have been shown to 
generate/manipulate MP number and function. Thus, the need for a consensus on both MP 
nomenclature and methods for isolation, identification and quantification has accelerated over 
the last 5 years and is a major goal for the ISEV. A motion to support this consensus will 
improve vital aspects for future MP research, as the current lack in methodological clarity 
obfuscates MP identification, renders inter-study comparisons troublesome and hinders the 
molecular elucidation of their biogenesis and physiological function. 
 
1.4.5.1 Pre-analytical protocols: Isolation 
MPs have been successfully isolated from various biological fluids and cell culture medium. 
Pre-analytical protocols have been extensively discussed in a review by Théry and colleagues 
(181). Most published studies have employed ultra-centrifugation based protocols for the 
isolation of MPs. This procedure is based upon the ability of the centrifugation force to 
sediment matter based on size and density, where larger and denser components migrate away 
from the axis of the centrifuge and vice versa for smaller, less dense components. Differential 
ultra-centrifugation involves sequential centrifugation steps with the aim of separating smaller 
and less dense constituents at each step. However, there is much variation in ultra-centrifugation 
protocols and this approach may also isolate a complex assortment of non-MP material. 
Arguably, this problem is more troublesome in biological fluids (i.e. plasma) than cell culture 
medium. The removal of cells from biological fluids is also challenging, where apoptotic bodies 
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and even platelets can often overlap in size with MPs in a viscous and dense fluid such as 
plasma. Additionally, it has been proposed that ultra-centrifugation itself may activate cells and 
in turn induce MP production during the isolation protocol. Additionally, the washing of MP 
pellets has been shown to reduce MP concentration, where studies have shown between 20-60% 
of PMPs are lost with every wash step (182). 
Recently, Boing et al, (183) demonstrated that MPs could be purified from platelet poor plasma 
(PPP, healthy subjects) by sepharose CL-2B size exclusion chromatography. This approach 
allowed MPs to be separated from proteins and HDL-cholesterol. It is however unclear if this 
approach has any effect on MP function and needs to be fully explored in differing biological 
fluids. During the latter stages of my research, MP isolation by size-exclusion chromatography 
has received increasing attention. However, preliminary data on size-exclusion chromatography 
from our laboratory and other laboratories (Dr Aled Clayton, Velindre hospital - Cancer 
Research Wales) have failed to repeat findings described by Boing and colleagues, where in our 
hands, MPs and protein co-elute with only modest separation (unpublished observations). Table 
1.10 summarises MP isolation protocols.  
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Table 1.10 Differing pre-analytical protocols 
Blood collection Plasma processing Sequential centrifugation steps Reference 
Anticoagulant Centrifugation 
(g) 
Time (Min) Temp (°C) Centrifugation (g) Time (Min) Temp (°C) 
EDTA 1,200 20 4 100,000 x 2 60 4 (184) 
Citrate 700 15 RT 13,000 x 2 60 RT (185) 
Citrate 2,750 10 n/a - - - (176) 
n/a 1,500 15 n/a 13,000 
18,000 
2 
20 
n/a 
 
(186) 
Citrate  1,550 15 n/a 1,300 60 n/a (187) 
EDTA  1,550 20 20 17,500 60 20 (188) 
Citrate 1,500 15 n/a 13,400 120 n/a (189) 
EDTA 270 20 n/a 1,500 
21,000 
20 
45 
n/a (190) 
Citrate 11,000 2 n/a 13,000 45 n/a (191) 
Cells (in vitro) 
Medium 4,300 5 n/a 100,000 90 10 (187) 
Medium 400  5 n/a 2,000 
10,000 
100,000 x2 
15 
40 
60 x 2 
n/a (182) 
Medium 2,000 10 n/a 100,000 120 4 (192) 
Medium 300 10 n/a 2,000 
10,000 
100,000 
10 
30 
70 
n/a (193) 
EDTA, ethylenediaminetetraacetic acid; n/a, not applicable refers to information not stated; RT, room temperature.  
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1.4.5.2 Pre-analytical protocols: Storage 
It is impractical to immediately undertake a comprehensive assessment of MPs from clinical 
studies in which there may be several time points in succession and a large subject cohort. Thus 
the storage of MPs is of fundamental importance for clinical studies. To date, several cryo-
preservation protocols have been described in the literature. Mobarrez and colleagues 
demonstrated that the number of PMPs increased 10-fold in frozen/thawed PPP compared to 
freshly analysed PPP, where phalloidin (binds to actin filaments) was used to detect fragmented 
cell debris (194).  
Furthermore, the number of annexin V positive MPs (MPs bearing PS on their surface) also 
increased 10-fold with freezing compared to fresh sample, even when various methods of 
preservation were utilised (such as dimethyl sulfoxide, trehalose and paraformaldehyde) (195). 
In our laboratory, Connolly et al, (196) recently compared different freezing protocols and 
investigated the effect of time-in-storage on MP size and concentration. Storage time, regardless 
of method (freezing protocol) significantly increased MP concentration, suggesting samples 
should be analysed fresh whenever possible.  
 
1.4.5.3 Qualitative and quantitative methods of 
microparticle analysis 
Once the pre-analytical protocols have been chosen, researchers have a growing number of 
techniques to choose from for quantitation and characterisation of MPs. In contrast to the 
viewpoint proposed by many who claim one particular technique should be considered the gold-
standard, currently there is no gold-standard technique used for the identification of MPs, with 
each technique harbouring its own advantages and limitations.  
 
Numerous methods for the detection of MPs have been employed including flow cytometry, 
EM and enzyme linked immunosorbent assay (ELISA). More recently, novel techniques such as 
nanoparticle tracking analysis (NTA) and tuneable resistive pulse sensing (TRPS) have allowed 
more accurate quantification of vesicles, which were typically non-detectable by other methods. 
Each method of detection has certain limitations and advantages, thus the choice of technique 
used depends on the particular research question. Arguably, the greatest limitation in the MP 
field is the pre-analytical protocol for isolation and storage, whereas, the techniques employed 
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for MP quantification reflect advances in current scientific understanding and capabilities of 
methodology (154).  
 
Van der Pol et al, (154) reported the magnitude of this problem and suggested the  differing pre-
analytical protocols and techniques, each with their own limitations and respective detection 
limits, that plasma MP concentrations range from 1 x 103 /ml to 1 x 1014/ml.  
 
1.4.6 Microparticle composition 
MP membranes consist of mainly lipids and proteins. The exact composition is variable and 
depends upon the cellular origin and cellular stimuli. Numerous MP cell origins have been 
described in the circulation, including erythrocyte, platelet, endothelial and leukocyte-derived 
MPs (LMPs). During their biogenesis, MPs engulf an array of bioactive cargo from their 
parental cell. This cargo includes genetic information in the form of mRNA and microRNA 
(miRs), bioactive free fatty acids (FFAs) and protein. The bioactive cargo can reflect the 
stimulus which triggered MP formation (197), suggesting specific packaging of “message” prior 
to export from the parent cell. Following secretion, MPs may shuttle around this cargo, and can 
initiate a spectrum of cellular interactions that are now regarded as a novel means of cell-cell 
communication but also the potential for endocrine communication between organs/tissue 
locations (198).  
 
1.4.6.1 Microparticle composition reflects stimuli 
In vitro studies have demonstrated that the protein and RNA levels in exosomes secreted by ECs 
reflects the culture and medium conditions and physiological / pharmacological / pathological 
stimulus that triggers MP release (197). This suggests that ECs may secrete MPs as a means of 
coping with cellular stress. Moreover, during their biogenesis, MPs become enriched with an 
array of surface antigens. Identification of such antigens with a cocktail of antibodies is often 
used to determine the MPs parental cell. However, certain antigens are believed to be 
constitutively expressed and are not affected by stimuli or apoptotic status of the parental cell. 
For example, antigens such as CD144 (VE-Cadherin); CD11b and CD41 are commonly used 
antigens for endothelial, monocyte and platelet-derived MPs, respectively. Additionally, EMPs 
can be detected using markers against CD54 (ICAM-1), CD106 (VCAM-1), CD61E (E-
selectin), CD62P (P-selectin) and TF. The presence of such antigens may dictate their fate, 
govern target cell interaction and ultimately their biological function. The degree of expression 
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of such antigens is believed to reflect parental cells activation/apoptotic status. Interestingly, 
CD54, CD62 and CD106 expression on MPs is known to reflect inflammatory activation of 
ECs. Additionally, MPs derived from apoptotic ECs have been shown to exhibit CD31 
(PECAM-1) and CD62P. In comparison, CD51 (intergrin alpha5) and CD54 are preferentially 
expressed on activated EMPs (199).  
 
1.4.7 Microparticle-mediated biological effects: cell-cell 
communication  
MP–target cell interaction is likely to be cell and MP specific. Emerging evidence has 
demonstrated integrin activation, PS-dependent internalisation of MPs, IL-1 receptor activation, 
sonic hedgehog signalling, FFA transfer and miR transfer as possible mediators of MP-induced 
biological effects (169). However the precise mechanisms by which MPs interact with cells and 
induce functional responses remain unclear. 
 
Terrisse et al, (200) found that fluorescently labelled human umbilical vein endothelial cells 
(HUVEC)-derived MPs were internalised as intact vesicles in HUVECs. Furthermore, confocal 
microscopy images suggested that MPs did not localise with markers of early or late 
endosomes.  
Diehl et al, (201) demonstrated a different mode of action for MP–target cell interaction. They 
reported that MPs fuse with target cells and off load their bioactive cargo (miRs), which in turn 
alters the transcriptome potential of the target cell. In accordance, Hergenreider et al (202) 
recently demonstrated that ECs and SMCs communicate via exosomes that are enriched with 
miR – 143 / 145. These miRs regulate Krüppel-like factor 2 (KLF2), a transcription factor 
involved in a cardio-protective phenotype within ECs. They showed that these miRs are 
transferred to SMCs acting on miR targets and prevent SMC differentiation. In contrast, another 
study investigating the physical interaction between MPs and ECs, found that MP–target cell 
interactions is restricted to phospholipid surface interaction only. Furthermore, Burger and 
colleagues loaded HUVEC derived-MPs with carboxyfluorescein diacetate succinimidyl ester 
(CFSE, a non-fluorescent cell permeable compound that fluoresces when exposed to 
intracellular esterases). They found little evidence to suggest that CFSE labelled-MPs fuse with 
target cells to offload their bioactive cargo, as CFSE was undetectable in target cells (203).  
Collectively there are many schools of thought regarding MP-cell communication. Thus, with 
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such variation, MP-cell interaction is likely to be MP and cell specific.  
1.4.8 Microparticle clearance 
In contrast to their biogenesis, much less is known about the mechanisms of MP removal. On 
the basis that MPs have been found to be engulfed by phagocytic cells in vitro (204), it is 
postulated that phagocytosis is the principle mechanisms governing MP elimination in vivo. In 
this regard, Willekens et al, (205) injected chromate (Cr)-labeled erythrocyte-derived MP into 
the inferior vena cava in rats and demonstrated that MPs are taken up by cells of the reticulo-
endothelial system in vivo. The phagocytosis and interaction of MPs is thought to be chiefly 
governed by externalised PS, which may signal scavenger receptors, to promote endocytosis of 
MPs (200, 205). PMPs have been shown to be endocytosed and internalised in HUVECs, 
suggesting a role for EC clearance of MPs (206). In accordance with this, Dasgupta and 
colleagues noted that developmental endothelial locus-1 (Del-1), an EC membrane associated 
protein, was pivotal in this process. Inhibition of Del-1 prevented MP uptake/endocytosis in 
ECs in vitro and in vivo in mice deficient in Del-1 (207). 
 
1.4.9 Cellular functions of microparticles 
MPs, by mechanisms that remain controversial, can transfer biological information between 
cells, in turn acting as potent endocrine signalling vectors. MPs have been reported to play a 
pivotal role in several pathological conditions, such as inflammation, metastasis, thrombosis and 
endothelial dysfunction. The cellular effects of these biological vectors depend on their 
composition – (both membrane and cytoplasmic) and of course, the nature of the target cell. 
 
MPs, being encased in a phospholipid bilayer themselves, provide an additional procoagulant 
surface for the assembly of the clotting enzyme complexes promoting thrombin generation. It 
has been proposed that their catalytic property relies on the exposure of the negatively charged 
PS on the outer bilayer, arguably a key characteristic for MP identification, which increases the 
potency of target cell interactions. For example, increased exposure of PS on the surface of 
PMPs renders their surface ~50 – 100 fold more procoagulant than the surface of activated 
platelet membranes (180) (figure 1.7). 
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Figure 1.6. Schematic representation of an endothelial derived-MP and the associated 
biological effects. EPCR indicates endothelial protein C receptor; PECAM-1, platelet 
endothelial cell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, 
intercellular cell adhesion molecule-1; E-selectin, endothelial selectin; VE-cadherin, vascular 
endothelial cadherin; eNOS, endothelial NO synthase; MMP, matrix metalloproteases; uPA, 
urokinase plasminogen activator; EPC, endothelial protein C; TM, thrombomodulin; TF, tissue 
factor; mRNA, messenger ribonucleic acid; miR, micro ribonucleic acid. Adapted from (167). 
 
1.4.9.1 Inflammation and adhesion 
MPs are involved in a variety of proinflammatory activities that may contribute to the 
pathophysiology of CVD. Notably, MPs have been shown to promote the adhesion, rolling and 
migration of leukocytes, harbour proinflammatory cytokines and initiate the further release of 
MPs in target cells in vitro (187, 208-211).  
Forlow et al, (212) found that PMPs can enhance the binding of neutrophils to other neutrophils 
pre-bound to the surface of a flow chamber. The molecular mechanism for this phenomenon 
appears to be an interaction between P-selectin on PMPs and P-selectin glycoprotein ligand-1 
on neutrophils, since administration of blocking antibodies against these surface molecules 
abrogates the effects of PMPs. Furthermore, PMPs have been shown to promote cell–cell 
contact by inducing adhesion molecule expression (209). 
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Membrane associated receptors and surface adhesion molecules enable crosstalk between MPs 
and target cells. In vitro studies indicate that MPs can fuse and pass this fatty acid biosignature 
into target cells, where it can alter cellular lipid metabolism and subsequent lipid-mediated cell 
signalling. Barry and co-workers (213)found that PMPs induce platelet activation through the 
transfer of arachidonic acid (C20: 4n6) (213). Arachidonic acid was shown to propagate pro-
inflammatory effects by its subsequent metabolism to thromboxane. Moreover, in these studies, 
the transfer of arachidonic acid also stimulated the expression of cyclooxygenase-2 (COX-2) 
and the production of prostaglandins in ECs, a state which was mimicked by the direct 
treatment of arachidonic acid. To date, little is known about the lipid content of circulating MPs, 
although Fourcade et al (214) found differences in lipid composition between synovial fluid 
MPs from patients with arthritis compared to MPs from healthy controls. 
In addition to PMPs, MPs released from various cell types can demonstrate proinflammatory 
properties. EMPs have been shown to harbour tissue factor (TF), a potent initiator of the 
coagulation pathway (187). The thrombin generating capacity of EMPs was first demonstrated 
using primary HUVECs, by the reduction of the clotting time of normal plasma incubated with 
increasing amounts of EMP released in vitro. The thrombogenic capacity of EMPs was 
confirmed via a thrombin generation assay where EMPs initiated TF-dependent thrombin 
formation in vitro and thrombus formation in vivo (rat thrombosis model) (215). 
Moreover, TF-positive EMPs expressing endothelial adhesive molecules can bind to other cell 
types, such as monocytes, and transfer their bioactive TF in vitro (216). EMPs have been 
demonstrated to express surface adhesive molecule profiles similar to those expressed by 
activated ECs (216). Expression of endothelial antigens by THP-1 (monocyte) cells incubated 
with EMP was shown by immunoperoxidase staining and flow cytometry using antibodies 
directed against E-selectin, VCAM-1, and endoglin. EMP binding to THP-1 cells following a 4 
hour EMP treatment, (50:1, EMP:THP-1) led to an increase in THP-1 procoagulant activity 
(determined by a clotting assay). Concomitantly, THP-1 exhibited elevated TF antigen levels 
and TF mRNA compared to control cells. Interestingly, the ability of EMPs to promote THP-1 
procoagulant activity was restricted when THP-1 cells were incubated with ICAM-1 and β2 
integrin blocking agents. This, suggests that EMPs interact with THP-1 cells in vitro and 
stimulate TF-mediated procoagulant activity that is partially dependent on the interaction of 
ICAM-1 on EMP and its counter receptor, β2 integrins on THP-1 cells (216). 
In human aortic ECs, Curtis and colleagues found that EMP release was positively correlated 
with IL-6 release, thus postulating a relationship between MP generation and cytokine 
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production (217). Additionally, this interaction triggers elevated ICAM-1 mRNA expression 
and increased secretion of sICAM-1 in targeted unstimulated ECs. Interestingly, the functional 
effects of EMPs was influenced by conditions of generation (the stimulus), whereby non-TNF 
induced MPs exerted no effect.  
In vitro studies have shown that polymorphonuclear leukocyte (PMNL)-derived MPs modulate 
EC activation and IL-6 release (208). In contrast to other studies, Mesri and coworkers observed 
that in response to blockage of adhesion molecules to β2 integrin, ICAM-1 or TNFα did not 
reduce IL-6 release. Furthermore, MPs did not activate nuclear factor- κB (NF-κB) or 
extracellular-signal-regulated kinases (ERK-1) signalling pathways (208). 
Contrary to the bulk of MP literature, other studies have shown that MPs may have either no 
impact on target cell inflammation or even exhibit anti-inflammatory effects. Neutrophil-
derived MPs exerted no pro-inflammatory activity on human macrophages as assessed by the 
release of IL-8 and TNFα. Furthermore, Gasser and Schifferli, (218) noted that LPS-induced 
pro-inflammatory cytokine secretion (TNFα, IL-8, and IL-10) was significantly reduced in ECs 
pre-treated with neutrophil-derived MPs. This effect was observed in a dose-dependent manner. 
In addition, MPs derived from formyl-methionine-leucine-phenylalanine (fMLP) stimulated 
neutrophils up-regulated the expression of the anti-inflammatory cytokine transforming growth 
factor β1 (TGFβ1) in macrophages (218), in turn suggesting that MPs down-regulate cellular 
activation in macrophages. Methodologically, several notable differences between this study 
and others might have influenced the results. For example, Gasser and Schifferli (218), 
stimulated their neutrophils for 20 minutes, whereas in other studies, stimulation periods have 
been for 24 hours. Furthermore, by collecting and using the MPs generated from a short 
stimulation period, Gasser and Schifferli may have selected MPs released early after 
stimulation, which might differ (compositionally / functionally) from MPs released at later time 
points. However, this remains unconfirmed. Additionally, all these studies have all employed 
different pre-analytical protocols and quantitatively determined MP amount using different 
techniques, making inter-study comparisons difficult.  
 
1.4.9.2 Microparticles and endothelial dysfunction 
In vitro studies have shown that EMPs impair acetylcholine-induced vasodilatation and decrease 
NO production by aortic rat vessels in a concentration-dependent manner. Concomitantly, the 
reduction in NO was coupled with an increase in O2- production. Moreover, Brodsky et al, 
(219) noted the presence of the p22phox subunit of NADPH-oxidase in EMPs. Interestingly, 
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when EMPs were pre-incubated with SOD, endothelial function was improved, in turn 
suggesting that EMPs induce EC dysfunction via ROS (203).  
 
Ex vivo studies provide evidence that MPs isolated from patients with acute MI can cause 
significant endothelial-dependent impairment of rat aorta vessels. This impairment was not 
affected by diclofenac or the SOD mimetic Mn(III)tetra(4-benzoic acid) porphyrin chloride. No 
difference was noted in endothelial-independent relaxation (to sodium nitroprusside) or in EC 
eNOS expression (191). These data indicate that circulating MPs from patients with an acute MI 
selectively impair the endothelial NO transduction pathway. 
Similarly, ex vivo treatment of ECs with MPs from patients with metabolic syndrome resulted in 
decreased eNOS expression and consequently decreased NO production. Interestingly, a 
reduction in O2- and an increase in protein tyrosine nitration were also noted in ECs treated 
with MPs from patients with metabolic syndrome, but not from MPs from healthy controls. MPs 
from both groups did not affect the inflammatory status of ECs. However, in vivo injection of 
metabolic syndrome patient-derived MPs into mice impaired endothelium-dependent relaxation 
and decreased eNOS expression (220). 
 
In contrast to the majority of studies, Agouni et al (221) found that MPs derived from human 
lymphoid T cells harboured the morphogen sonic hedgehog (Shh). Previously, Shh has been 
shown to be involved in erectile dysfunction, a state associated with a reduced NO production. 
Moreover, eNOS and VEGF are established downstream targets of exogenous Shh signalling. In 
this study, treatment of HUVECs with T cell-derived MPs resulted in increased NO release and 
triggered increased phosphorylation of eNOS enzymes and reduced ROS production. In 
addition, in vivo injection of T cell-derived MPs in mice (10 µg/ml blood) was also able to 
improve endothelial function. Mouse blood, aorta, and lung tissue exhibited a greater NO-Fe2+ 
diethyldithiocarbamate Fe(DETC)2 electron paramagnetic resonance (EPR) signal in mice 
treated with MPs than in control mice. This enhanced NO production by MPs provided cardio-
protective properties. Endothelial dysfunction, initiated by an ischaemia reperfusion insult, was 
entirely reversed by the administration of MPs 24 hours prior to ischaemia, showing that MPs 
may serve as cardio-protective vectors against endothelial injury. These findings were also 
abolished when Shh was silenced, suggesting Shh was central to this protective mechanism 
(221). Supporting this, other studies have investigated chronic (21 days) in vivo treatment with 
Shh bearing MPs in mice. Following an ischaemic insult, Benameur and colleagues showed that 
the recovery of the blood flow was 1.4 fold higher in MPsShh+ treated mice than in controls and 
that this was associated with an increase in NO production in both aorta and muscles (222). 
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A later study from the same research group, also looking at T cell-derived MPs displayed 
conflicting results (223). In contrast to Agouni and colleagues (221), this more recent study 
demonstrated that ECs treated with MPs demonstrated a decreased NO production. 
Furthermore, MPs enhanced ROS production by a mechanism sensitive to xanthine oxidase. 
Also, in vivo injection of MPs (10 μg/ml) in mice impaired endothelial function.  
 
On balance, there is a burgeoning awareness that MPs may play an important role in the 
pathogenesis of endothelial dysfunction and a spectrum of CVD entities. Studies have shown 
that MPs not only harbour ROS but can induce an oxidative burden in target cells.  However, 
when interpreting the above studies it is important to consider that the studies mentioned used 
different MP-target cell/vessel incubation times, ranging from 3-24 hours. Additionally, pre-
analytical protocols and cellular stimuli also differed between studies. 
 
1.4.10 Apportion of circulating microparticles in vivo 
MPs have been detected from a variety of biological fluids, including urine, seminal fluid and 
synovial fluid. By far the greatest research has focused on circulating MPs, where erythrocyte, 
leukocyte, platelet and endothelial-derived MPs have been detected. However, there is much 
variation in the reported origin and apportion of circulating MPs in plasma. 
 
Methodologically, although ELISA, immunofluorescence and immunogold labelling (EM) have 
been employed, arguably the most established means of determining MP origin is by flow 
cytometry, using antibodies against specific parental cell markers. This presents several 
limitations. It is well established that cytometric analysis of MPs struggles to capture the entire 
MP spectrum, whereby many circulating MPs fall below the detection limit of conventional 
flow cytometers (limitations of flow cytometry furthered discussed in chapter 7). 
 
In a recent study looking at 6 healthy volunteers, the majority of circulating MPs were observed 
to be of erythrocyte origin (37.5%), whilst PMPs occupied 24.3%, LMPs occupied 12% (of 
which 3.4% were monocyte derived) and 6.6% of circulating MPs were from endothelial origin. 
Additionally, in this study the MP concentration for platelet poor plasma (PPP)-derived MPs 
was ~2.5 × 106 / ml (224). Conversely, Shah et al (225) found higher percentages of endothelial 
and monocyte-derived MPs in healthy subjects (43% and 10.4%, respectively), which may 
reflect different methodologies and pre-analytic protocols. However, most studies report that 
MPs derived from platelets are the most abundant. 
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1.4.11 Microparticles in disease 
In addition to playing a fundamental role in CVD, MPs have been implicated in a diverse 
spectrum of pathological conditions. Arguably, the most widely researched discipline of MPs 
falls within cancer. In cancer, MPs have been shown to play an important role in tumor 
metastasis and tumor angiogenesis. Tumour derived MPs have been shown to harbour and off-
load oncogenic cargo in non-cancerous cells, propagating the cancer’s pathology (226). 
Increased levels of EMPs and PMPs have been detected in the serum of patients with multiple 
sclerosis (227). Also, circulating MPs have been found to be increased in several infectious 
diseases including sepsis regardless of the causative pathogen. Of interest, in highly contagious 
disorders such as Ebola, the overexpression of TF from monocytes/macrophages is recognised 
as a primary event in the haemorrhagic and thrombotic complications. In non-human primate 
models, TF-bearing MP production was increased following Ebola infection (228). MPs derived 
from T cells are elevated in other infectious diseases such as HIV (229). Also, MPs have been 
shown to be pivotal in malaria, where the knockdown of ATP-binding cassette transporter-1 
(ABCA1), a lipid transporter implicated in MP biogenesis in transgenic mice, protects from 
severe malaria and is associated with lower MP levels in plasma (230, 231). Table 1.11 
highlights diseases where circulating MPs levels are elevated. 
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Table 1.11 Diseases where circulating microparticles are increased 
Disease  MP population increased 
Acute coronary syndrome Total, EMPs, PMPs 
T2DM Total, PMPs 
Hypertension PMPs, EMPs 
Inflammatory disorders PMPs 
Pre-eclampsia LMPs 
Lupus anticoagulant EMPs 
PCOS Total, PMPs 
Stroke EMPs 
Metabolic syndrome Total 
Total, total microparticle (MP level); EMPs, endothelial derived-MPs; PMPs, platelet derived-
MPs (PMPs); LMPs, leukocyte derived-MPs. Adapted from (157). 
 
1.4.12 Microparticles in cardiovascular disease 
The multifactorial nature and complex pathophysiology of CVD and the development of 
endothelial dysfunction and atherothrombotic complications involves numerous interactions 
between multiple cell types and tissues. A recent focus in the field is on the role of circulating 
MPs in EC damage, hypercoagulability and inflammation.  
MPs appear to play an important role in the pathogenesis of CAD, where MPs derived from 
monocytes and lymphocytes have been found in atherosclerotic plaques (232). Also, in addition 
to acute coronary syndromes and stable CAD (233, 234) increased number of MPs have been 
identified in risk states for CVD, such as diabetes mellitus (234) and hypertension (235). 
Specifically, EMPs (CD144/CD31/CD51 and annexin V positive) were increased in diabetic 
patients. Furthermore, circulating EMPs have been correlated with the presence of non-calcified 
coronary plaques in diabetic patients (236). Several studies have also demonstrated that diabetic 
patients have increased circulating LMP and PMP levels. Studies in type 1 diabetics found that 
patients present with increased levels of PMPs and EMPs, whilst patients with type 2 diabetes 
have increased levels of PMPs (237). 
Additionally, EMPs appear to be sensitive to even modest haemodynamic changes in 
hypertension, where increases in EMPs rise in proportion to elevations in pressure (238). 
Interestingly, TF-bearing MPs are increased in patients with hypertension (239). Notably, 
pulmonary hypertension is associated with an increase in circulating MPs derived from 
platelets, leukocytes and ECs (240). However, Amabile and colleagues found that increased 
EMPs (CD62P positive) but not LMPs predicted adverse clinical events in patients with 
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pulmonary hypertension in a prospective 12 month follow up study. Also, PMPs have been 
correlated with diastolic blood pressure (241). 
Further evidence for a potential role in CVD pathogenesis comes from observations of increased 
numbers of MPs during inflammatory states in vivo (240). To date, the question of whether 
antithrombotic therapy has any impact on plasma MP levels in hypercoagulable conditions has 
not been answered. One study examining PMPs in atrial fibrillation, reported that treatment with 
aspirin and/or warfarin had no effect on MP count or function (242). However whether 
antithrombotic therapy has an effect on MP levels in other hypercoagulative states remains 
unclear. Current US based clinical trials are on-going, investigating the impact of ticagrelor, an 
anti-coagulant drug on circulating MPs in patients with heart disease (243).  
Circulating MPs harbor eNOS. In patients with CAD, endothelial dysfunction was associated 
with an increase in the total number of circulating MPs as well as a significant decrease in the 
expression and activity of eNOS in MPs (244). However, no difference in ROS was noted in 
MPs isolated from CAD patients and the control group. In one study looking at 44 patients with 
end-stage renal failure, Amabile and colleagues noted that circulating levels of annexin V 
positive MPs were increased compared with 32 healthy subjects (245). However, only EMPs 
correlated with elevated FMD, increased aortic and increased carotid artery augmentation index. 
Interestingly, PMPs, erythrocyte-derived MPs and annexin V positive MP levels did not 
correlate with measures of endothelial dysfunction. Furthermore, in vitro studies have shown 
that MPs derived from patients with end-stage renal failure, impaired endothelium-dependent 
relaxation and cGMP generation, whereas MPs from healthy control subjects did not (245). 
 
In another study, increased MP levels were positively correlated with impairment of coronary 
endothelial function. Moreover, increased MP counts were able to predict severe endothelial 
dysfunction independent of classic CVD risk factors, such as hypertension, 
hypercholesterolaemia, diabetes, age and sex (246).  
 
1.4.13 Scott syndrome 
There is a vast amount of literature suggesting MPs play a detrimental role in disease pathology. 
However, MP biogenesis remains a natural phenomenon and is a process that happens in 
virtually all prokaryotic and eukaryotic cells. The physiological importance of MPs is perhaps 
best illustrated by Scott syndrome, a rare autosomal recessive disorder of platelet coagulant 
activity. It is characterised by a rare inherited defect of lipid scramblase within the membrane of 
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platelets. Consequently, the underlying defect is an inability to generate scramblase and regulate 
membrane symmetry. In turn, this results in reduced PS expression/externalisation and reduced 
MP production. The ability to activate prothrombin is impaired and patients with the syndrome 
exhibit severe bleeding (169).  
 
1.4.14 Microparticles in polycystic ovary syndrome 
MPs have been implicated in several CVD entities, which are linked to PCOS. However, to 
date, little is known about circulating MPs in PCOS. Koiou et al (186) found that circulating 
PMP levels were increased in patients with ‘severe’ PCOS compared to healthy controls. 
Specifically, patients diagnosed against the NIH 1990 criteria, where patients exhibit 
anovulation and hyperandrogenism presented with elevated levels of PMPs, however those 
diagnosed according to the more recent Rotterdam criteria did not (hyperandrogenism and PCO 
or anovulation and PCO phenotypes). However, the distribution and content of circulating MPs 
was not assessed. PMPs were also detected and quantified using flow cytometry. Koiou and 
colleagues did use calibration beads 0.5, 0.9 and 3.0 μm, but did not comment on the sensitivity 
of the cytometric analysis. Moreover, Van der Pol et al, (247) previously noted that on 
conventional flow cytometers, determining sensitivity and detection limits based upon 
calibration beads (often carboxylated polystyrene) does not truly reflect the refractive index 
characteristic of a heterogeneous MP population. This would over-estimate the detection limit, 
as the refractive index of a polystyrene bead is typically greater than that of an unknown, lipid 
enclosed cell/endogenous MP. In addition, Van der Pol et al, (248) introduced the concept of 
’swarm theory’ when employing flow cytometry for MP detection. Briefly, this refers to 
coincidence, whereby instead of a single MPs passing through the laser interception point at a 
given time point, multiple MPs may pass and be qualitatively and quantitatively assessed as one 
MP (as discussed in chapter 7).   
 
Of interest, Koiou et al, (186) also found that plasma PMPs correlated with serum testosterone 
levels across all PCOS categories. Thus, PMPs, either as a cause or consequence, may be 
associated with hyperandrogenism in PCOS patients. Additionally, in a follow up study, Koiou 
et al, (249), assessed the status of plasma PMPs in overweight/obese women with PCOS. As 
previously noted, this study also found elevated plasma PMPs in women with PCOS than in 
age/BMI-matched controls. Furthermore, PMPs correlated with the mean number of ovarian 
follicles in PCOS patients. In turn, this suggests that independent of obesity, PCOS subjects 
have elevated PMPs in the circulation (186).  
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1.4.15 Biomarkers, therapeutics and diagnostics  
As a growing field, to date, the majority of published studies have been observational in nature, 
trying to detect, measure, characterise and understand the function of MPs in numerous disease 
states. In vitro and more recently in vivo experiments have begun challenging MPs as diagnostic 
and therapeutic targets for the management of several disorders.   
Much research has focused on MPs as potential biomarkers for CVD entities such as endothelial 
dysfunction as well as other pathological conditions. MPs released into blood, urine and other 
body fluids offer a unique opportunity to noninvasively access important biological information 
which could be potentially applicable to several disease states. In a 30 month prospective 
follow-up study looking at heart failure patients, Nozaki and colleagues (2010) found that 
endothelial dysfunction (as assessed by plasma levels of EMPs) was able to independently 
predict future cardiovascular events (250). Similarly, in CHD patients (n = 154), increased 
CD31/annexin V positive MPs were predictors of CHD related death and increased risk of 
recurrent hospitalisation due to CHF (251).  
 
1.4.15.1 Potential role of microparticles as biomarkers 
in personalised medicine 
If MPs truly reflect disease states (i.e. endothelial damage), it may be possible to use them as 
biomarkers in clinical practice. The ability to detect alterations in MPs, before the disease 
manifests (i.e. pre-disease stage), raises the exciting possibility of early intervention and 
potentially reversing certain pathologies.  
MPs have already been used in diagnostics and therapeutics in cancer (specifically prostate 
cancer). Caris Life Sciences, a US based diagnostic, prognostic and therapeutic service 
company have developed Carisome technology. This patented technology has the ability to 
detect, identify and profile circulating MPs. Areas of diagnostic clinical practice include early 
diagnostic testing where circulating MPs shuttle a unique biosignature useful in the early 
detection of several types of cancer. Additionally, the bioactive cargo can be extensively 
profiled, generating valuable molecular information from diseased cells so that clinicians can 
tailor a therapeutic intervention. Also, the biosignature carried by diseased MPs could be used 
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to assess an individual’s response to therapy. The prospect of utilising circulating MPs as 
biomarkers or as therapeutic targets is an exciting challenge with potential beneficial 
implications across several disorders.  
 
1.4.16 Microparticles: cause or consequence of 
disease? 
In the process of furthering the current understanding of MPs, paradoxical biological actions 
have surfaced in numerous disease pathologies. Firstly, it has been demonstrated that MPs 
shuttle an array of bioactive cargo including genetic information (mRNA, miRs) as well as 
bioactive fatty acids and surface cell receptors. Collectively they have been shown to represent a 
novel endocrine network playing a crucial role in cell-cell communication. Their influence on 
the target cells sometimes evokes paradoxical physiologic processes.  
 
Although the literature is heavily influenced by studies highlighting the damaging nature of 
MPs in CVD and other disease states, there have also been numerous studies demonstrating 
cardio-protective roles of MPs. Interestingly, Nieuwland et al, (185) identified procoagulant 
MPs in patients undergoing cardiac bypass operations. The procoagulant nature of MPs seemed 
to provide beneficial intrinsic and extrinsic clotting in patients post cardiopulmonary bypass.  
 
Considering the diverse functions of MPs and potential applications across several disciplines, 
our general understanding of MPs is accelerating rapidly. It remains a great challenge to 
decipher whether MP production is a cause or consequence of disease. However, understanding 
and characterising MPs in different diseases, such as PCOS, will potentially enable 
identification of new cellular pathways that are amenable to clinical intervention and therapeutic 
manipulation.  
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1.5 Thesis Aims and Objectives 
The overall aim of this thesis was to provide a clearer understanding of mechanisms that may 
predispose young patients with metabolic risk factors to cardiovascular disease (CVD). 
 
Hypothesis 
Nitro-oxidative stress is central to the development of endothelial dysfunction in CVD and may 
play an important role in releasing pathologically relevant MP populations into the blood 
stream. 
 
In order to achieve the aim of this thesis and challenge the hypothesis, the work was split into 
several themes, presented in individual result chapters, each with their own specific aims and 
objectives (a specific aims section is given in each results chapter). 
 
Overall aims were: 
 Using a phenotypically detailed PCOS cohort as a model of metabolic disease where 
patients appear to be prone to developing endothelial dysfunction, I chose to undertake 
a comprehensive characterisation of nitro-oxidative stress.  
 The characterisation of circulating MP populations in PCOS patients and healthy 
controls.  
 To translate the findings of the clinical investigations in order to explore the effect of 
pathologically relevant insults (akin to those featured in PCOS) by establishing in 
vitro models to study EC MP production. 
 To examine the functional characteristic of EMPs formed in the in vitro models. 
 To assess the effect of LDL-apheresis on circulating levels of MPs in patients with 
familial hypercholesterolaemia (FH).  
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2. METHODS  
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2.1 Details of ethical approval 
The clinical studies were approved by Cardiff University (study sponsors), Cardiff & Vale 
University Health Board and the South East Wales research ethics committee. All subjects gave 
written informed consent before study commencement (Date awarded: 26/09/08; ethical 
approval: ref 08/WSE04/53). Ethical approval was sought by Dr Aled Rees (Institute of 
Molecular and Experimental Medicine – Cardiff University).  
 
2.2 Subjects  
Seventeen patients with PCOS (age 16-45 years) were recruited from the endocrine clinic at the 
University Hospital of Wales (UHW). Studies were carried out in a quiet, temperature 
controlled room where subjects were required to rest for 10 min before measurements. A 
diagnosis of PCOS was based on the Rotterdam criteria. Congenital adrenal hyperplasia, 
Cushing’s syndrome, hyperprolactinaemia, androgen-secreting tumours and thyroid disease 
were excluded by biochemical testing. Subjects were excluded from participation if they were 
pregnant, breastfeeding, had a history of hypertension, hyperlipidaemia or diabetes, or had a 
history of current or recent (within 3 months) use of antidiabetics, lipid lowering agents, 
antioxidant medication, antihypertensives and/or antiandrogens. Healthy volunteers (n = 18; age 
16-45 years) were recruited among medical students and staff within our institution. Volunteers 
had regular menstrual cycles (every 27-32 days). Their healthy state was established by history, 
physical examination and hormonal evaluation (thyroid function, prolactin, testosterone and 17-
hydroxyprogesterone); those with features of hirsutism or a family history of PCOS were 
excluded. Patient recruitment was co-ordinated by Dr Maneesh Udiawar (Centre for endocrine 
and diabetes sciences – University Hospital of Wales).  
66 
 
2.3 Body composition assessment 
Subjects attended the University Hospital of Wales Clinical Research Facility at 0800h after an 
overnight fast. Height, weight, hip and waist circumference were measured as per our research 
group’s published protocols (252). Abdominal subcutaneous and visceral fat areas were 
measured by CT (Hawkeye, GE Medical Systems) on one cross-sectional scan obtained at the 
level of L4-L5. Scans were performed with subjects in the supine position using standard 
acquisition parameters (140 kV, 2.5 mA, 10 mm slice width, 13.6 second rotation time, 2562 
pixel matrix). CT images were segmented into fat and non-fat areas according to our previously 
published protocol (252). CT scans were co-ordinated by Dr Maneesh Udiawar and performed 
by Dr Helen Blundell (Dept. medical physics - University Hospital of Wales). 
 
2.4 Biochemical measurements 
Serum total cholesterol (TC), HDL-cholesterol, and TG were assayed using an Aeroset 
automated analyser (Abbott Diagnostics, Berkshire, UK); LDL-cholesterol was calculated using 
Friedewald’s formula. Insulin was measured using an immunometric assay specific for human 
insulin (Invitron, Monmouth, UK) and glucose was measured using the Aeroset chemistry 
system (Abbott Diagnostics, Berkshire, UK). High sensitivity C-reactive protein (hsCRP) was 
assayed by nephelometry (BNTM II system, Dade Behring, Milton Keynes, UK) and total 
testosterone was measured by liquid chromatography-tandem mass spectrometry (Quattro™ 
Premier XE triple quadruple tandem mass spectrometer, Waters Ltd, Watford, UK). The intra- 
and inter-assay coefficients of variation were all less than 9%. Biochemical and testosterone 
measurements were carried out at the University Hospital of Wales [Department of Medical 
Biochemistry]. After basal sampling, subjects underwent a standard 75g oral glucose tolerance 
test (OGTT). Glucose and insulin was measured at 0, 30, 60, 90 and 120 minutes. The area 
under the curve (AUC) for insulin and glucose was calculated using the trapezoid method: 
where AUC = 15 X (C0 + C120) + 30 X (C30 + C60  + C120). 
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2.5 Blood sampling 
Fasting blood samples were drawn from an antecubital vein into EDTA, citrate or hirudin 
vacutainers. Samples were promptly centrifuged (1,024g x 10 min, 4 °C) to yield PPP. Ex-vivo 
oxidative stress measurements (lipid-derived radicals, described in section 2.7.1) were 
performed immediately whilst the remaining samples were stored at -80 °C for no longer than 2 
months before analysis. For use, samples were thawed in a preheated (37 °C) thermostatically-
regulated water bath for 3 min. 
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2.6 Plasma nitric oxide metabolites: Ozone-based 
chemiluminescence 
2.6.1 Theory 
NO metabolites (NO2- and NO3-) were assessed using well-established ozone-based 
chemiluminescence techniques, as previously described by our lab (247). Specifically, plasma 
NO2- and NO3- levels were measured using a NO analyser, ((NOA), Sievers NOA 280i, 
Analytix, UK) following cleavage from the species of interest by the use of specific cleavage 
reagents. NO in a flow of inert gas is passed via a NaOH trap to the NOA, where it reacts with 
ozone (O3) in a reaction cell. This reaction forms NO2*, an excitable form of NO2 which 
dissipates energy in the form of photons (hv) as they move back to their ground state. These 
photons are then amplified by a photomultiplier tube (PMT) and converted to an electrical 
signal (mV) where the potential difference was recorded in real time (Sievers, Liquid NO 
analysis software) (28). The area-under-curve (AUC) for each peak is calculated and compared 
to a set of relevant reference standards to obtain a concentration. This is summarised below: 
 NO + O3 →O2 + NO2* 
 NO2* → NO2 + hv 
 
2.6.2 Plasma nitrite  
For plasma NO2- analysis, 5ml tri-iodide reagent (I3-, consisting of KI 70 mM, iodine crystals 29 
mM in 13.5 M glacial acetic acid) was placed in a glass purge vessel and heated at 50°C via a 
water bath thermostatically controlled by a hotplate. The carrier gas (O2-free N2) purging I3- was 
linked to a sodium hydroxide (NaOH) trap (1M), connected to an NO analyser. Samples (200 
µl) were injected directly into the purge vessel through a rubber septum injection inlet (figure 
2.1). Results were compared to a NaNO2 standard curve performed daily to account for 
temperature and other performance variation (figure 2.2). Room temperature was typically 18±2 
°C. The limit of sensitivity for plasma NO2- is >10nM and the intra-assay coefficient of variation 
was <5%. 
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Figure 2.1. Schematic representation of ozone-based chemiluminescence set up. Typically, 
a 200 μl sample is injected through the rubber septum directly into the purge vessel containing 5 
ml tri-iodide reagent heated to 50 °C by a thermostatically regulated water beaker. Cleaved NO 
is carried in an inert N2 gas stream (regulated to 200 cm3/min) to a sodium hydroxide (NaOH) 
trap (10 ml, 1M). NaOH inhibits hot acid vapour reaching the NOA and ensures that N-oxide 
contaminants are not converted to NO (no false positives). NO is directed to the NOA where it 
reacts with ozone (O3) in the reaction cell; photons released from this reaction are amplified via 
a photo-multiplier tube (PMT) and recorded as a potential difference (mV).  
 
0 500 1000 1500
0
20
40
60
Time (S)
N
O
 s
ig
n
a
l 
(m
V
)
0 200 400 600 800 1000
0
500
1000
1500
2000
2500
NO2
- (nM)
A
U
C
A B
 
Figure 2.2. Representative NaNO2 standard curve. Typical NaNO2 trace signals (A). A 
standard curve was undertaken using multiple NaNO2 concentrations (62.5 nM, 125 nM, 250 
nM, 500 nM and 1000 nM, diluted in deionised H2O), [R2 = 0.999, Y = 1.0382X]. Peak AUC 
was determined using NOA Liquid analysis software. (B) The AUC was then plotted against 
known standard NaNO2- concentrations. 
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2.6.3 Plasma nitrate  
For NO3- analysis, plasma (30 µl) was injected into vanadium chloride (30 ml; 49.9 mM 
vanadium chloride (VCl3) in 0.8 M hydrochloric acid (HCl)) heated at 80 °C prior to detection 
via an NO analyser (Sievers NOA 280i, Analytix, UK, figure 2.3). Vanadium chloride is 
capable of measuring the same NO metabolites as tri- iodide, coupled with the additional 
reductive capacity to reduce NO3- to NO. In this sense values obtained from vanadium analysis 
represent the total NOx- in the sample. To obtain true NO3- values, the AUC obtained from tri-
iodide analysis is subtracted from the AUC from vanadium analysis. 
Results were compared to a NaNO3- standard curve performed daily to account for temperature 
and performance variation (figure 2.4). Room temperature was 18±2 °C. The limit of sensitivity 
for plasma NO3- is >500nM and the intra-assay coefficient of variation was <8%. 
 
Figure 2.3. Schematic representation of NO3- analysis. Typically, a 30 μl sample is injected 
through the rubber septum into a round bottomed flask containing 30 ml vanadium chloride 
reagent, thermostatically maintained at 80 °C. Released NO is carried in an inert N2 gas stream 
(200 cm3/min) and directed through a water cooled condenser to a NaOH trap (1 M, 10 ml).  
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Figure 2.4. Representative NaNO3 standard curve. Typical NaNO3 trace signals (A). A 
standard curve of known NaNO3 concentrations (6.25 μM, 12.5 μM, 25 μM, 50 μM and 100 
μM), was undertaken on a daily basis to account for variations in temperature [R2 = 0.995, Y = 
68.585X]. (B) Corresponding AUC was plotted against known standard NO3- concentrations. 
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2.7 Electron paramagnetic resonance 
spectroscopy – spin trapping 
Electron paramagnetic resonance (EPR) is a technique employed to detect species with an 
incomplete outer electron shell (i.e. a free electron or free radicals). Due to the high reactivity 
and short half-life of free radicals, specific spin traps (i.e. α-phenyl-N-tert-butyl nitrone (PBN)) 
are utilised to stabilise the free radical for detection. Akin to all other forms of spectroscopy, 
EPR detects changes during promotion between energy levels (absorption/emission). The two 
energy states are caused by the application of an external magnetic field and the spectrum 
recorded relates to the absorption of microwave energy as the unpaired electron is promoted 
between these two states. Only species with an unpaired electron exhibit EPR signals due to the 
electron inducing a spin orientation in the magnetic field, which is then flipped on introduction 
of the appropriate amount of microwave energy. This is usually recorded as the first derivative 
of the absorption and the signal is split depending on the molecules immediately adjacent/linked 
to the electron. The extent of this splitting is dependent on the interaction of neighbouring 
species and in this way detailed information is provided on the chemical structure of the free 
radical detected. 
 
Numerous studies have used nitrone based probes to investigate lipid radical formation, where 
resulting EPR spectra typically yield a triplet of doublets (hyperfine coupling constant 
characteristics). This is due to the free radical interaction with a neighbouring nitrogen atom and 
an additional hydrogen atom within the chemical structure on the PBN probe (figure 2.7). A 
typical EPR spectrum is given in section 3.4.3. 
 
 
Figure 2.5. PBN/Radical adduct species. PBN/ R adduct formation, where the extracted lipid 
hydrogen forms a hydroxyl radical. R represents a radical. 
 
R
 
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2.7.1 Free radical spin trapping in blood (ex vivo): 
oxidative stress 
EPR spectroscopy coupled with spin trapping was used as a direct measure of ex-vivo oxidative 
burden (circulating lipid radicals). Briefly, the nitrone-based spin trap on interaction with a free 
radical forms a stable spin adduct, detectable via EPR spectroscopy and exhibiting unique 
spectral characteristics associated with a particular species. Blood samples were collected 
directly into a 6 ml EDTA vacutainer containing 2 ml PBN (200 mM, Sigma-Aldrich, UK). 
Lipid-radical/PBN adducts underwent repeated toluene (Sigma-Aldrich, UK) extraction 
followed by reconstitution in 100 µl of chloroform (Sigma-Aldrich, UK) before EPR analysis 
(e-scan, Bruker, Coventry, UK). In order to test in vitro radical generating capacity ferrous 
sulphate (100 mM, Sigma-Aldrich, UK) was added to plasma and PBN (125 mM, 1:1:1, v/v) 
before lipid extraction and EPR analysis as above. Typical measurement conditions were: 
modulation amplitude 1.43 G, power 48.1 mW, time constant 40.96 seconds, sweep time 41.94 
seconds. EPR signals generated are proportional to radical amount, thus peak height was used to 
reflect relative spin adduct concentration. A typical EPR spectrum is shown in section 3.4.3, 
figure 3.2.  
 
2.7.2 Oximetry 
EPR oximetry was used to investigate the amount of O2 present in cell medium, as previously 
described Dada et al, (253). Briefly, N15 per-deuterated tempone (PDT) is a stable nitroxyl spin 
probe that is sensitive to the presence of molecular oxygen. The extent of this interaction will be 
a function of the amount of O2 present. This amount of O2 present is assessed by the extent of 
broadening of the EPR spectral peak (253). The spectral line width (peak-to-peak splitting along 
the magnetic field axis) is measured and converted to PO2 or concentration of O2 using an 
appropriate calibration curve.  Briefly, PDT (5 mM) was diluted in distilled water (500 μM). 
Cell medium (RPMI), exposed to a known O2 concentration was used as standards (0%, 21% 
and 95% O2). Cell medium exposed to 21% oxygen was achieved by equilibration at 
atmospheric O2 prior to analysis. Following this, 2 μl of probe (500 μM) was added per 100 μl 
of cell medium and used for each standard. The 0% and 95% standards were achieved by 
assessing the probe in gas permeable tygon tubing placed in a narrow hollow quartz tube used 
for EPR spectroscopy. The tube was then perfused with N2 or 95% O2 to equilibrate to 0% or 
95% O2, respectively. The point at which the spectral line width no longer changed was taken as 
the equilibration point for each standard. 
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2.8 Plasma hydroperoxides: Ferrous oxidation-
xylenol orange assay 
Hydroperoxides (ROOH) are well-established ROS associated with oxidative stress. Total 
plasma ROOH concentrations were determined using the ferrous iron/xylenol orange (FOX) 
assay, as previously described (254). The FOX assay is a colorimetric method of ROOH 
estimation, based on the oxidation of Fe2+ (ferrous) to Fe3+ (ferric) by ROOH, which binds to 
xylenol orange to give a distinctive dark purple colour, detected by measuring absorbance at 
560 nm. Briefly, sample (90 μl, PPP) was transferred into 1.5 ml Eppendorf tubes with 10 μl of 
methanol. The samples were then vortexed and incubated for 30 min at room temperature. The 
FOX reagent (FOX2, 900 μl, consisting of 250 µM ammonium sulphate; 100 µM xylenol 
orange, 25 mM sulphuric acid and 4 mM butylated hydroxyl-toluene in 90 v/v methanol) was 
added to the samples, vortexed and incubated for 30 minutes. Samples were then centrifuged at 
12,000 g for 10 min prior to determination of the absorbance of the supernatants at 560 nm. 
Samples were compared to a H2O2 standard curve (0 – 250 µM, figure 2.6).  
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Figure 2.6. FOX assay - H2O2 standard curve. A standard curve of known H2O2 
concentrations (0.9 μM, 1.95 μM, 4 μM, 7.8 μM, 15.6 μM, 31 μM, 62.5 μM, 125 μM, 250 μM), 
[R2 = 0.9708, Y = 0.0026X]. H2O2 concentration was confirmed by absorbance at 560 nm 
(spectrometer), checking against the manufacturer’s excitation co-efficient (H2O2 concentration 
= absorbance / excitation co-efficient).  
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2.9 Antioxidant capacity: oxygen radical 
absorbance capacity – fluorescence  
Total plasma antioxidant capacity was assessed by oxygen radical absorbance capacity 
(ORACfl) whereas lipophilic antioxidant capacity was assessed using a modified extraction 
process as previously described (255). ORACfl assesses the ability of plasma antioxidants to 
buffer an insult from a thermally activated peroxyl radical generator. This inhibition is 
conceptualized by the preservation of the fluorescent probe intensity over time. Results are often 
calculated by the resultant difference in AUC and are usually reported in comparison to an 
established antioxidant equivalent (figure. 2.7). 
 
For total plasma antioxidant capacity, samples were diluted (1:500) in PBS and added in 
triplicate to a 96-well plate (25 μl) loaded with 150 μl sodium fluorescein (10 nM). Following 
this, 25 μl of 70 μM 4-hydroxy-TEMPO (tempol; Sigma) was used as a standard antioxidant on 
each plate. Just prior to analysis, either 25 μl of phosphate buffer saline (PBS) (blank) or 2,2’-
azobis-2-methyl- propanimidamide (AAPH, 240 mM) were added prior to measurement. AAPH 
is a thermally activated peroxyl radical generator. 
 
Lipophilic antioxidant capacity was assessed using a modified extraction procedure. Briefly, 
100 μl of plasma sample was transferred to a 5 ml glass tube, 200 μl of ethanol and 100 μl of 
water was added and vortexed, followed by the addition of 400 μl of hexane. The mixture was 
vortexed and left to settle until two layers appeared (~ 2 minutes), followed by centrifugation at 
12,000 g for 10 min. The hexane layer was removed and added to a 2.5 ml amber tube. This 
extraction step was repeated. The two-hexane layers were combined. The combined hexane 
extracts were dried down under a gentle N2 flow, and resuspended in 100 μl PBS. Following 
this, 25 μl of resuspended lipophilic antioxidant sample was assessed as described above. 
Fluorescence measurement was performed on the FLUOstar OPTIMA for 90 min at 37 °C with 
485 nm excitation and 520 nm emission. Fluorescence readings were measured every minute. 
Samples were run in triplicate and results were expressed in arbitrary units compared to a 
standard anti-oxidant, tempo (Sigma-Aldrich, UK) equivalent. 
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Figure 2.9. The effect of antioxidant concentration on free radical induced fluorescent 
probe degradation. AAPH 240 mM (Black). Tempo 50 μM (pink). Tempo 100 μM (red). 
Tempo 200 μM (green). Tempo 300 μM (blue). 
 
2.10 Isolation of plasma derived microparticles  
Fasting blood samples were drawn from an antecubital vein into ethylenediaminetetraacetic acid 
(EDTA) vacutainers. Blood samples were promptly centrifuged (1,024g × 10 min at 4 °C) to 
yield platelet-poor plasma. Plasma-derived MPs were isolated via differential 
ultracentrifugation. Brieﬂy, plasma (1 ml) was ultracentrifuged (100,000g × 1 hr at 4 °C; 
Beckman Coulter, UK). The supernatant was discarded and the remaining pellet was 
resuspended in 250 ml of RNAase-free phosphate- buffered saline (Fisher Scientiﬁc, UK) which 
had been ﬁltered using a 0.22 µm Millipore (MerckMillipore, UK). Isolated MPs were stored at 
-80 °C, for no longer than 6 months before analysis. For use, samples were thawed in a 
preheated (37 °C) thermostatically regulated water bath for 3 min. 
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2.11 Nanoparticle tracking analysis  
NanoSight (LM10) uses NTA technology. NTA determines the size, concentration and 
distribution of nano-sized particles based upon their light scattering and Brownian motion 
in a controlled liquid suspension. Briefly, a laser beam (405 nm) is passed through a 
sample chamber where it illuminates all particles in the suspension, rendering them 
detectable by a x20 magnification microscope (figure 2.8). The microscope, equipped with 
a camera captures a video of the particles moving under Brownian motion. NTA software 
in turn tracks each particle individually and calculates their hydrodynamic diameters (256). 
 
Figure 2.8. Nanoparticle tracking analysis. A schematic diagram illustrating nanoparticle 
tracking analysis (NTA) technology. Firstly, the particles are diluted in particle-free sterile H2O. 
The samples are then loaded across the optical flat using a 1 ml syringe, taking care not to 
introduce bubbles. Particles are illuminated by a 405 nm laser (50 nm beam diameter), allowing 
particle visualisation by eye/camera, and consequently quantification by assessment of 
Brownian motion. Adapted from (256). 
 
Within the microscopic field of view, particles are simultaneously identified and tracked for a 
set time period on a frame-by-frame basis. The NTA analysis software calculates the distance 
moved (two dimensional) over a set period of time, allowing the particle diffusion coefficient 
(Dt) to be determined when coupled with recorded temperature (T) and solvent viscosity (η). 
The sphere-equivalent hydrodynamic diameter (d) of the particles can be identified using the 
Stokes-Einstein equation (figure 2.9).  
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Fig. 2.9. Stokes-Einstein equation. Particle diffusion coefficient (Dt). Temperature (T). 
Solvent viscosity (η). Sphere-equivalent hydrodynamic diameter (d). Boltzmann’s constant 
(KB). Equation (A) accounts for the Brownian motion of particles across two dimensions, 
however, in a suspension the Brownian motion occurs in three dimensions, thus NTA analysis 
uses a modified equation (B) to account for three dimensional Brownian motion. Adapted from 
(256). 
 
2.11.1 Nanoparticle tracking analysis methodology 
MP size and concentration were determined using NTA (NanoSight LM10 system, UK) as 
described previously (182). Brieﬂy, NTA is a laser illuminated microscopic technique equipped 
with a 405 nm laser and a high sensitivity digital camera system (OrcaFlash2.8, Hamamatsu, 
NanoSight Ltd) that determines the Brownian motion of nanoparticles in real-time to assess size 
and concentration. Sixty-second videos were recorded and particle movement was analysed 
using NTA software (version 2.3). Camera shutter speed was ﬁxed at 30.01 milliseconds. 
Camera gain was ﬁxed to 500. Camera sensitivity and detection threshold were (14–16) and (4–
5), respectively. MP samples were diluted in MP-free sterile water (Fresenius Kabi, Runcorn, 
UK). Samples were run in quintuplicate, from which MP distribution, average concentration and 
MP size was calculated.  
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Figure 2.10. Carboxylated polystyrene bead standardisation. Sub-micron diameter beads of 
known size were used daily to check the machine’s functional parameters. Standardized beads 
were used for validation experiments. NTA results were in good accordance with 50 nm, 100 
nm and 300 nm beads in mono-dispersed samples. In biological samples, the particle size, 
concentration and distribution are unknown. Thus, a poly-dispersed bead sample containing 50 
nm, 100 nm and 300 nm beads was used to assess the ability of NTA to measure complex 
samples [right graph]. Peak broadening and poor clarity (especially between 50 and 100 nm 
beads) were apparent in the polydispersed bead sample. 
 
2.12 Tunable resistive pulse sensing  
TRPS was carried out using the qNano (Izon Science, New Zealand), which uses an 
electrophoresis-based method to determine the size and concentration of MPs on a particle-by-
particle basis. Particles pass through a tunable nanopore which detects particles within a specific 
size range. Therefore, in order to analyse MP size and concentration across a full spectrum, 
nanopore 100 (np100) and nanopore 200 (np200) were used. TRPS was performed by Ms Katie 
Connolly (Cardiff University). 
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Table 2.1 Common methods used to detect microparticles 
Method Detection limit Size Concentration Morphology ζ-potential Measurement time 
DLS 1 nm  +/- +/- - + S 
NTA 30 nm  + +/- - +/- M 
Flow 
cytometry 
~>400 nm  + +/- - - S 
Cryo-EM ~ 1 nm + - + - H 
TEM ~ 1 nm + - + - H 
AFM < 1 nm + +/- + - H 
TRPS 70 nm + +/- - +/- M 
A method which is capable of (+), capable of but is subject to limitations (+/-) or not capable of (-) providing information on MP size, concentration, 
morphology, zeta potential. The measurement time (S, M or H) reflects the measurement time is < 1 min (S), minutes (M) or hours (H). DLS, dynamic 
light scattering; NTA, nanoparticle tracking analysis; EM, electron microscopy; TEM, transmission electron microscopy; AFM, atomic force 
microscopy; TRPS, tunable resistive pulse sensing. Adapted from (257). 
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2.13 Gas chromatography 
Fatty acid profiles (both plasma and plasma derived MPs) were analysed using gas 
chromatography (GC) with a flame ionisation detector (FID) as described previously (258). 
Briefly, lipids were extracted from either 100 µl of plasma or 250 µl of re-suspended MPs, 
using the method of Garbus et al (259). Fatty acid methyl esters (FAME) were prepared by 
incubation for 2 hr with 2.5% H2SO4 in dry methanol:toluene (2:1, v/v) at 70 °C. A known 
amount of C17:0 (margaric acid, Nu-Chek Prep. Inc, MN, USA) was added as an internal 
standard. FAME were analysed by gas chromatography (GC) using a Clarus 500 gas 
chromatograph (Perkin-Elmer 8500, CT, USA), fitted with a 30 m × 0.25 mm inner diameter 
(i.d), 0.25 μm film thickness capillary column (Elite 225, Perkin Elmer). The column 
temperature was held at 170 °C for 3 min and then temperature-programmed to 220 °C at 4 °C / 
min. Nitrogen was the carrier gas at a flow rate 2 ml / min. FAME were identified routinely by 
comparing retention times of peaks with those of standards (figure 2.11, Supelco 37 Component 
FAME Mix, Sigma-Aldrich, UK). Negative controls included hexane alone, where no fatty 
acids were detected.  
 
 
Figure 2.11 An example GC-FID chromatogram: External FAME (Supelco 37) standard 
(scanned image of raw chromatogram). External FAME standards were used routinely to 
qualitatively assess the fatty acid profile of plasma and plasma derived MPs. No peaks (fatty 
acids) were retained on the column >30 minutes. Internal standards (C17:0) were used to 
quantify the amount of fatty acids. 
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2.14   Analysis of microRNA expression within 
circulating microparticles 
MP miR expression was analysed on a small subset of PCOS patients (n = 6, age: 33.8 ± 5 
years, BMI: 28 ± 5 kg/m2) and healthy controls (n = 6, age: 29.3 ± 5 years, BMI: 28 ± 6 kg/m2). 
Total RNA was extracted from equal volumes of isolated MPs with TRIzol LS Reagent 
(Ambion, Austin, TX, USA) according to the manufacturer’s instructions.  miR profile analysis 
was performed using Toray 3D-Gene™ DNA Chip microarrays (Toray Industries Inc, Tokyo, 
Japan) according to the manufacturer’s protocol. Briefly, total MP RNA was labelled with a 
mercury LNA microRNA Array Power Labelling kit (Exiqon, Vedbaek, Denmark). Labelled 
miRNAs were hybridized onto 3D-Gene miRNA oligo chips containing more than 1,600 
antisense probe spots (Toray Industries Inc). The annotation and oligonucleotide sequences of 
the probes correspond to miR Base database version 16.  The chips were washed stringently, 
and fluorescent signals were scanned and analysed with a 3D-GeneTM Scanner 3000 (Toray 
Industries Inc). Hybridised probe spots with signal intensity greater than the mean intensity plus 
two standard deviations of the background signal were considered valid. The background 
average was subtracted from the signal intensity, which was then multiplied by the 
normalisation factor (25 divided by the median signal intensity of all the subtracted background 
data) to generate the normalised data. Additionally, miR 4700-5p was selected for validation by 
standard quantitative PCR (qPCR, PCOS patients (n = 12, age: 30 ± 6 years, BMI: 30 ± 6 
kg/m2) and healthy controls (n = 9, age: 25 ± 2 years, BMI: 26 ± 6 kg/m2)). MP RNA fraction 
(25 ng), isolated as described for the microarray, was converted into miR 4700-5p 
complementary (c)DNA (and RNU48 housekeeping control cDNA) using miR 4700-5p and 
RNU48 probes (Life Tech) in a reverse transcriptase reaction. 7.5 ng cDNA was used in each 
PCR reaction following the manufacturer’s instructions. miR 4700-5p MP levels were 
expressed as fold changes compared to healthy volunteers. I undertook sample preparation and 
interpretation whilst the TORAY micro-array was performed by Central Biotechnology 
Services - Cardiff University, and qPCR was performed by Dr Thomas Davies - Cardiff 
University.  
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2.15 Cell culture 
The HECV cell line (obtained from human umbilical vein endothelial cells, IST, Italy) were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM, PAA Laboratories Ltd, UK) 
supplemented with 10% fetal bovine serum (PAA Laboratories Ltd, UK), penicillin, and 
streptomycin (Invitrogen, UK). The cells were maintained in an incubator at 37 °C and 5% CO2. 
Cells were sub-cultured using Trypsin/EDTA (Invitrogen).  
 
Primary HUVECs (Cell Applications Inc, CA, USA) were cultured in endothelial cell growth 
medium (Cell Applications Inc) as recommended by the manufacturers. The cells were 
maintained in an incubator at 37 °C and 5% CO2. Cells were sub-cultured using a specialised 
sub-culture reagent kit (Cell applications Inc) and all experiments were carried out prior to 16 
population doublings. All cells were counted using Cellometer® (Nexlon Biosciences Auto T4) 
and expressed as cells/ml.  
 
 
Figure 2.12. Cell images. (A) HECV cells. (B) HUVECS. Both images were captured at x20 
magnification. 
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2.16 Cellular treatments 
HECV and HUVEC cultures were treated with several pathological stressors. Upon cells 
reaching ~80% confluence, cell culture medium was removed (all experiments were undertaken 
when cells reached ~80% confluence, unless indicated). Cells were washed with PBS and 
incubated with 10 ml MP-free serum free medium (SFM) for 24-hours (37 °C and 5% CO2) 
containing either SFM alone (non-stimulated/control) or with addition of a cellular insult 
(hydrogen peroxide [H2O2 0.1 – 20 mM]; hypoxia [1 – 21% O2]; glucose [0 – 22.5 mM]; insulin 
[0 - 2.5 nM] or testosterone [0 -1 µM]).  For detailed characterisation and functional analysis, 
experiments were carried out on MPs subjected to; H2O2 (10 mM); testosterone (1 μM); glucose 
depleted (thus no glucose present); insulin (2.5 nM) or hypoxia (1 % O2) insults.  
 
2.17 Isolation of cell derived microparticles 
MPs were isolated direct from cell culture as previously described (182). Cells were cultured in 
serum-free medium (SFM) for 24 hours before MP isolation. Cell culture medium was extracted 
direct from the culture flask and subjected to differential ultra-centrifugation, (300 × g for 10 
min, 2,000 × g for 15 min, and 100,000 × g for 60 min). The resulting MP pellet was 
resuspended in sterile PBS (Fisher Scientific, UK).  
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2.18 Confocal microscopy: cell and 
microparticle morphology 
Confocal microscopy was utilised in several ‘proof of concept’ experiments to support NTA 
observations, visualise cellular MP release in real-time, visualise MP-EC adhesion, MP annexin 
positivity and HECV morphology. HECV cells were grown on a 35 mm glass bottom dish (In 
Vitro Scientific, CA, USA), maintained in ~250 µl of DMEM medium in tissue culture 
conditions previously described in section 2.16.  Fluorescent labelling and phase-contrast 
images were visualised using a Leica SP2 confocal microscope. Images were captured and 
analysed using Leica Application Suite Advanced Fluorescence (LAS AF).  
 
EMP Morphology: Cells were gently washed with 1 ml PBS followed by the addition of 250 
µl of MP-free SFM.  Cells were incubated with 250 µl Cell-Trace Red-Orange (dilution 1:1000, 
Invitrogen) for 30 minutes at 37 °C and 5% CO2. Post incubation, free Cell-Trace was removed 
by 2 x 1 ml PBS washes and maintained in 250 µl of MP-free SFM (or pathologically relevant 
stressor, as indicated) until visualised under confocal microscopy. Following Cell-Trace 
labelling, cells were treated with 250 µl annexin V (dilution 1:200, FITC, Biolegend) for 15 
minutes (37 °C and 5% CO2). Free annexin V was removed by 2 x 1 ml PBS washes and 
maintained in 250 µl of MP-free SFM until visualised by confocal microscopy.  
 
EMP Adhesion: Cell-Traced EMPs (red-orange) were derived from cells treated with 8 ml 
Cell-Trace Red-Orange (dilution 1:1000 in DMEM) for 30 minutes incubation at 37 °C and 5% 
CO2. Post incubation, free Cell-Trace was removed by 2 x 10 ml PBS washes and maintained in 
10 ml of MP-free SFM for 24 hours. After 24 hours, cell culture supernatant was taken and 
subjected to differential ultra-centrifugation to isolate EMPs (as described previously in section 
2.18. The supernatant from the last wash stage in the differential ultra-centrifugation step was 
kept and used as a control, to eliminate Cell-Trace contamination.  HECV cells grown to 75% 
confluence were then treated with Cell-Traced EMPs for 3 hours (37 °C and 5% CO2). To 
remove non-adherent EMPs, 2 x 10 ml PBS washes were performed. Cells and adhered EMPs 
were maintained in growth medium until confocal microscopy. 
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2.19 Electron Microscopy 
EM was used to visualise MPs shedding from stimulated and non-stimulated HECV cells. EM 
was also used to assess isolated MP sample morphology and purity. EM work was carried out in 
collaboration with Dr Christopher Von Ruhland (Central Biotechnology Services - Cardiff 
University).  
 
2.19.1 Scanning electron microscopy  
HECV cells were grown on a 35 mm glass bottom dish (In Vitro Scientific, USA), maintained 
in ~250 µl of DMEM medium in tissue culture conditions previously described in section 2.14. 
Cells were washed twice in PBS and then fixed in 1% glutaraldehyde in Sorensen's phosphate 
buffer (v/v) for 1 hour. Following fixation, cells were kept in PBS until imaging. Cell samples 
were then dehydrated in graded isopropanol (IPA) at 50, 70, 90 and 100% (10 minutes each 
grade) followed by hexamethyldisilazane (HMDS, 3 x 5 minutes; Sigma-Aldrich, UK). Surplus 
HMDS was removed and remaining residue was allowed to evaporate. A 12mm diameter 
adhesive carbon disc was then attached to the underside of the glass window. A diamond pen 
was used to break / release the glass before the sample was sputtered in gold. Specimens were 
viewed using a JEOL 840A scanning electron microscope (Joel UK, Hertfordshire, UK). Images 
were acquired using analySIS (Munster, Germany) and processed using Photoshop (Adobe, 
USA). 
 
2.19.2 Transmission electron microscopy  
MPs derived from unstimulated HECV cells were isolated via differential ultra-centrifugation as 
described in section 2.18. Post final ultra-centrifugation, MPs were resuspended in 100 µl 
particle-free PBS. Isolated MPs were then fixed in 1% glutaraldehyde in Sorensen's phosphate 
buffer (1:1 v/v for 1 hr). Negative staining was carried out on 80 nm thick sections on a 400 
mesh / carbon-coated grid floated on 50 μl drops of the fixed isolated MP Sample (30 min), 
followed by 100 mM phosphate buffer pH 7.4 (3 x 1 min), H2O (6 x 10 min) and finally 2% 
uranyl acetate (20 min). Residual surplus was allowed to air dry. Isolated MPs were examined 
in a Philips CM12 TEM (FEI UK Ltd) at 80 kV. Images were captured with a Megaview III 
camera and presented using Photoshop (Adobe, USA). 
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2.20 Cell viability and apoptosis  
2.20.1 Trypan blue exclusion 
For trypan blue exclusion, HECV cells were stained with trypan blue (1:1 v/v) and assessed 
using a Cellometer Auto T4 (Nexlon Biosciences, USA).  
 
2.20.2 The CellTiter 96® AQueous one solution cell 
proliferation assay  
The CellTiter 96® AQueous one solution cell proliferation assay (Promega, Southampton, UK) 
is a colorimetric technique used to ascertain cell viability. Briefly, 100 μl of 1 x 106 cells was 
incubated with 20 μl of reagent for 1 hr (37 °C, 5% CO2). During this incubation period the 
formation of a coloured product named formazan is achieved by dehydrogenase enzymes, which 
are only located in metabolically active cells. This facilitates the bio-reduction of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.  
 
Following incubation, absorbance was measured at 490 nm using a FLUOstar OPTIMA (BMG 
Labtech, USA). The quantity of formazan product as measured by the amount of 490 nm 
absorbance is directly proportional to the number of living cells in culture, as previously 
described (260). 
 
2.20.3 Caspase-Glo® 3/7 assay 
The Caspase-Glo® 3/7 assay (Promega, Southampton, UK) was undertaken to assess apoptosis, 
as previously described (260). This assay measures caspase-3 and -7 activity using 
luminescence. These members of the cysteine aspartic acid-speciﬁc protease (caspase) family 
play key eﬀector roles in apoptosis in mammalian cells. Briefly, cells were added to Caspase-
Glo® 3/7 assay reagent (1:1, v/v) prior to incubation for 3 hrs at 37 °C, 5% CO2. Luminescence 
of the test samples was measured using a FLUORstar OPTIMA. 
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2.21 Multiple electrode aggregometry 
To assess the potential coagulability of EMPs, aggregation assays were undertaken using a 
Multiplate® analyser (Roche, Switzerland). Briefly, bioelectrical impedance aggregometry 
measures the ability of blood cells (typically platelets) to adhere to an artificial surface.  The 
assay requires measurement of impedance of an alternating current applied across electrodes. 
The magnitude of adhesion from platelets/MPs to an artificial electrode is determined by 
quantifying the change in impedance over a set time. This quantification of adhesion is 
expressed as area-under-curve (AUC) of electrical impedance over the set time (expressed as 
arbitrary aggregation units).  
As an indication of MP coaguability, the multiplate analyser was used to investigate the ability 
of EMPs to adhere to the surface of an artificial electrode. Briefly, MPs (300 µl, 1 x109/ml) 
were mixed 1:1 v/v with 0.9% NaCl preheated to 37 °C in a Multiplate® electrode aggregometer 
cell. Samples were continuously mixed using a Teflon coated stirring bar (micro-flea) at 1000 
rpm. Following three minutes incubation, aggregation was assessed after either: 20 µl of 0.9% 
NaCl preheated to 37 °C (non-stimulated) or H2O2 (20 µl, final concentration 10 mM) initiated 
aggregation.  An increase in electrical impedance from the electrode pairs within a test cell was 
recorded for 6 minutes and expressed as a mean of the areas under curve (AUC, arbitrary 
aggregation units of AU*min). 
 
2.22 Whole blood aggregometry: electrical 
impedance 
To assess the effect of MPs on whole blood platelet aggregation, blood samples were taken 
from 8 healthy volunteers. Blood was collected from a vein in the antecubital fossa with a 21 G 
butterfly needle into a Hirudin vacutainer (3 ml). A tourniquet was lightly applied proximal to 
the site of blood sample acquisition. The first 3 ml was discarded, the sampling blood was then 
slowly inverted two / three times for optimal mixing. 
 
The blood (300 µl) was first mixed 1:1 v/v with 0.9% NaCl preheated to 37 °C in a Multiplate® 
electrode aggregometer. Samples were continuously mixed using a Teflon coated stirring bar 
(micro-flea) at 1000 revolutions per minute (rpm). Following a 3-min incubation, platelet 
activation was initiated by the addition of ADP (20 µl, Multiplate® ADP-test reagent; final 
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concentration 6.5 μM) or thrombin receptor activating peptide (20 µl, Multiplate® TRAP-test 
reagent; final concentration 32 μM). An increase in electrical impedance from the electrode 
pairs within a test cell was recorded for 6 min and expressed as a mean of the areas under curve 
(arbitrary aggregation units of AU*min).  
 
Pre-conditioning: Endothelial microparticles. To assess the effect of EMPs on whole blood 
platelet aggregation, blood (300 µl) was first mixed 1:1 v/v with EMPs (1 x102/ml - 1 x1010/ml) 
derived from pathologically relevant stressors, constituted in 0.9% NaCl preheated to 37 °C in a 
Multiplate® electrode aggregometer. As previously described, following a 3-min incubation, 
platelet activation was initiated by the addition of the ADPtest or TRAPtest. Electrical 
impedance from the electrode pairs was recorded for 6 min. 
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2.23 Flow cytometry 
2.23.1 Theory  
Flow cytometry is a laser-based technique, which is employed across a range of scientific 
disciplines. Briefly, a MP/cell suspension is injected into the machine and enters the flow cell. 
The flow cell consists of a central core containing the cell sample surrounded by an outer core 
of sheath fluid. The pressure of the sheath fluid against the cell/MP sample in the narrowing 
flow cell creates a laminar sheath flow that transports the cells (or MPs) upward in single file 
through the centre of the flow cell where they are intercepted by multiple lasers, this is referred 
to as hydrodynamic focusing. Light scattered in a forward direction, is collected by the forward 
scatter channel (FSC) lens, and is indicative of cell size and can distinguish between cellular 
debris and viable cells. Light deflected from cell organelles is detected perpendicular to the laser 
beam and is measured by the side scatter channel (SSC). This provides information regarding 
the cytoplasmic complexity or granularity of a cell/MP (figure 2.13). A number of fluorescence 
channels are used to detect any light emitted by the cells or MPs. The specificity of detection is 
controlled by several optical filters that only permit the passage of light at specific bandwidths 
(261). Limitations of flow cytometry for the detection of MPs are discussed in chapter 7. 
 
Figure 2.13. Flow cytometer – flow cell and detectors. Cells are hydrodynamically focussed 
within the flow cell (left) to yield a singular single stream of cells (or MPs) for interrogation by 
multiple lasers. Light scattered in a forward direction is detected by the forward scatter channel 
(FSC) and is often indicative of size, whereas the side scatter channel (SSC) provides 
information about the granularity of each cell (or MP) (right). Adapted from (261). 
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2.23.2 Cytometric applications within this thesis 
Within this thesis, cytometric techniques were used to characterise: 
 Cellular origin of circulating MPs (described in section 1.22.3) 
 HECV cell and MP surface adhesion molecule profiles (described in section 1.22.4) 
 MP annexin V positivity (described in section 1.22.4) 
 Platelet activation (P-selectin) - (described in section 1.22.5) 
Cytometric measurement of plasma derived MPs was undertaken by Ms Katherine Connolly 
and Dr Kristin Ladell (Stem Cell and Flow Cytometry Unit, Cardiff University). I undertook all 
the necessary sample preparation and data analysis.  
Antibodies used for cytometric analysis were obtained from Biolegend® (BioLegend, San 
Diego, CA, USA). They include; mouse anti-human CD62P- allophycocyanin (APC) 
conjugated (clone AK-4) [P-selectin], mouse anti-human CD144- phycoerythrin (PE) 
conjugated antibody (clone BV9) [VE-Cadherin], mouse anti-human CD41 – PE-Cy7 [Integrin 
alpha chain 2B], annexin V-FITC, mouse anti-human αCD41-PECy5, mouse anti-human 
αCD11b-PECy7 and mouse anti-human αCD144-APC (fluorescent spectra are shown in figure 
2.17). All samples were run against non-stained controls and fluorescence minus one. 
 
2.23.3 Cellular origin of circulating microparticles 
Flow cytometric measurements were performed using a custom-built FACSAria II (BD 
Biosciences, San Jose, CA, USA). Forward scatter area and side scatter area were set to log 
scale. Plasma-derived MPs were resuspended in 100 µl of 0.22 µm-filtered annexin V binding 
buffer (BD Biosciences). MPs were then stained for 15 min in the dark at room temperature 
with annexin V-FITC (1.57 µg/ml), αCD41-PECy5 (0.12 µg/ml), αCD11b-PECy7 (7.9 µg/ml) 
and αCD144-APC (4.1 µg/ml). Fluorescent calibration beads of sizes 200, 500 and 800 nm were 
detected and distinguishable as three distinct populations (Submicron bead calibration kit, 
Bangs Laboratories, Inc., IN, USA). The MP gating strategy was based on their forward scatter 
versus side scatter profile and in relation to platelets in fresh plasma. The MP gate was tested 
for annexin V positivity and subsequently for monocyte (CD11b), platelet (CD41) and 
endothelial (CD144) antigens to determine PS exposure and the cellular origin of MPs. FSC-A 
threshold was set to 1000 to minimize recording of debris. Fluorescence minus one (FMO) 
stains were used to set the positive gates for each antibody. Data were exported from 
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FACSDiva™ software version 6.0 (BD Biosciences) and subsequently analysed with FlowJo 
software version 9.6.4 (Tree Star, Inc., Ashland, OR, USA). 
 
2.23.4 Surface adhesion molecule profiling of HECV 
cells and microparticles 
Flow cytometry was used to determine the surface adhesion molecule profiles of HECV cells 
(both unstimulated and HECV cells treated with pathological stressors) and their corresponding 
MPs. Additionally, flow cytometry was used to investigate the effect of MPs on HECV surface 
adhesion molecule profiles.  
 
HECV cells were grown in T25 flasks as previously described. The medium was carefully 
removed from the cells and Acutase® (4 ml, Sigma-Aldrich, UK) or trypsin (4 ml, Invitrogen, 
UK) was added to the cells and incubated at 37 °C for 3 min. Flasks were gently ‘tapped’ to 
encourage cell detachment.  Detached cells were transferred to 15 ml tubes, and topped up to a 
15 ml final volume with medium. The flasks were washed with 10 ml medium to ensure all cells 
had been obtained and the medium was aspirated to the relevant 15 ml tube. The cells were 
centrifuged (1,200g x 3 min at RT) and supernatant removed. Cells were re-suspended in 1ml 
PBS/annexin V binding buffer (Sigma-Aldrich, UK).  
Cells were re-suspended at 1 x 106 cells / ml and 1 ml of the cell suspension was transferred to 
1.5 ml Eppendorfs; the cells were centrifuged and the supernatant aspirated. Conjugated primary 
antibody was added to each tube, re-suspended and incubated for 15 min at room temperature 
(in the dark). Following incubation the cells were centrifuged, and washed in PBS.  Finally, 
cells were re-suspended in 0.2 ml PBS/annexin V binding buffer into 12 mm FACS tubes 
(Falcon, BD Biosciences, UK) and viewed on a BD FACS Canto flow cytometer (BD 
Biosciences). 
Flow cytometry was performed using a BD Canto dual laser bench top flow cytometer, 
equipped with 488 nm and 633 nm lasers and BD FACS Diva software (v 5.0.3). Single colour 
analysis was performed using primary antibodies conjugated to FITC, PE, PE-Cy7 or APC, 
excitation and emission spectra for these fluorophores can be seen in figure 2.15. Carboxylated 
polysterene beads (200, 500 and 1000 nm in diameter) were used to set the MP gate (figure 
2.14. IZON Science, NZ).  
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HECV cells were analysed for forward scatter area and side scatter area whilst MPs were run on 
forward scatter area and side scatter area that were set to logarithmic (log) scale. Firstly, density 
dot-plots were used to show the distribution of cells using the forward scatter and side scatter 
parameters. The voltage was adjusted accordingly so that all the cells were optimally aligned. A 
dense area of concentrated pixels (cells/MPs) was selected using a gate. For antibody enabled 
cytometric analysis, single parameter histograms were used (i.e. relative fluorescence intensity 
on the x-axis and the cell count of the y-axis). The voltages were adjusted for individual 
fluorophores so that the negative controls (unstained samples) were set to the first log decade. 
Instrument settings were adjusted using unstained cell/MP samples. Acquisition was terminated 
upon recording 10,000 events, gated based on their forward scatter and side scatter 
characteristics. Fluorescence minus one (FMO) stains were used to set the positive gates for 
each antibody (gates shown in figure. 2.16).  
 
Figure 2.14. Cytometry analysis of < 1 μm diameter carboxylated polystyrene beads. Top 
graphs represent forward scatter histograms. Bottom graphs represent side scatter histograms. 
Beads were obtained from Izon Science Ltd. [Orange] - 1 μm beads. [Aqua] – 500 nm beads. 
[Purple] – 200 nm beads. [Dark blue] – Polydispersed bead sample.  
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Figure 2.15. Fluorophore spectra: Spectra illustrating the excitation spectrum (dotted/dashed 
lines) and emission spectra profile (coloured histogram) of (A) FITC (green); (B) APC (red); 
(C) PE (yellow) and (D) PE-Cy7 (Brown). The shaded areas demonstrate the band pass filter 
used for each fluorophore (adapted from BD Biosciences 2014). 
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Figure 2.16. Cytometry gating pathway for HECV cell surface adhesion molecule profile. (A) Represents HECV cell gate, excluding cell 
aggregates and potential debris. (B). Accounts for the CD144+ positive population. (C). HECV control (unstained) in quadrant 4. (D). HECV cells 
stained for APC (CD54) only, quadrant 1. (E). HECV cells stained with PE (CD144+) only, quadrant 3. (F). Combined staining of CD144+ and CD54 
on HECV cells in quadrant 2. FSC, forward scatter channel; SSC, side scatter channel; APC, allophycocyanin; PE, phycoerythrin; A, area.  
  
  
  
    
A 
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2.23.5 Flow cytometry: Effect of MPs on whole blood 
platelet activation 
Blood sample collection and preparation: To assess the effect of MPs on whole blood platelet 
electrical impedance aggregometry, blood samples were taken from 4 healthy volunteers (n = 
4). Blood was collected from antecubital fossa veins with a 21 G butterfly needle into a citrate 
vacutainer (3 ml) for platelet activation analysis and into an EDTA vacutainer (4 ml) for a full 
blood count. A tourniquet was lightly applied proximal to the site of blood sample acquisition. 
As previously described, the first 3 ml was discarded, the sampling blood was then slowly 
inverted two / three times for optimal mixing.  
Platelet counts were derived from a full blood count preformed on an ABX Pentra X120 
haematology blood analyser (Horiba UK Ltd, Northampton, UK). Whole blood was diluted with 
saline (37 °C) to yield a final platelet count of 150 x103/mm3. Whole blood (containing 150 
x103/mm3, 300 μl) was mixed with MPs (MP conc. 1 x 109/ml, 250 μl) for 3 minutes (using a 
Teflon coated stirring bar (micro-flea) at 1000 rpm). Post incubation, platelet activation was 
initiated by the addition of ADP (50 µl, Multiplate® ADP-test reagent; final concentration 13 
μM), thrombin receptor activating peptide (50 µl, Multiplate® TRAP-test reagent; final 
concentration 64 μM) or equivalent volume of saline.  200 μl of sample was then fixed with 
paraformaldehyde 1% v/v for 15 minutes.  Following fixation, 40 μl sample was mixed with 
CD41 (5 μl), CD62P (5 μl) and CD144 (5 μl), reconstituted to a final volume of 150 μl in 
HEPES buffer solution and stored at 4 °C until analysis. Incubation was terminated by diluting 
the sample (40 μl) in 960 μl HEPES buffer. 
 
Platelet activation was assessed using a dual laser Canto flow cytometer (BD) within two hours 
of incubation. Data collection and analysis was performed using FACS DIVA and FlowJo, 
respectively. Acquisition was terminated upon recoding 10,000 platelets (gated based on their 
forward scatter and side scatter characteristics).  
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2.23.6 Thrombin generation assay (microparticles) 
To provide a working reservoir of plasma in which to test thrombin generation of MP, blood 
was drawn gently from healthy volunteers into a syringe containing 6 mM trisodium citrate 
(Sigma-Aldrich) and 20 μg/ml corn trypsin inhibitor (Cambridge BioScience, UK) and 
centrifuged (1,024 g, 10 min, 4 °C) to yield “vehicle” PPP. Samples were then stored at −80 °C 
until analysis.  
To asses MP thrombin generation, calibrated automated thrombography was used, as described 
previously (262), with minor modifications. Samples were measured in duplicate using 96-well 
plates (round-bottomed, Immulon 2HB, Thermo Scientific). Eighty microliters of vehicle PPP 
(containing endogenous clotting factors) were added to each well with 20 μl of diluted 
HEPES/NaCl buffer (NaCl 280 mM, KCl 10 mM, Na2HPO4 1.5 mM, Glucose 12 mM, HEPES 
50 mM, pH 7.4) tissue factor (TF) solution to yield a final concentration of 1 pM (Innovin, 
Sysmex UK Ltd, UK). Familial hypercholesterolaemia patient MP samples were assayed for 
thrombin generation both with and without exogenous TF addition. MPs (20 μl) were added to 
sample wells with the addition of either saline (20 μl, 0.9% w/v NaCl) or TF (20 μl, 1 pM final). 
Each sample was calibrated to a well containing 80 μl of PPP and 40 μl of thrombin calibrator 
(600 nM, Synapse BV, Netherlands). The plate was then warmed to 37 °C for 5 min before 
addition of fluorogenic substrate (20 μl, Z-Gly-Gly-Arg-AMC, Bachem, UK). The fluorescent 
signal was then measured using a Fluoroskan Ascent plate reader (ThermoLabsystems, Finland) 
equipped with a 390/460 nm filter set (excitation/emission) at 15 second intervals until the 
thrombin generation reaction was complete. Data were analysed using Thrombinoscope™ 
software (Synapse BV, Netherlands) and correlated with MP concentration data. 
 
2.24 Silencing RNA / transfection  
In an attempt to decipher the role of hypoxia-inducible factor-1α (HIF-1α), in hypoxia mediated 
MP formation, silencing RNA (siRNA) targeting HIF-1α expression in HECV was used. 
Briefly, HECV cells were seeded on a T25 flask and grown as previously described in section 
1.14. When cells reached 50 % confluency, the cell medium was discarded and incubated with 4 
ml antibiotic free medium (DMEM, 10 % FCS) for 1 hr. Then 20 µl of SMARTpool HIF-1α 
siRNA (taken from a 20 µM stock solution made up in sterile Dharmacon RNase free siRNA 
buffer (Dharmacon, USA)) was placed in a sterile polymerase chain reaction (PCR) Eppendorf 
to which 1 µl of Dharmafect reagent was added, gently mixed and left at room temperature for 
98 
 
20 minutes. Cell medium was again discarded and replaced with 4 ml of fresh antibiotic free 
medium (DMEM, 10% FCS), to which the transfection reagent mix was added, to yield a final 
siRNA concentration of 100 nM per flask. Control experiments consisted of medium alone and 
Dharmafect transfection reagent with non-targeting scrambled siRNA (also 100 nM per flask 
(Dharmacon, USA)).  
 
2.25 Western blot 
A western blot was carried out on HECV cells to detect the presence of HIF-1α protein. The 
multiple stages of the Western blot and associated methods are detailed below.  
 
2.25.1 Cell lysis  
HECV cell culture medium was discarded and cells were washed with sterile PBS (Fischer-
scientific) three times. Immediately, 200 µl of ice cold lysis buffer (containing 
protease/phosphatase inhibitors detailed in table 2.2) was added to the cells. A cell scraper was 
used to distribute the lysis buffer and detach cells from the flask. Following this, samples were 
transferred to sterile Eppendorfs and centrifuged at 21,913g x 20 min at 4 °C. The resulting 
supernatant was carefully transferred to Eppendorf tubes and stored at -20 °C until use. 
 
Table 2.2 Lysis buffer 
Constituent (pH 7.5) 
Tris buffer 50 mM Phenylmethylsulfonylflouride 1 mM 
EGTA 5 mM Sodium flurodioxide 50 mM 
NaCl 150 mM Phenylarsine oxide 20 µM 
Triton 1 % Sodium molybdate 10 mM 
Sodium orthovanadate 2 mM Leupeptin 10 µg/ml 
Aprotinin 10 µg/ml  
EGTA, ethylene glycol tetraacetic acid; NaCl, sodium chloride. 
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2.25.2 Bio-Rad (Bradford) assay 
The Bio-Rad protein assay is a colorimetric assay that was used for measuring total protein 
concentration. It is based upon the established Bradford assay where Coomassie dye binds to 
protein and is associated with a colour change from brown to blue. Briefly, bovine serum 
albumin (BSA) standards or samples (100 µl) were added to 400 µl of Bio-rad reagent, vortexed 
and left to settle for 10 min. After this, the absorbance was analysed at 590 nm. Samples were 
compared to a standard curve of known protein concentration, (0 – 25 µg/ml BSA). Standards 
and samples were run in triplicate on a 96-well plate.  
 
2.25.3 Sample preparation 
Once the protein content of the cells had been quantified, the protein in the samples had to be 
denatured. Briefly, 20 µg of sample was diluted 1:1 with dithiothreitol (DTT), followed by 
heating for 5 min at 95 °C.  
 
2.25.4 Polyacrylamide gels 
Polyacrylamide gels (running buffer and stacking gel) were assembled in blotting cassettes 
using the constituents detailed in table 2.3. Samples (20 µg) were loaded on to wells within the 
stacking gel to ensure each sample contained an equivalent protein concentration. Also, a broad 
range molecular weight indicator was loaded as a positive molecular weight standard. The gels 
were placed in a tank and the reservoir between the blotting cassettes was filled with running 
buffer (0.25 M Tris buffer, 1.92M glycine and 0.1 % sodium dodecyl sulfate (SDS); pH 8.3). 
The gel was run at 180 volts (V) for 45 min (or until the bands migrated to the base of the gel). 
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Table 2.3 Gel constituents 
Constituent Resolving gel Stacking gel 
Deionised H2O 4.8 ml 6.1 ml 
Tris Buffer  2.5 ml 2.5 ml 
Acrylamide solution  2.5 ml 1.3 ml 
10 % (w/v) SDS page 0.1 ml 0.1 ml 
10 % (w/v) ammonium persulphate  0.1 ml 0.1 ml 
TEMED 6 µl 10 µl 
Values based on a 10 ml loading volume. Resolving gel - 7.5%, MW range 70-200 kDa. 
Stacking gel – 4%gel. Tris buffer, pH 8.8 – resolving buffer or pH 6.8 for stacking buffer. 
Acrylamide solution consists of: Acrylamide/Bis-acrylamide 30 % solution (37.5:1 ratio). 
 
2.25.5 Transfer 
After SDS-PAGE, the resulting gel was transferred to a nitrocellulose membrane. The gel-
nitrocellulose membrane was embedded within blotting paper and foam pads, all encased within 
blotting cassettes. The gel was run at 180 V for 45 min (or until the bands migrated to the base 
of the gel). The transfer cassette and transfer tank was filled up with cold transfer buffer (0.25M 
Tris, 1.92 M glycine, methanol 20%; pH 8.3) and run at 100 V for 1 hr. This process encourages 
the movement of protein from the gel to the membrane. Following transfer, the membrane was 
placed in Ponceau stain (10 ml), to assess even bands / loading, and the presence of any air 
bubbles.  
 
2.25.6 Incubation of antibodies 
Following Ponceau stain inspection, the membrane was washed in tris-buffer saline 
(TBS)/tween (10 mM Tris, 150 mM NaCl, tween 0.05 %; pH 7.6) three times. Blocking of non-
specific sites of antibody binding was achieved by soaking the membrane in TBS/tween 
containing 5% w/v non-fat dried milk, with an agitation rocker for 1 hr. The membrane was 
then incubated with the primary antibody (HIF-1α, mouse monoclonal or β-actin, 1 in 200 in 
1% milk-TBS/Tween; GE healthcare, Dharmacon, Germany) overnight at room temperature. 
After overnight incubation, the membrane was washed 3 x 10 min in TBS/Tween. The 
secondary antibody (horseradish peroxidase, goat anti-mouse, Sigma-Aldrich) was added at a 
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concentration of 1 in 1000 made up in 1% milk-TBS/Tween and incubated on the rocker for 1 
hour at room temperature. Following this, the membrane was washed (5 x 5 min washes in 
TBS/Tween). 
. 
2.25.7 Developing  
To detect protein bands, equal volumes (1:1 v/v) of Western blot detection agents (Sigma-
Aldrich, UK) were mixed and 100 µl of Western Blot detection reagent (Sigma-Aldrich, UK) 
was applied to the membrane.  GeneSys was used to develop and detect blots. The membrane 
was exposed to ultraviolet (UV) radiation for 5 min in the GeneSys, after which the image was 
captured and recorded using GeneSys analysis software.  
 
2.26 Statistics 
Statistics are described in each results chapter.  
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3. RESULTS CHAPTER 
 
Detailed characterisation of circulatory nitric oxide and free 
radical indices – is there evidence of nitro-oxidative stress in 
young women with polycystic ovary syndrome? 
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3.1 Introduction 
PCOS is a common condition characterised by hyperandrogenism, oligo/anovulation and 
defects in insulin secretion and sensitivity (263), leading to an increased risk of type 2 diabetes 
(153). Patients also have an increased prevalence of hypertension (78), dyslipidaemia (79) and 
premature atherosclerosis (264) although it is not yet clear whether this translates into an 
increased risk of cardiovascular mortality (153). 
 
Endothelial dysfunction, an early marker of vascular disease in the general population, is a state 
linked to reduced NO bioavailability and increased oxidative stress. A recent meta-analysis of 
21 studies comparing FMD, a non-invasive measure of endothelial function, in PCOS and 
healthy women, concluded that endothelial dysfunction was evident in women with PCOS even 
if they are young and non-obese (265). Few studies have examined NO biochemistry in women 
with PCOS but these have all used insensitive methodologies that fail to directly resolve total 
NO into its major component fractions, NO2- and NO3- (138, 139, 142, 266-269). All failed to 
show any differences in total NO levels between PCOS subjects and controls, although two 
studies did note an inverse relationship between total NO and fasting insulin (138, 267), 
implying that insulin resistance may be mechanistically important in altering NO bioavailability 
in PCOS. Given that plasma NO3- is largely governed by dietary intake (~75%) and plasma 
NO2- is taken to reflect endothelial NO bioavailability, analytical techniques based on 
colorimetric or fluorometric analysis do not provide sufficient sensitivity for accurate plasma 
NO2- analysis and may contribute to uncertainty regarding NO bioavailability in PCOS. 
 
Oxidative stress, an imbalance arising from excess production of oxidants in the presence of 
reduced antioxidant capacity, can also reduce NO bioavailability and induce endothelial 
dysfunction. A recent meta-analysis found evidence of altered antioxidant capacity (increased 
SOD and reduced glutathione levels) and indices of oxidative stress in PCOS subjects compared 
to controls (145). However, the studies that underpinned the meta-analysis were generally 
limited to measurement of oxidant or antioxidant molecules in isolation and/or measurement of 
reaction end-products as surrogates of oxidative stress. Direct detection of ROS is challenging 
due to their potent reactivity but is essential if over-estimation of oxidative burden is to be 
avoided.  
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3.2 Aims 
The aim of this chapter was to establish whether NO bioavailability and oxidant status is altered 
in a cohort of carefully characterised young women with PCOS free of overt cardiovascular 
disease, using sensitive, validated methodologies to directly assess plasma NO2- / NO3-, plasma 
antioxidant capacity and lipid-derived free radicals. 
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3.3 Methods  
3.3.1 Clinical study design 
Ethical approval is detailed in section 2.1 (General Methods). Subject characteristics, 
anthropometric measurements and blood sampling are described in sections 2.2, 2.3 and 2.5, 
respectively. Biochemical measurements were carried out at the Department of Medical 
Biochemistry at the University Hospital of Wales, as noted in section 2.4. 
 
3.3.2 Determination of NO metabolites 
Plasma NOx was measured using ozone-based chemiluminescence, as detailed in section 2.6. 
Specifically, plasma NO3- was assessed using VaCl/HCL cleaving reagent, as described in 
section 2.6.3. This reagent reduces all plasma NOx (total plasma NOx apart from nitrated fatty 
acids). Plasma NO2- concentration was determined using I3- reducing reagent as described in 
section 2.6.2. This cleaves NO from non-NO3- associated NO metabolites (i.e. NO2- and RSNO). 
To distinguish between these two metabolites, acidified sulphanilamide is used to remove NO2-, 
and allows detection of RSNO alone. Plasma NO3- level was calculated by: NOx concentration 
(determined by VaCl) minus NO concentration determined by I3-. Plasma NO2- was calculated 
by: NO concentration determined by I3- minus NO level following acidic sulphanilamide pre-
treatment. 
 
3.3.3 Assessment of circulating free radicals and 
systemic oxidative burden 
Circulating lipid-derived radicals were qualitatively and quantitatively assessed using EPR – 
spin trapping and the FOX assay, respectively, as described in sections 2.7.1 and 2.8. Computer 
simulations were carried out using Bruker WIN-EPR (Simfonia, Coventry, UK) computer 
simulation software (version 1.25). Plasma antioxidant capacity was determined using ORACfl, 
as described in section 2.9. 
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3.3.4 Statistics 
Data were analysed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) and Graphpad 
prism 5 (Graphpad software, CA, USA). The Kolmogorov–Smirnov test was used to check the 
data for normality. Analysis between groups was performed using the independent t-test or 
Mann–Whitney U-test for normally or non-normally distributed data, respectively. Age-adjusted 
correlation coefﬁcients were used to explore the strength of the relationships between in vitro/ex 
vivo oxidation and testosterone, regional fat area and insulin sensitivity. Multiple regression 
analysis was performed to explore the dependence of in vitro and ex vivo oxidation on age, 
regional fat area, testosterone and insulin AUC. Results are expressed as mean ± SD or median 
(range), unless otherwise stated. A p-value <0.05 was regarded as statistically signiﬁcant. 
Sample size calculations were based on previous published data (within our research group), 
which demonstrated a 0.28-fold shift in SD in lipid-derived radicals in women with type 2 
diabetes compared with controls (270). To detect a similar shift in SD with >90% power at the 
5% α level, we sought to recruit at least 14 women in each group. A shift in SD of this 
magnitude was deemed clinically signiﬁcant, because this has previously been associated with 
endothelial dysfunction (270). 
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3.4 Results  
3.4.1 Clinical and metabolic characteristics 
Table 3.1 shows the baseline clinical and metabolic characteristics of the PCOS subjects and 
healthy volunteers. There were no significant differences observed between the groups in age, 
BMI, waist/hip circumference, subcutaneous/visceral/total fat area, lipids, hsCRP or glucose 
area under the curve (AUC). As anticipated, insulin AUC and total testosterone were higher in 
PCOS subjects.  
 
Table 3.1 Anthropometric and metabolic characteristics of study population 
 
PCOS 
(n = 17) 
Healthy volunteers 
(n = 18) 
p value 
Age (years) 31 ± 6 31 ± 7 0.9 
Weight (kg) 78 ± 21 76 ± 15 0.68 
BMI (kg/m2) 30 ± 6 29 ± 6 0.61 
Waist circumference (cm) 91 ± 15 86 ± 13 0.31 
Hip circumference (cm) 111 ± 16 106 ± 12 0.24 
Waist–hip ratio 0.82 ± 0.05 0.82 ± 0.01 0.94 
Visceral fat area (cm2) 31 ± 23 26 ± 14 0.46 
Subcutaneous fat area (cm2) 287 ± 119 298 ± 114 0.78 
Total fat area (cm2) 318 ± 133 324 ± 124 0.89 
Testosterone (nmol/l) 1.4 ± 0.6 0.9 ± 0.6 0.02 
hsCRP (mg/l) 1.25 (0.24 - 21.8) 0.9 (0.17 - 16.73) 0.73 
Total cholesterol (mmol/l) 4.6 ± 1.3 4.8 ± 1.1 0.67 
Triglycerides (mmol/l) 1.2 ± 1.4 1.0 ± 0.5 0.52 
LDL cholesterol (mmol/l) 2.4 ± 1.4 2.5 ± 1.3 0.79 
HDL cholesterol (mmol/l) 1.2 ± 0.5 1.3 ± 0.6 0.65 
Insulin AUC (pmol min/l) 80 ± 46 52 ± 29 0.04 
Glucose AUC (nmol min/l) 764 ± 217 692 ± 133 0.24 
HOMA-IR 1.9 ± 0.9 2.5 ± 2.4 0.37 
Data are presented as mean ± SD or median (range). BMI, body mass index; hsCRP, high 
sensitivity C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; 
HOMA-IR, homeostatic model assessment – insulin resistance; AUC: area under the curve. 
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3.4.2 Plasma NO metabolites 
No significant differences were found between PCOS subjects and healthy volunteers in plasma 
NO2- (257 ± 116 nM versus 261 ± 135 nM, respectively, p = 0.93) (figure 3.1. A) or NO3- levels 
(27 ± 7 μM versus 26 ± 6 μM respectively, p = 0.89, figure 3.1. B). Plasma RSNO levels were 
also similar between PCOS patients and healthy volunteers (40 ± 34 nM versus 42 ± 39 nM, 
respectively, p = 0.88, figure 3.1. C). These values are within the expected range for healthy 
adult individuals, as previously reported by our laboratory and other research groups (28, 33). 
P
C
O
S
H
V
0
100
200
300
400
N
O
 (
n
M
)
P
C
O
S
H
V
0
10
20
30
N
O
 (
µ
M
)
P
C
O
S
H
V
0
20
40
60
N
O
 (
n
M
)
A B
C
 
Figure 3.1. Plasma NO metabolite levels: (A), (B) and (C) show plasma NO2-, NO3- and 
RSNO concentrations, respectively. [PCOS: n = 17, HV: n = 18]. Each sample was analysed in 
duplicate and the mean was used in further analysis. Data is expressed as the group mean ± 
SEM. The intra-assay coefficient of variation was <5 % for NO2- (A) and RSNO (C) 
measurements, and <8 % for NO3- measurements (C). 
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3.4.3 Free radical determination in blood 
Qualitatively, the spectral characteristics (hyperfine coupling constants) were used to 
specifically identify radical species against reference/standard values (270). The radicals trapped 
were identified as lipid-alkoxyl radicals (LO−, characterised by coupling constants αN = 14 
Gauss (G), αH = 2.3 G, figure 3.2).  The EPR spectra also revealed the presence of a PBN 
radical artefact (αN = 15 G; αH = 5 G) which has been recognised in the literature and is not 
considered to adversely affect radical detection. To control for possible experimental initiation 
of radical/PBN adducts, blood was collected directly into EDTA vacutainers containing 200mM 
PBN covered in foil which limited transient extracellular leakage of Fe3+ and photolytic 
degradation of PBN. No species were detected from PBN alone. In addition, no species were 
detected when blood was taken into a syringe and transferred to an EDTA vacutainer containing 
PBN (figure 3.3).  
 
Quantitatively, circulating lipid-derived radicals were similar between PCOS subjects (7.2 (0.17 
– 16.73) x 106 arbitrary units (a.u.) and healthy volunteers (7.2 (1.7 – 11.9) x 106 a.u, p = 0.57, 
figure 3.4 A). Ferrous sulphate-oxidised plasma was used as a measure of in vitro lipid radical 
formation potential. No difference in susceptibility to form lipid-derived radicals was observed 
between PCOS subjects and healthy volunteers (1.23 (0.3 – 5.62) x 107 a.u. and 1.1 (0.48 – 15.7) 
x 107 a.u. respectively, p = 0.71, figure 3.4 B). 
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Figure 3.2. Typical EPR spectrum obtained by ex vivo free radical measurement. The 
PBN/radical adducts measured herein yield a six line ('triplet of doublets') spectrum. The six 
line spectra is the result of the interaction between the free electron and the probe (PBN, which 
possess a nitrogen (αN) and hydrogen nucleus (αH)). Hyperfine coupling constants (shown in 
brackets, * and **) of the paramagnetic species are an intrinsic and unique property of the 
trapped radical and is thus utilised for identification. (*) Indicates the primary alkoxyl (LO-) 
radical, αN = 14 Gauss (large bracket) αH = 2.3 Gauss small bracket, (**) indicates 
PBN/artifact, αN = 15 Gauss αH = 5 Gauss. 
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Figure 3.3. Representative EPR spectrum: Plasma lipid-derived radicals and experimental 
controls. (A) Example ex-vivo spectrum. (B) Example in vitro spectrum. Computer 
programming (Simfonia©) was used for qualitative confirmation of radical species identified in 
(A) and (B). (C) Simulation of the primary alkoxyl radical (LO-, αN = 14 Gauss, αH = 2.3 
Gauss). (D) Simulation of an established PBN artefact detected within the experimental spectra 
(αN = 15 G; αH = 5 G). Ferrous sulphate/PBN generated an additional PBN artifact that was 
subtracted from the in vitro oxidation spectrum (E). No signal was generated from blood drawn 
into a syringe and then transferred directly to an EDTA vacutainer containing PBN, eliminating 
experimental initiation of radicals as an artifact (F). (G) PBN and saline alone produced no 
signal. Ordinates for all the spectra are plotted normalised to the same scale. 
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Figure 3.4. EPR measurements – Oxidative burden.  Figure. (A) and (B) show the results of 
EPR analysis (ex vivo oxidative stress and in vitro oxidative potential, respectively) where the 
peak height was considered proportional to the amount of relative spin adduct concentration. 
[PCOS: n = 17, HV: n = 18]. Results are expressed as mean ± SEM.  
 
The FOX assay was used to provide a marker of gross oxidative stress. Plasma hydroperoxide 
(ROOH) levels were similar between PCOS subjects and healthy volunteers (7.5 ± 4 µM and 
6.7 ± 5 µM, respectively, p = 0.21, figure 3.5).  
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Figure 3.5. FOX assay – total plasma hydroperoxides (ROOH). Total plasma hydroperoxide 
(ROOH) concentration was measured by the FOX assay, a colorimetric method that involves 
the selective oxidation of ferrous to ferric ions by plasma ROOH. [PCOS: n = 17, HV: n = 18]. 
Results are expressed as mean ± SEM.  
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3.4.4 Antioxidant capacity 
Total plasma antioxidant capacity and the lipophilic antioxidant capacity was assessed using 
ORACfl. Results reflect the ability of plasma (or selectively the lipophilic components of 
plasma) to buffer against AAPH, a thermally activated peroxyl-radical insult. Total plasma 
antioxidant capacity was similar between the PCOS group and healthy volunteers (94 ± 30 % 
and 79 ± 24 % respectively, p = 0.09, figure 3.6 A). However, PCOS subjects displayed a 
reduced lipophilic antioxidant capacity in comparison to healthy volunteers (92 ± 32 % and 125 
± 48 % respectively, p = 0.02, figure 3.6 B).  
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Figure 3.6 Plasma antioxidant measurements: (A) and (B) show plasma (total) antioxidant 
capacity and lipophilic antioxidant capacity, respectively. Antioxidant measurements represent 
the ability to buffer an insult from a thermo-activated peroxyl radical insult. [PCOS: n = 17, 
HV: n = 18]. Results are expressed as a percentage of 100 µM Tempo equivalents, a validated 
antioxidant. Each sample was analysed in triplicate and the mean was used in further analysis. 
Data is expressed as the group mean ± SEM.. * p<0.05. 
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3.4.5 Relationship of oxidative burden with insulin 
sensitivity, hyperandrogenism and regional 
adiposity 
In PCOS subjects, after adjustment for age, in vitro oxidative capacity correlated moderately 
with testosterone (r = 0.64, p = 0.07) and insulin AUC (r = 0.51, p = 0.04), and strongly with 
visceral fat area (r = 0.76, p = 001). No significant relationships were noted with ex vivo radical 
generation in PCOS subjects. In control women, in vitro oxidative capacity correlated 
moderately with subcutaneous fat area (r = 0.53, p = 0.03) and visceral fat area (r = 0.58, p = 
0.01), and negatively with testosterone (r = -0.55, p = 0.02). Ex vivo radical generation 
correlated moderately with visceral fat area (r = 0.49, p = 0.046). When PCOS and control 
women were analysed together, in vitro oxidative capacity correlated moderately with insulin 
AUC (r = 0.42, p = 0.01) and strongly with visceral fat area (r = 0.72, p <0.001) but in multiple 
linear regression analysis, only visceral fat area remained significant in the model (β = 0.6, p = 
0.002).   
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3.5 Discussion 
3.5.1 Main Findings 
Previous studies have measured indices of global NO metabolism and oxidant status in subjects 
with PCOS with mixed results. To my knowledge this is the first study to specifically assess 
plasma NO2-  (reflecting endothelial NO bioavailability), and directly measure circulating ROS 
levels (lipid-derived free radicals) in blood, in patients with PCOS using a series of sensitive, 
‘gold standard’ methodologies. There was no evidence for altered NO bioavailability or stressed 
nitrosative/oxidative metabolism in these patients, other than PCOS subjects did show reduced 
lipophilic antioxidant capacity compared with healthy volunteers.  
 
3.5.2 Interpretation 
Plasma NO2- and NO3- levels were unaltered in PCOS subjects compared to age- and BMI-
matched controls. These findings are consistent with previous reports (138, 139, 142, 266-269) 
but contrast with observations from many studies of endothelial function in patients with PCOS 
which have shown reduced FMD compared to healthy volunteers (265). These discrepancies 
may relate to the difficulties in measuring local, endothelial-derived NO that has an extremely 
short circulatory half-life estimated at less than 1 second. Researchers are thus reliant on 
measurement of NO2- and NO3-, the major metabolites of NO generated by stepwise oxidation, 
which are widely used as an index of endothelial NO synthase activity (41, 271). However, 
plasma NO2- and particularly NO3- reflect not only endogenous NO production but also dietary 
NO3- ingestion. I was careful to minimise the influence of dietary variation by fasting subjects 
overnight prior to measurement, however I cannot entirely rule out the possibility that dietary 
factors might have impacted upon my findings. Furthermore, in some instances plasma NO 
status may not reflect tissue NO status (272). Notwithstanding these limitations, my 
observations do not support a major alteration in NO bioavailability in women with PCOS, with 
values measured in the control and PCOS group similar to those measured across a broad range 
of healthy subjects (30).  
 
Oxidative stress was also unaltered in PCOS patients compared with healthy volunteers. This is 
in contrast to most previous studies in women with PCOS which have shown an increased 
oxidative burden but have relied upon measurement of reaction end-products as biomarkers of 
damage to lipids and proteins (145). These measures are associated with a complex 
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biochemistry where the different thermodynamic and kinetic properties may contribute to 
overestimation of oxidative burden and inconsistent results. To my knowledge, this study is the 
only one to directly assess oxidative burden by EPR spectroscopy, the only analytical technique 
capable of direct detection of free radical species. Analysis of EPR spectra identified alkoxyl 
free radicals (LO−) as the dominant species present in the circulation of both subject groups. 
Previous studies have suggested that alkoxyl radicals evolve during a reaction catalysed by Fe2+ 
reductive decomposition of extracellular lipid hydroperoxides formed subsequent to primary 
radical-mediated damage to membrane phospholipids (144). Lipid-derived radical 
concentrations, whether measured directly ex vivo or in vitro, and plasma hydroperoxide levels 
were not different in women with PCOS compared to controls. However, the strongest 
implication of an oxidative burden from the observed relationship between visceral fat area and 
insulin AUC, implying that oxidative stress is linked predominantly with central adiposity and 
insulin resistance rather than PCOS per se. This may reflect accelerated adipocyte lipolysis in 
the pro-inflammatory obese state, leading to increased non-esterified fatty acids and 
subsequently increased ROS generation in mononuclear cells (123).  
 
Interestingly, lipophilic but not total antioxidant capacity was reduced in PCOS subjects 
compared to healthy volunteers. Previous studies have noted reduced total antioxidant capacity 
in women with PCOS, independent of BMI or insulin resistance (151, 273). In contrast, a meta-
analysis of six studies of total antioxidant capacity, including 470 women, found no significant 
difference between women with PCOS and controls (145). This is in agreement with our 
findings, although a trend towards an increased total antioxidant capacity in PCOS subjects was 
noted, but this did not quite achieve statistical significance, suggesting that antioxidant activity 
in the hydrophilic compartment may have undergone a compensatory increase to maintain 
homeostasis. The antioxidant capacity of the aqueous compartment is accounted for by proteins 
(including albumin) and ascorbic acid whereas fat-soluble antioxidants such as carotenoids and 
α-tocopherol are located in the lipoprotein core. Individual carotenoids may reflect dietary 
intake of fruits and vegetables, whereas plasma tocopherol concentrations correlate with vitamin 
E intake. Circulating vitamin E concentrations may be lower in women with PCOS compared 
with controls but vitamin A and β-carotene levels appear to be unchanged (149). 
 
A depletion of antioxidant defences, accompanied by increased ROS production, is a hallmark 
of other diseases characterised by insulin resistance, notably type 2 diabetes (149). This redox 
imbalance leads to increased production of free radicals such as O2-, which promote vascular 
smooth muscle contraction via inhibition of endothelial-dependent relaxation. Lipophilic 
antioxidant capacity may be especially important in regulating oxidation of LDL-cholesterol. 
LDL oxidation induces an inflammatory cascade and binding to scavenger receptors on the 
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surface of macrophages leading to foam cell generation and atherosclerotic plaque formation. 
Whilst oxidised LDL was not measured in this study, others have found that circulating 
concentrations are increased in women with PCOS (148, 274) although this is not a consistent 
finding (275). 
 
3.5.3 Limitations 
This study is the first to employ a series of sensitive methodologies to specifically assess plasma 
NO metabolites and directly detect free radical formation in the circulation of patients with 
PCOS. A detailed metabolic and anthropometric characterisation was also undertaken in order 
to understand the relationships of NO/oxidative status with insulin sensitivity and body fat 
distribution. However, although the well-established Rotterdam criteria was used to classify the 
PCOS population in this study, this may be associated with a less severe metabolic phenotype 
than other definitions of the syndrome (276). Hence it is possible that patients defined by NIH 
or Androgen Excess Society criteria might have more significant disturbances in cardiovascular 
homeostasis and oxidative burden. This particular cohort were also relatively young and it is 
tempting to speculate that disturbances in vascular NO metabolism and oxidative stress may not 
emerge until later in the disease course, in line with findings from studies of carotid intima 
media thickness where meaningful differences in atheroma burden were not apparent until 
middle age (264). Long-term dietary influences on antioxidant status are also difficult to adjust 
for, but we sought to minimise these effects by asking subjects to abstain from antioxidant 
medication prior to participation.  
 
3.5.4 Conclusion 
Further studies are needed to establish the causes and consequences of altered antioxidant 
capacity in women with PCOS but in the meantime our study confirms there is little evidence of 
abnormal NO/oxidative metabolism in young, overweight women with PCOS. This is in 
agreement with a recent finding within our research group, from a large population-based study 
in which Morgan et al (153) found no evidence for an increased incidence of cardiovascular 
events in young women with PCOS. Whilst these data may reassure clinicians treating young 
patients with PCOS that cardiovascular risk is not increased at this age, young women with 
PCOS are at increased risk of type 2 diabetes which is worsened by weight gain (153). Since a 
strong association of visceral fat with oxidative capacity was found, I speculate that weight loss 
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may be the most important measure in reducing oxidative stress and cardiometabolic risk in 
women with PCOS, although further trials are still needed to confirm if this is the case. 
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3.5.5 Key findings 
 There was no evidence for altered NO bioavailability (plasma NO2- and NO3-) in 
PCOS patients when compared to age/BMI matched healthy volunteers. 
 Indices of oxidative stress were also unaltered in PCOS patients. 
 The total antioxidant capacity of plasma was similar between women with PCOS and 
healthy volunteers.  
 PCOS patients presented with a decreased lipophilic antioxidant capacity compared to 
healthy volunteers.  
 Within the PCOS group, in vitro oxidative capacity correlated with testosterone, 
insulin AUC and visceral fat area. Across both group’s, in vitro oxidative capacity was 
independently associated with visceral fat.  
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4. RESULTS CHAPTER 
 
Comprehensive characterisation of circulating microparticles in 
women with polycystic ovary syndrome 
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4.1 Introduction 
Even though there is little biochemical evidence of nitro-oxidative stress in women with PCOS, 
there remains significant evidence suggesting that PCOS patients may be at increased risk of 
CVD, including hypertension (78) and endothelial dysfunction (11, 92, 277) but the 
mechanisms by which these occur are not yet fully established. Endothelial dysfunction, an 
early marker of vascular disease, is associated with reduced NO bioavailability and increased 
oxidative stress. However, in the PCOS patients (cohort studied and described in chapter 3), 
there was little direct evidence to suggest the presence of an increase in nitro-oxidative stress. 
More recently, elevated circulating MP levels has been associated with endothelial dysfunction 
(245, 278), however little is known about MPs in PCOS. 
 
MPs are small (30-1000 nm diameter) membrane-enclosed vesicles released from a variety of 
prokaryotic and eukaryotic cells including platelets, monocytes and endothelial cells (154). 
They represent a homeostatic communication network between source and target cells, but may 
also play a role in disease pathology. Marked elevations in MP concentration have been 
reported in patients with cancer (279), diabetes (280), sepsis (188), hypertension (235) and 
myocardial ischaemia (191). Furthermore, elevations in PMPs have been observed in patients 
with CAD (233, 280). 
 
MPs are formed during cell activation by a range of stimuli including apoptosis, inflammation 
and cellular differentiation (154).  During formation, the phospholipid membrane asymmetry of 
the parental cell is altered causing translocation of PS moieties from the inner to the outer 
membrane bilayer. This exposure of negatively charged phospholipids to the outer bilayer, a key 
characteristic for MP identification, increases the potency of target cell interactions. For 
example, increased exposure of PS on the surface of PMPs renders their surface approximately 
50 to 100 fold more procoagulant than the surface of activated platelet membranes (180). 
 
Communication between MPs and target cells occurs via membrane-anchored receptors and 
surface adhesion molecules. Additionally, MPs are enriched with bioactive cargo from the 
parent cell including cytokines, chemokines, growth factors, fatty acids, mRNA and miR (281). 
In vitro studies indicate that MPs can pass this cargo into target cells, leading to alteration of 
cellular lipid metabolism, cell signalling and transduction. Barry and colleagues (282, 283) 
found that PMPs induce platelet activation through the transfer of arachidonic acid (C20:4n6, 
AA), which propagates pro-inflammatory effects via metabolism to thromboxane.  
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These observations suggest that MPs may play an important role in the pathogenesis of vascular 
dysfunction in ‘at risk’ populations. In this sense, MPs may play a critical role in the 
progression of PCOS pathology. The characteristics of circulating MPs in patients with PCOS is 
poorly described. Koiou et al (186) reported increased PMP concentrations in patients with 
hyperandrogenic PCOS, but the MP cell-of-origin, fatty acid composition and cellular cargo 
were not assessed in their study.  
 
4.2 Aims 
In light of these considerations, the aim of this chapter was to undertake a detailed 
characterisation of circulating MP populations in patients with PCOS, hypothesising that PCOS 
patients would carry an adverse MP profile, which might represent an early marker of disease 
progression that contributes to increased vascular risk leading to the eventual clinical sequelae. 
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4.3 Methods 
4.3.1 Subjects and protocol 
Details of ethical approval are detailed in section 2.1. Subject characteristics and anthropometric 
measurements are described in sections 2.2 and 2.5, respectively. Biochemical measurements 
were carried out by the Department of Medical Biochemistry at the University Hospital of 
Wales, as noted in section 2.4. 
 
4.3.2 Isolation and storage of microparticles 
Blood sampling is described in section 2.5. Plasma derived MPs were isolated by differential 
ultra-centrifugation as detailed in section 2.10.  
 
4.3.3 Microparticle size, concentration and distribution 
Plasma derived MP size, concentration and distribution was assessed using NTA as described in 
section 2.11. Following ultracentrifugation sample pellets were resuspended in MP-free PBS. 
For NTA, the isolated MP fraction was diluted to achieve an optimum concentration of 2-10 
MPs x108/ml in MP-free sterile H2O. NTA detection and analysis settings were modestly 
optimised for each sample. Specifically, camera sensitivity and detection threshold were (14–
16) and (4–5), respectively. Samples were run in quintuplicate.  
 
4.3.4 Cellular origin of microparticles 
Antibody enabled flow cytometry was used to determine the cellular origin and extent of 
annexin V positivity of plasma derived MPs, as described in section 2.23.3. Results are 
expressed as a percentage of total events (MPs).  
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4.3.5 Lipid extraction and fatty acid analysis: 
microparticle and plasma  
MP and plasma lipid extraction details are described in section 2.13. GC-FID was used to 
generate detailed fatty acid profiles of plasma and corresponding plasma-derived MPs, as noted 
in section 2.13. For plasma fatty acid concentration, results are expressed as µg/100µl of 
plasma. MP fatty acid concentration is normalised to MP count (determined by NTA) and 
expressed as pg / 1x106 MPs. MP and plasma fatty acid composition represents the proportion 
(%) of individual fatty acids in relation to the total concentration.  
 
4.3.6 Analysis of microRNA expression within plasma 
derived microparticles 
Comprehensive miR expression profiling of plasma derived MPs was undertaken on a small 
subset of PCOS patients (n = 6, age: 33.8 ± 5 yrs, BMI: 28 ± 5 kg/m2) and healthy controls (n = 
6, age: 29.3 ± 5 yrs, 28 ± 6 BMI kg/m2). miR profile analysis was performed using Toray 3D-
Gene™ DNA Chip microarrays (Toray Industries Inc, Tokyo, Japan) as described in section 
2.13. Additionally, miR 4700-5p was selected for validation by standard quantitative PCR 
(qPCR, PCOS patients (n = 12, age: 30 ± 6 yrs, BMI: 30 ± 6 kg/m2) and healthy controls (n = 9, 
age: 25 ± 2 yrs, BMI: 26 ± 6 kg/m2)), detailed in section 2.14.  
 
4.3.7 Statistics 
Data were analysed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, 
USA). D'Agostino's K-squared test was used to check data for normality. Analysis between 
groups was performed using the independent t-test or the Mann-Whitney U-test for normally or 
non-normally distributed data, respectively. Spearman’s rank correlation coefficients were used 
to explore the strength of the relationship between MP concentration and biochemical 
parameters. The normalised microarray data were subjected to a Quantile-Quantile 
normalisation, log2 transformed then analysed using an unpaired Student’s t-test.  Results are 
expressed as mean ± SD unless indicated. A p-value <0.05 was considered statistically 
significant. Sample size calculations were based on previous data, which demonstrated a 0.55 
fold shift in mean circulating MP concentration in women with hyperandrogenic PCOS 
compared to control subjects (186). Thus, to detect a similar shift in MP concentration, with 
>90% power at the 5% α level, a minimum of 15 subjects were recruited in each group.  
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4.4 Results 
4.4.1 Clinical and metabolic characteristics 
The metabolic and clinical characteristics of the PCOS and healthy volunteer groups are 
previously described in table 3.1 and section 3.4.1. Briefly, PCOS subjects (n = 17, 31 ± 6 and 
30 ± 6 age (yrs) / BMI kg/m2) had higher testosterone levels and a greater insulin response to an 
oral glucose challenge, indicating reduced insulin sensitivity compared to healthy volunteers (n 
= 18, 31 ± 7 and 29 ± 6 age (yrs) / BMI kg/m2). No significant differences were observed 
between groups with respect to age, BMI, waist/hip circumference, lipid profile, hsCRP or 
glucose AUC.  
 
4.4.2 Circulating microparticle concentration and size 
PCOS subjects had increased total circulating MP concentration compared to healthy volunteers 
(11.45 ± 5 x1012/ml vs. 9.98 ± 4 x1012/ml, respectively; p = 0.03; figure. 4.1 A). In PCOS 
subjects, total MP concentration correlated significantly with HOMA-IR (r = 0.53, p = 0.03). 
MP size was similar in both groups (123 ± 7 nm vs. 114 ± 4 nm, respectively; p = 0.18; figure 
4.1 B). To assess MP distribution, MP concentrations were grouped in 50 nm bin sizes (figure 
4.1 C). PCOS subjects displayed an elevated concentration of small MPs (in the exosomal 
range, <150 nm in diameter) only, compared to healthy volunteers (as highlighted in table 4.1). 
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Table 4.1 Distribution of plasma derived-MPs: PCOS versus HV.  
MP size (nm) PCOS (n = 17) HV (n = 18) p value 
0-50 4.27 ± 1.08 x108/ml 2.8 ± 1.48 x108/ml 0.002 
51-100 3.71 ± 1.08 x109/ml 2.52 ± 1.07 x109/ml 0.002 
101-150 4.71 ± 1.92 x109/ml 3.38 ± 0.9 x109/ml 0.001 
151-200 2.04 ± 1.12 x109/ml 1.51 ± 0.36 x109/ml 0.07 
201-250 5.34 ± 4 x108/ml 3.91 ± 1.25 x108/ml 0.17 
251-300 1.3 ± 1.07 x107/ml 9.55 ± 5.1 x107/ml 0.24 
301-350 3.58 ± 2.57 x107/ml 3.34 ± 2.68 x107/ml 0.79 
351-400 1.31 ± 0.9 x107/ml 1.34 ± 1.3 x107/ml 0.93 
401-450 1.89 ± 1.1 x107/ml 2.04 ± 1.62 x107/ml 0.75 
451-500 1.91 ± 1.56 x106/ml 2.91 ± 2.5 x106/ml 0.18 
501-550 2.83 ± 2.3 x105/ml 4.56 ± 3.93 x105/ml 0.13 
551-600 5.86 ± 6.3 x103/ml 1.27 ± 2.56 x104/ml 0.28 
600-1000 - - - 
[PCOS: n = 17, HV: n = 18]. MPs with a diameter of 600 – 1000 nm were infrequent. MP, 
microparticle; PCOS, polycystic ovary syndrome. Each sample was analysed in quintuplicate 
and the mean was used in further analysis. Data is expressed as the group mean ± SEM. 
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Figure 4.1. Quantification of circulating microparticles. (A) Plasma MP concentration in 
PCOS patients and healthy volunteers determined by NTA. (B) MP size. (C) Size distribution of 
plasma-derived MPs (presented in 50 nm bin sizes). [PCOS: n = 17, HV: n = 18]. Each sample 
was analysed in quintuplicate and the mean was used in further analysis. Data is expressed as 
the group mean ± SEM. * denotes p <0.05.  
128 
 
4.4.3 Cellular origin of circulating microparticles 
MP cellular origin was determined by flow cytometry using monoclonal antibodies specific for 
the lineage markers CD41 (platelet), CD144 (endothelium) and CD11b (monocyte). In order to 
adhere to standard definitions, MPs were defined as annexin V positive MPs <1 µm in diameter. 
A greater percentage of annexin V+ MPs was detected in PCOS subjects compared to healthy 
controls (83.6 ± 18 % vs. 74 ± 24 %, respectively; p = 0.05; Figure 4.2 A). PMPs (CD41 
positive MPs) occupied by far the greatest proportion of annexin V positive circulating MPs in 
both PCOS subjects and healthy volunteers (99.3 ± 0.9 % vs. 98.6 ± 2.5 %, respectively; p = 
0.27; figure 4.2 A). Annexin V and CD144 or CD11b positive MPs (endothelial and monocyte-
derived MPs, respectively) were infrequent (figure 4.2 B). A similar trend was observed in the 
annexin V negative MP population. PMPs occupied the largest proportion of circulating MPs in 
both PCOS subjects and healthy volunteers (94 ± 4% vs. 94 ± 9%, respectively; p = 0.8). 
Annexin V negative but CD144 or CD11b positive MPs were infrequent. 
 
 
Figure 4.2. Annexin positivity and cellular origin of annexin V positive plasma-derived 
MPs. (A) The percentage of annexin V positive MPs in PCOS patients and healthy controls 
determined by flow cytometric analysis. (B) Plasma MP cellular origin, determined by flow 
cytometric analysis of the lineage-specific markers CD41 (platelet), CD144 (endothelium) and 
CD11b (monocyte) of annexin V positive MPs <1 µm in diameter. [PCOS: n = 17, HV: n = 18]. 
Data are presented as mean ± SEM.  
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4.4.4 Fatty acid analysis 
Since an altered lipid metabolism may be a feature of PCOS, I explored if MPs similarly 
exhibited an altered fatty acid profile. Using GC-FID, the total fatty acid concentration of MPs 
was similar in PCOS subjects and healthy volunteers (9 ± 9 pg/106 MPs vs. 12 ± 11 pg/106 MPs, 
respectively; p = 0.39; figure. 4.3 A).  No differences in individual MP fatty acid composition 
were found between PCOS patients and healthy controls (figure. 4.3 B).  
 
To assess whether MP fatty acid composition was unique to MPs and not simply reflecting 
plasma fatty acid distribution, I also undertook an analysis of plasma fatty acids (figures 4.3 C 
and D). In an analysis of all PCOS and healthy volunteer samples, MP fatty acid composition 
was found to be different from the fatty acid composition of plasma, whereby 14 fatty acids 
were differentially enriched (p <0.05, table 4.2). No differences were found between PCOS 
patients and healthy volunteers with respect to total plasma fatty acid concentrations (426 ± 99 
µg / 100 µl and 335 ± 51 µg / 100 µl, respectively, p = 0.65, figure. 4.3 C) but individually, 
several plasma fatty acid concentrations were elevated in PCOS subjects including C14: 1 
(myristoleic acid), C16: 1n9 (hexadecenoic acid), C22: 3n6 (docosatrienoic acid) and C22: 5n3 
(docosapentaenoic acid, all p<0.05). 
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Figure 4.3. Fatty acid analysis. GC-FID was used to measure fatty acids in plasma and circulating MPs. (A) Fatty acid concentration in circulating 
MPs. (B) Fatty acid composition of plasma derived MPs. (C) Total fatty acid concentration in plasma, reflecting fatty acid concentration per 100 μl of 
plasma (D) Fatty acid composition of plasma (%). [PCOS: n = 17, HV: n = 18]. Data are presented as mean ± SEM. * denotes p <0.05. 
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Table 4.2 Comparison between microparticle and plasma fatty acid composition 
 MP Plasma  
Fatty Acid Mean SD Mean SD p value 
C14 :0 0.93 % 0.60% 0.67% 0.35% 0.038 
C14: 1 0.20 % 0.21 % 0.09 % 0.11 % 0.012 
C16: 0 27.32 % 5.82 % 20.80 % 3.27 % <0.001 
C16: 1 0.56 % 0.64 % 0.78 % 1.94 % 0.519 
C16: 1n7 1.59 % 2.15 % 1.82 % 0.68 % 0.562 
C18: 0 12.95 % 4.07 % 7.59 % 1.24 % <0.001 
C18: 1n9 30.69 % 5.58 % 22.07 % 3.32 % <0.001 
C18 1n7 0.36 % 1.73 % 1.67 % 2.94 % 0.028 
C18 2n6 12.72 % 6.04 % 28.20 % 4.05 % <0.001 
C18 3n6 0.20 % 0.20 % 0.42 % 0.20 % <0.001 
C18: 3n3 0.51 % 0.43 % 0.74 % 0.24 % 0.008 
C20: 0 0.56 % 0.53 % 0.93 % 2.91 % 0.466 
C20: 2n6 0.95 % 0.61 % 1.67 % 0.41 % <0.001 
C20: 4n6 5.74 % 3.85 % 6.83 % 1.61 % 0.139 
C20: 5n3 0.31 % 0.25 % 0.77 % 0.30% <0.001 
C22:0 1.40 % 0.95 % 0.48 % 0.20 % <0.001 
C22: 3n3 0.39 % 0.55 % 0.23 % 0.27 % 0.137 
C22: 3n6 0.23 % 0.25 % 0.25 % 0.13 % 0.743 
C22: 5n3 0.34 % 0.32 % 0.44 % 0.13 % 0.114 
C22: 6n3 0.86 % 0.68 % 1.83 % 0.54 % <0.001 
C24: 0 0.51 % 1.06 % 0.33 % 0.13 % 0.346 
C24: 1n9 0.33 % 0.27 % 0.70 % 0.27 % <0.001 
MP, microparticle. Mean and SD values represent data from across both subject groups [n = 
37].  
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4.4.5 Analysis of microRNA expression 
Toray 3D-Gene™ chip analysis was employed to profile the miR content of circulating MPs in 
a subpopulation of PCOS patients and healthy controls. In excess of 1,600 antisense probes 
were plated onto the miR chip. All subjects analysed had a total miR count of >500. Similar 
miR expression profiles were observed between groups for the most highly expressed miRs. 
However, among the lowly expressed miRs, 16 were differentially expressed between groups 
(figure 4.4, table 4.3). qPCR was used to validate the differentially expressed miR 4700-5p.  
Women with PCOS displayed a threefold-elevated expression of miR 4700-5p compared to 
healthy volunteers, but this did not quite reach significance (p = 0.1).  
 
 
 
Figure 4.4. microRNA (miR) expression in plasma-derived microparticles. In excess of 
>1,600 miRs were analysed using the Toray 3D-Gene™ microarray platform. The volcano plot 
depicts differentially expressed miRs between PCOS patients and healthy volunteers. A -log10 
p-value >1.3 equates to p <0.05. 16 miRs were differentially expressed at this threshold. [PCOS 
patients (n = 6), healthy controls (n = 6)]. 
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Table 4.3 Differentially expressed miRs in circulating microparticles 
microRNA (miR) Expression ratio p value 
hsa-miR-551a 0.91 <0.001 
hsa-miR-4324 0.80 0.007 
hsa-miR-3689b, hsa-miR-3689c 1.11 0.009 
hsa-miR-1293 0.84 0.012 
hsa-miR-3936 1.10 0.012 
hsa-miR-4481 0.88 0.019 
hsa-miR-629 1.16 0.019 
hsa-miR-4425 1.19 0.019 
hsa-miR-30b 0.89 0.021 
hsa-miR-3622a-3p 0.86 0.022 
hsa-miR-514b-5p 0.83 0.025 
hsa-miR-4700-5p 1.25 0.029 
hsa-miR-4708-3p 0.88 0.037 
hsa-miR-574-3p 1.19 0.038 
hsa-miR-4283 0.85 0.041 
hsa-miR-23a 0.86 0.043 
hsa-miR-3156-5p 1.18 0.047 
[PCOS patients (n = 6), healthy controls (n = 6)]. Expression ratio was calculated as average 
PCOS miR expression / average healthy control miR expression. All samples tested had total 
miR counts >500. 
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4.5 Discussion 
4.5.1 Main findings 
This study shows that patients with PCOS have increased concentrations of circulating annexin-
V positive MPs compared with age- and BMI-matched healthy volunteers. This study also 
found that these MPs are predominantly platelet-derived. Thus, it is tempting to speculate that 
these alterations may contribute to an increased cardiovascular risk. The findings in this chapter 
are consistent with those found in two previous studies in which PMPs were found to be 
elevated in lean (186) and overweight/obese (186, 284) hyperandrogenic patients with PCOS. 
However, this study extended these observations to characterise the fatty acid and miR profile 
of circulating MPs, and show an association between MP concentration and insulin resistance in 
this patient population.   
 
4.5.2 Interpretation 
A similar proportion of MPs derived from platelets, monocytes and ECs were detected in PCOS 
patients and healthy volunteers. In accordance with previous reports, we found that PMPs 
occupied the greatest percentage of circulating MPs (188). In contrast, others have found higher 
percentages of endothelial- and monocyte-derived MPs in healthy subjects (43% and 10.4%, 
respectively) (225) which may reflect different methodologies and pre-analytic protocols. 
Previous studies have shown that PMP concentrations are elevated in lean and overweight/obese 
women with PCOS compared to controls (186, 284). These studies used CD41-directed flow 
cytometry to assess PMPs only, hence they were unable to compare MP cellular origin. Using 
NTA I found that the increases in MP concentration in subjects with PCOS were largely due to 
an increased concentration of MPs in the small (<150 nm), exosomal range. This may suggest 
selective stimulation of the intracellular classical exosomal pathway compared to larger MPs 
(150-1000 nm diameter) formed via cell membrane shedding. The clinical significance of this 
elevated MP population remains unclear. Flow cytometry and sorting methodologies typically 
struggle to detect MPs that are <200 nm in diameter, however sucrose density gradients have 
isolated MPs (within the exosomal range) based on their density. Future studies could attempt to 
isolate the MPs in the exosomal range via sucrose density gradients and explore their functional 
characteristics (for example in isolated vessel experiments).  
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Koiou et al., (186) found a weak, but significant correlation between PMPs and serum 
testosterone levels in their study of lean patients with PCOS. In contrast, I noted a moderately 
strong correlation of MP concentration with homeostatic model assessment (HOMA)-IR in 
PCOS subjects, suggesting that elevated MP levels may be attributable, at least in part, to 
increased insulin resistance. This is in line with several reports of increased MP concentrations 
in patients with type 2 diabetes (175) including those with end-organ damage (285). Metabolic 
syndrome, a disorder underpinned by insulin insensitivity, is also characterised by an increased 
circulating MP concentration compared to healthy controls (190, 220, 286), where they may 
contribute to endothelial dysfunction via increased oxidative stress (190) and reduced NOS 
expression (220), although there is no evidence of this, as yet in this study. Hyperglycaemia 
(200), inflammation and stress (287) might also contribute to MP production. PCOS patients 
presented with a greater percentage of annexin V positive MPs. The extent of annexin V 
staining is largely taken to reflect binding to PS which increases the potency for target cell 
interactions and may contribute to enhanced pro-coagulant activity (180).  
 
Fatty acids are recognised as potent endocrine signalling molecules, which play an important 
role in MP function, via the direct transfer of bioactive fatty acids to induce pro-inflammatory 
responses in target cells (282). No differences were observed in MP fatty acid composition 
between PCOS patients and healthy controls. However, MP fatty acid composition was 
significantly different from that of plasma, perhaps indicating that MPs are ‘packaged’ with a 
unique fatty acid signature rather than merely reflecting the fatty acid composition of their 
environment. 
 
This is the first study to investigate the miR content of circulating MPs in patients with PCOS. 
In an exploratory sub-population, miR expression profiles were similar amongst women with 
PCOS and healthy volunteers for the most highly expressed miRs. However, 16 lowly-
expressed miRs were found to be differentially expressed. Of these, miR-1293, miR-551a and 
miR-574-3p may be particularly noteworthy, as these target cellular functions of relevance to 
PCOS pathology. miR-1293 targets peroxisome proliferator-activated receptor gamma (PPAR-
γ) co-activator (PPARGCA1), a pivotal regulator of glucose homeostasis. miR-551a regulates 
H6PD, mutations of which are recognised as a cause of hyperandrogenic PCOS (288), whilst 
mir-574-3p targets the follicle-stimulating hormone beta-subunit (FSHB) and follicle-
stimulating hormone receptor (FSHR) as previously noted in ovarian follicle fluid of PCOS 
patients (289). Previous studies have shown that MPs harbour a spectrum of miRs, and can 
offload their genetic content in target cells, altering their biological activity. Thus, data in this 
chapter suggests a novel mechanism by which PCOS may affect cardiometabolic risk.  
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4.5.3 Limitations  
There are a number of potential limitations to this study. Firstly, PCOS patients were classified 
by the Rotterdam criteria, which describes a less severe metabolic phenotype than other 
definitions of the syndrome (276). Thus, these findings may not necessarily be generalisable to 
all patients with PCOS, but the presence of an altered MP profile in this young, mildly insulin 
resistant population suggests that changes in MP expression may occur early in the disease 
course. Secondly, miR expression analysis was only undertaken in an exploratory subset of the 
overall study population, hence validation of these findings in a larger cohort is mandatory. 
Furthermore, miR levels were unaltered for the highly expressed miRs and it is unclear whether 
differences in the lowly expressed miRs carries pathological relevance. Finally, methodological 
variability at both the sample preparation and analysis stage may make inter-study comparisons 
difficult. Whilst attempts were made to minimise the number of centrifugation steps, it is 
conceivable that platelet contamination might generate PMPs in the freeze-thaw process. 
Additionally, whilst flow cytometry is acknowledged as the current gold standard for the 
determination of MP origin, the detection of smaller MPs (30-400 nm, representing ~80% of the 
MP range) is imperfect and it cannot observe the entire spectrum of MPs assessed using NTA. 
Retrospectively, with the majority of circulating MPs derived from platelets, platelet activity 
and functional pro-thrombotic analysis (for example via Multiplate and/or thrombinoscope 
experiments) would perhaps provide information/associations with PMP levels.  
 
4.5.4 Conclusion  
In summary, this study suggests that patients with PCOS have an elevated concentration of 
circulating MPs compared with healthy volunteers. These MPs are predominantly platelet-
derived, are associated with increased annexin V binding and an altered miR expression profile. 
Further studies are needed to confirm these findings, to explore the relevance of such changes to 
cardiovascular risk in women with PCOS and to establish whether therapies that improve 
insulin sensitivity are able to reduce circulating MP concentrations. 
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4.5.5 Key points 
 PCOS subjects presented with an elevated concentration of annexin V positive plasma 
derived MPs compared to age/BMI matched healthy volunteers. 
 The increase in MP concentration in women with PCOS was related to an increased 
concentration of MPs in the small (<150nm) exosomal range. This may suggest 
selective stimulation of the intracellular classical exosomal pathway compared to 
larger MPs (150-1000 nm diameter) formed via cell membrane shedding.  
 PMPs occupied by far the greatest proportion of plasma derived MPs in both PCOS 
subjects and healthy volunteers. EMPs and monocyte-derived MPs were infrequent. 
 MP miR expression profiles were similar between women with PCOS and healthy 
volunteers amongst the most highly expressed miRs. However, 16 lowly-expressed 
miRs were found to be differentially expressed.  
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5. RESULTS CHAPTER 
The effects of metabolic stressors on endothelial cell 
microparticle production  
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5.1 Introduction 
In the previous chapter, PCOS patients presented with an elevated circulating concentration of 
annexin V positive MPs compared to healthy volunteers. Mechanisms by which this occurs 
remain unclear. This chapter seeks to establish a series of in vitro models that mimic the key 
features of PCOS, using pathologically relevant stressors, with the goal of assessing their effect 
on EC MP production. 
 
The vascular endothelium occupies a unique interface between circulating blood and 
extravascular tissues. It is a dynamic autocrine and paracrine organ that maintains vascular 
homeostasis by modulating vascular tone, governing local cellular growth and regulating 
inflammatory responses (8). Under physiological conditions the vascular endothelium maintains 
an anti-thrombotic surface. In contrast, under pathological stresses, alterations in the vascular 
endothelium may shift the pattern towards a pro-thrombotic state. EC activation can also 
promote cellular interactions with circulating cells by elevated expression of surface adhesion 
molecules. Moreover, EC activation is associated with a reduction in anticoagulant surface 
molecules such as TM and a concomitant elevation in prothrombotic components such as TF (8, 
9). 
 
An additional feature of an activated EC is the elevated secretion of MPs into the extracellular 
space (167). MPs derived from the endothelium harbour an array of adhesion molecules 
including VE cadherin, ICAM-1, VCAM-1, PE-CAM-1, endoglin, E-selectin and P-selectin. 
Moreover, EMPs have been shown to posess eNOS, vascular endothelial growth factor receptor 
(VEGF-R2) and NADPH oxidase (167). MPs derived from the endothelium externalise PS to 
the outer membrane bilayer rendering them annexin V positive. This exposure of negatively 
charged phospholipids to the outer bilayer may increase the potency of target cell interactions. 
However, in vivo studies have found that annexin V negative MPs expressing endothelial 
markers are present in human plasma, suggesting that not all EMPs externalise PS (199). The 
mechanisms governing the release of EMPs remain unclear. In vitro experiments have shown 
that MP release is associated with μ-calpain activation and increased protein tyrosine 
phosphatase activity (170). However, the protein composition and functional characteristics of 
EMPs is hypothesised to depend on the stimulus triggering their release (197).  
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The vascular endothelium, which forms the barrier between blood and the surrounding tissues, 
is known to efficiently respond to stress signals such as hypoxia by adaptation of cellular 
physiology, secretion of growth factors and modulation of vascular tone (9). ECs can secrete 
MPs and have the ability to also be targeted by MPs from multiple cellular origins (200). Thus, 
with the endothelium playing a crucial role in regulating vascular homeostasis, as a first line 
blood-tissue defensive barrier against a spectrum of acute and chronic stressors, this study 
compared MPs secreted by EC’s following exposure to pathologically relevant stressors. 
Building on the human PCOS model (as outlined in chapters 3 and 4), which is characterised by 
hyperinsulinaemia and hyperandrogenism, ECs were exposed to: testosterone 
(hyperandrogenism stressor); hypoxia (ischaemia model stressor); insulin (metabolic stressor); 
glucose (metabolic stressor) and H2O2 (oxidative stress stressor). 
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5.2 Aims 
The aim of this study was to assess the effect of metabolic stressors on EC MP production in 
vitro. Specifically, the aims of this work were to:  
 Examine the production and characteristics of MPs following exposure to stressors 
akin to those featured in patients with PCOS. 
 Characterise the distribution of surface adhesion molecules on ECs and their 
corresponding MPs. 
 Examine the pro-coagulant activity of EC derived-MPs in response to metabolic 
stress.  
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5.3 Methods 
5.3.1 Cell culture 
The HECV cell line was maintained as described in section 2.15. Primary HUVECs were 
cultured in Endothelial Cell Growth Medium as detailed in section 2.15. All cells were counted 
using Cellometer® (Nexlon Biosciences Auto T4) and expressed as cells/ml.  
 
5.3.2 Cell treatments (metabolic stressors) 
HECV and HUVEC cultures were treated with metabolic stressors as described in section 2.16 
(pathologically relevant stressors: hypoxia, glucose, insulin, H2O2, and testosterone). All 
stressors were diluted in SFM as described in section 2.16. Control ECs were treated with SFM 
only.  
 
5.3.3 Microparticle isolation 
MPs were isolated using differential ultra-centrifugation as detailed in section 2.17. MPs were 
analysed fresh.  
 
5.3.4 Microparticle size, concentration and distribution 
MP size and concentration was determined using the NanoSight LM10 system, as previously 
described in section 2.11. Specifically, 60-second videos were recorded. Camera sensitivity and 
detection threshold were (14-16 arbitrary units) and (4-5 arbitrary units), respectively. 
 
5.3.5 Confocal microscopy 
Confocal microscopy was employed in several ‘proof of concept’ experiments. Specifically, 
confocal microscopy was used to: 
 Visualise MP production in real-time 
 Assess annexin V positive/negative MPs 
 Examine MP adhesion / cell-interaction 
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 Visually support NTA data  
Cell / MP staining and confocal microscopy is detailed in section 2.18. 
 
5.3.6 Electron Microscopy 
SEM was used to visualise MPs shedding of stimulated and un-stimulated HECV cells, as noted 
in section 2.19.1. TEM was also used to assess isolated MP morphology and purity, as detailed 
in section 2.19.2. 
 
5.3.7 Cell viability and apoptosis  
To assess the effect of such pathological insults on cell viability and apoptosis, CellTiter 96® 
AQueous cell proliferation assay (Promega, UK), Caspase-Glo® 3/7 assay (Promega, UK) and 
trypan blue exclusion (Sigma-Aldrich, UK) were undertaken. Methods are described in section 
2.20.1, 2.20.2 and 2.20.3, respectively.  
 
5.3.8 Flow cytometry 
Antibody enabled flow cytometry was used to measure the proportion of MPs that were annexin 
V positive/negative as well as to characterise the surface adhesion molecule profile of: 
 HECV cells following exposure to a pathological stressor. 
 EMPs from HECV cells exposed to stressors. 
 Unstimulated HECV cells treated with EMPs derived from HECV cells treated with 
stressors. 
Methods are described in section 2.23.4. 
 
5.3.9 Microparticle coagulability   
As an indication of MP coagulability, the multiplate analyser was used to investigate the ability 
of EMPs to adhere to an artificial surface electrode, as detailed in section 2.21. 
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5.3.10 The effect of MPs on platelet function  
Two methods were used to assess the effect of MPs on whole blood (platelet) aggregation, 
including a Multiplate® multiple electrode aggregometer as described in section 2.22 and 
cytometric analysis of platelet activation, as detailed in section 2.23.5. 
 
5.3.11 Oximetry 
EPR-spin trapping was used to measure the O2 concentration in cell culture medium following 
exposure to 1 % O2 (hypoxia), as described in section 2.7.2. 
 
5.3.12 siRNA and Western blot 
To determine the role of HIF-1α in hypoxia-induced MP release, cells were transfected with 
HIF-1α siRNA as noted in section 2.26. Western blotting was used to compare the protein 
expression of HIF-1α, as detailed in section 2.27. 
 
5.3.13 Statistics 
Data were analysed using GraphPad Prism V6.0. The D'Agostino's K-squared test was used to 
check data for normality. Analysis between groups was performed using an ordinary one-way 
ANOVA coupled with a Dunnett’s or Tukeys post-analysis test. Results are expressed as mean 
± SD unless indicated.  A p-value of <0.05 was regarded as statistically significant.  
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5.4 Results 
5.4.1 MP production - ‘proof-of-principle’ 
Proof of principle experiments were undertaken to provide evidence that HECV cells produce 
extracellular MPs and to assess whether these EMPs can interact with other ECs. Firstly, to 
ensure confocal microscopy could visualise <1 μm MPs, FITC was conjugated to 100 nm 
carboxylated beads. These were clearly visualised under FITC fluorescence channels (Figure 
5.1 B, D). HECVs were seen to produce intact extracellular vesicles (figure 5.1 A, C), however 
not all MPs were annexin V positive (Figure 5.2). MP-EC interaction and adhesion was 
visualised by treating an 80 % confluent monolayer of unstimulated HECVs with Cell Trace 
stained EMPs (figure 5.3 A, B). MPs appeared to internalise as intact vesicles suggesting that 
EMPs are taken-up by neighbouring ECs and may reflect an important model by which MPs 
and ECs interact (figure 5.3 C). Of particular interest, MP formation and secretion appeared to 
originate from nanotubes/micro-spikes protruding from the cell membrane. 
 
Figure 5.1 HECV-derived microparticles. (A, C). Images showing intact MPs (stained with 
Cell Trace Red/Orange). (B, D). FITC bound 100 nm polystyrene beads. Arrows = selective 
MPs. Scale bars: 10 μm (A), 1 μm (B), 26 μm (C) and 2.5 μm (D). 
10 µm 
2.5 µm 
1 µm 
26 µm 
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Figure 5.2 Annexin V positive/negative MPs. [Left] HECV cell (stained with Cell Trace 
Red/Orange) secreting ‘intact’ spherical MPs. [Middle] Green represents annexin V positive-
FITC staining. [Right] Overlay image demonstrating annexin V positivity MPs. Scale bars: 10 
μm. 
 
A
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B
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Figure 5.3. EC-MP interaction/adhesion. (A). Confocal microscopy image showing intact 
MPs (derived from cell traced HECV cells) adhere to an unstimulated HECV monolayer (Red 
indicates MP stained with Cell Trace Red/Orange). (B). A 3D reconstruction of MPs (stained 
with Cell Trace) internalised in a HECV cell. MPs appear to endocytose / internalise as intact 
MPs in target HECV cells. The white dotted line represents the cell membrane (approximation). 
[Bottom right] schematic demonstrating the confocal viewing planes for figure C (X, Y and Z 
axis). (C). Control, showing no Cell Trace contamination from the supernatant from the last 
wash step. Scale bars: 10 μm (A, B) and 7.5 μm (C). 
10µm 
10µm 
7.5 µm 
10µm 10µm 10µm 
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5.4.2 The effect of metabolic stressors on microparticle 
production 
A range of physiological and supra-pharmacological concentrations of metabolic stressors was 
investigated to assess their effect on MP production. HECV cells were exposed to a metabolic 
stressor for 24 hours.  
 
5.4.2.1 H2O2 
H2O2 (10 mM) [n = 4] significantly increased MP production (control: 194 ± 125 MPs/cell vs. 
H2O2 (10 mM): 2036 ± 1605 MPs/cell p = 0.03), however, 125 μM, 500 μM and 1 mM H2O2 
concentrations did not alter MP release (612 ± 314 MPs/cell; 892 ± 738 MPs/cell and 756 ± 756 
MPs/cell, respectively, p >0.05, figure 5.4 A). H2O2 treatment did not affect MP size. H2O2: [n = 
4]: control (134 ± 8 nm); H2O2 125 μM, (144 ± 40 nm); H2O2 500 μM, (140 ± 9 nm), H2O2 1 
mM, (139 ± 20 nm) and H2O2 10 mM, (168 ± 31 nm,  p = 0.21, figure 5.4 B).  
Figure 5.4. The effect of H2O2 on microparticle production. (A) The amount of MPs 
produced per viable cell. (B) MP size. Control reflects H2O2 naïve treatment. Each sample was 
analysed in quintuplicate and the mean was used in further analysis. Data is expressed as the 
group mean ± SEM. * reflects p < 0.05. 
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5.4.2.2 Testosterone  
Treatment of HECV cells with testosterone (control [testosterone naïve], 3 nM, 30 nM, 300 nM 
and 1 μM) had no effect on MP production, p = 0.15 (figure 5.5 A). Testosterone treatments had 
no effect on MP size. Testosterone control; (134 ± 8 nm); 3 nM; (194 ± 125 nm); 30 nM; (212 ± 
31 nm); 300 nM; (210 ± 9 nm) and 1 μM; (166 ± 61 nm, p = 0.164, figure 5.5 B). 
 
Figure 5.5. The effect of testosterone on microparticle production. (A) The amount of MPs 
produced per viable cell (p = 0.15). (B) MP size. Control = no testosterone. Results represent [n 
= 4]. Each sample was analysed in quintuplicate and the mean was used in further analysis. Data 
is expressed as the group mean ± SEM.   
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5.4.2.3 Insulin 
Insulin had no effect on HECV MP concentration; control [no insulin] (194 ± 125 MPs/cell), 
0.15 nM (280 ± 217 MPs/cell), 0.6 nM (280 ± 217 MPs/cell), 1.25 nM (328 ± 218 MPs/cell), 
2.5 nM (419 ± 332 MPs/cell, p = 0.21, figure 5.6 A). Additionally, insulin treatment had no 
effect on MP size. Insulin: control (134 ± 8 nm); 0.15 nM (134 ± 8 nm); 0.6 nM (184 ± 27 nm); 
1.25 nM (158 ± 59 nm); 2.5 nM (168 ± 50 nm, p = 0.21, figure 5.6 B). 
Figure 5.6. The effect of insulin on microparticle production. (A) MPs produced per viable 
cell. (B) MP size. Control represents no insulin treatment. Results represent [n = 4]. Each 
sample was analysed in quintuplicate and the mean was used in further analysis. Data is 
expressed as the group mean ± SEM.   
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5.4.2.4 Glucose 
Glucose-depletion (0mM) [n = 4] significantly increased HECV cell MP production compared 
to HECV cells grown according to the manufacturers recommendations in medium containing 
22.5 mM glucose. Control (22.5 mM): 194 ± 125 MPs/cell vs. glucose depleted (0 mM): 2158 ± 
1168 MPs/cell p = 0.002, figure 5.7 A). However, 5, 10 and 20 mM glucose concentrations did 
not alter HECV MP release (892 ± 620 MPs/cell; 704 ± 560 MPs/cell and 376 ± 169 MPs/cell, 
respectively). Glucose treatment did not affect MP size. Glucose: [n = 4]: control (22.5 mM, 
134 ± 8 nm); glucose-depleted (0mM) (119 ± 18 nm); 5 mM (117 ± 11 nm); 10 mM (172 ± 180 
nm); 20 mM (148 ± 61 nm, p = 0.16 figure 5.7 B). 
 
Figure 5.7. The effect of glucose concentration on microparticle production. (A) MPs per 
viable cell (p = 0.002). (B) MP size (p = 0.65). Control refers to the HECV culture medium 
recommendations of 22.5mM glucose. Results represent [n = 4]. Each sample was analysed in 
quintuplicate and the mean was used in further analysis. Data is expressed as the group mean ± 
SEM.  . ** represents p <0.01.  
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5.4.2.5 Hypoxia 
Hypoxia (1% O2) [n = 4] enhanced HECV cell MP production in comparison to HECV cells 
grown in normoxia (95% air, control: 194 ± 125 MPs/cell vs. 1% O2: 409 ± 20 MPs/cell p = 
0.04). However 2, 5, 10 and 20% O2 did not change HECV MP production (279 ± 26 MPs/cell; 
290 ± 104 MPs/cell; 218 ± 79 MPs/cell; and 217 ± 98 MPs/cell, respectively, p >0.05, figure 5.8 
A). Hypoxic conditions did not affect MP size; [n = 4]: normoxic control (95% air, 134 ± 8 nm); 
1% O2 (131 ± 27 nm); 2% O2 (133 ± 33 nm); 5% O2 (143 ± 38 nm); 10% O2 (133 ± 38 nm), 
20% O2 (132 ± 30 nm, p > 0.05, figure 5.8 B). 
 
Figure 5.8. The effect of hypoxia (1% O2) on microparticle production. (A) MPs produced 
per viable cell. (B) MP size. Control refers to cells grown in normoxia (95% air, which equates 
to 21% O2). Results represent [n = 4]. Each sample was analysed in quintuplicate and the mean 
was used in further analysis. Data is expressed as the group mean ± SEM. * reflects p <0.05. 
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5.4.3 Microparticle size distribution following 
metabolic stressors 
Following these initial experiments, subsequent in vitro comparisons were all carried out at a 
single concentration: un-stimulated (control); H2O2 (10 mM); testosterone (1 μM), glucose-
depletion, insulin (2.5 nM) and hypoxia (1% O2). These concentrations were chosen because 
they either provoked the largest difference in MP production or, for cases where MP production 
was not affected, the highest concentration was used.  
 
On assessment of MP size distribution, no differences were observed for MPs derived following 
testosterone (1 μM), insulin (2.5 nM) and hypoxia (1% O2) cellular treatments (figure 5.9). 
H2O2 (10 mM) and glucose depletion produced an altered MP distribution compared to 
unstimulated/control MPs, displaying an elevated concentration of MPs within a diameter range 
of 51 – 300 nm and 51 – 200 nm, respectively (as highlighted in table 5.1). 
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The effect of cardiometabolic insults on HECV derived-MP distribution. NTA was used to assess the size distribution of MPs (normalised to cell count, 
presented in 50 nm bin sizes). Samples were measured in quintuplicate. SEM. Results represent [n = 4]. Each sample was analysed in quintuplicate and 
the mean was used in further analysis. Data is expressed as the group mean ± SEM. *, ** and **** reflects significance (p <0.05, p <0.01, p <0.0001, 
respectively). MP; microparticle.  
 
Table 5.1 
 
Distribution of endothelial cell (HECV) derived-MPs 
 Control H2O2  
(10 mM) 
Testosterone  
(1 μM) 
Glucose depleted Insulin  
(2.5 nM) 
Hypoxia  
(1% O2) 
p 
MP size (nm) MPs / cell 
0-50 11 ± 2 28 ± 20 3 ± 3 62 ± 45 47 ± 22 15 ± 4 >0.05 
51-100 74 ± 11 296 ± 110* 34 ± 14 442 ± 112**** 73 ± 20 64 ± 17 0.005 
101-150 136 ± 20 637 ± 268**** 52 ± 15 656 ± 103**** 82 ± 58 102 ± 20 0.01 
151-200 104 ± 14 665 ± 280**** 33 ± 8 370 ± 9** 59 ± 61 84 ± 10 0.03 
201-250 64 ± 6 457 ± 213**** 20 ± 8 189 ± 28 55 ± 39 57 ± 11 <0.01 
251-300 40 ± 5 274 ± 135** 11 ± 5 119 ± 29 26 ± 16 30 ± 9 <0.01 
301-350 20 ± 4 164 ± 172 5 ± 4 54 ± 15 8 ± 8 13 ± 7 >0.05 
351-400 11 ± 2 132 ± 150 3 ± 2 24 ± 12 6 ± 4 8 ± 5 >0.05 
401-450 10 ± 2 107 ± 150 2 ± 2 12 ± 8 6 ± 4 4 ± 2 >0.05 
451-500 6 ± 1 80 ± 120 1 ± 1 7 ± 5 4 ± 5 3 ± 2 >0.05 
501-550 3 ± 0.3 52 ± 71 1 ± 1 5 ± 3 2 ± 3 2 ± 1 >0.05 
551-600 2 ± 1 35 ± 52 0..5 ± 0.6 4 ± 2 2 ± 3 1 ± 0.6 >0.05 
601-650 2 ± 1 19 ± 32 0.4 ± 0.5 3 ± 3 2 ± 3 1 ± 0.3 >0.05 
651-700 2 ± 1 10 ± 18 0.2  ± 0.3 2 ± 2 2 ± 2 0.3 ± 0.3 >0.05 
701-750 2 ± 1 6 ± 11 0.1 ± 0.2 1 ± 2 1 ± 1 0.2 ± 0.3 >0.05 
751-800 2 ± 1 5 ± 9 0.06 ± 0.1 1 ± 1 1 ± 1 0.2 ± 0.2 >0.05 
801-850 1 ± 1 6 ± 11 0.07 ± 0.1 0.4 ± 1 1 ± 1 0.2 ± 0.2 >0.05 
851-900 1 ± 1 5 ± 10 0.1 ± 0.2 0.2 ± 0.3 1 ± 1 0.1 ± 0.1 >0.05 
901-950 0.3 ± 0.3 4 ± 7 0.1 ± 0.2 0.04 ± 0.07 0.4 ± 1 0.08 ± 0.06 >0.05 
951-1000 0.2 ± 0.1 3 ± 5 0.09 ± 0.2 0.01 ± 0.01 0.1 ± 0.2 0.05 ± 0.01 >0.05 
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Figure 5.9. The effect of cardiometabolic insults on HECV derived MP distribution. NTA was used to assess the size distribution of MPs 
(normalised to cell count). Results represent [n = 4]. Each sample was analysed in quintuplicate and the mean was used in further analysis. Data is 
expressed as the group mean ± SEM.   *, ** and **** reflects significance (p <0.05, p <0.01, p <0.0001, respectively). 
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5.4.4 The effect of pathologically relevant insults on 
cell viability and apoptosis 
Some MP production may relate to apoptosis. Thus, cell viability and apoptosis assays were 
undertaken on HECV cells. Cell viability was determined using a colourimetric method. Viable 
cells with active metabolism convert tetrazolium compounds into a formazan dye (purple 
colour). Cell death diminishes the ability of cells to convert tetrazolium compounds into 
formazan. Thus, results represent the absorbance of formazan at 490 nm. Improved cell viability 
was shown in HECV cells treated with testosterone (1 μM), insulin (2.5 nM) and glucose 
depletion compared to control HECV cells, [testosterone 1 μM]: 2.18 ± 0.17, [insulin 2.5 nM]: 
2.18 ± 0.12, [glucose depletion]: 2.4 ± 0.04 vs. control: 1.7 ± 0.22, p = 0.001, p = 0.001 and p = 
0.0001, respectively). H2O2 (10 mM): 1.8 ± 0.17, and hypoxia (1% O2): 1.9 ± 0.04 did not alter 
cell viability (figure 5.10 A).  
 
Apoptosis was determined by measuring caspase-3 and -7 activity via luminescence. Values 
represent relative luminescence (RLU) units. Testosterone (1 μM) enhanced caspase 3/7 activity 
in HECV cells compared to control HECV cells (testosterone (1 μM): 920 ± 73, Control: 612 ± 
75, p <0.0001). H2O2 (10 mM): 535 ± 129, glucose depletion: 758 ± 121, insulin (2.5 nM): 672 
± 7 and hypoxia (1% O2): 672 ± 79, had no effect on caspase 3/7 activity in cells (p > 0.05, 
Figure 5.10 B).  
 
H2O2 (10 mM) increased the proportion of trypan blue stained HECV cells compared to control 
HECV cells (H2O2 (10 mM): 78 ± 14% vs. Control: 89 ± 1%, p 0.02). Testosterone (1 μM): 92 
± 0.5%, glucose depletion: 87 ± 1%, insulin (2.5 nM): 88 ± 1% and hypoxia (1% O2): 87 ± 1%, 
had no significant effect on HECV trypan blue exclusion (p > 0.05, figure 5.10 C). Again, 
HECV cells were exposed to metabolic stressors for 24 hours for all apoptosis and cell viability 
experiments. 
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Figure 5.10. The effect of metabolic stressors on cell viability and apoptosis. (A). CellTiter 
96® AQueous one solution cell proliferation assay. Relative MTS activity obtained from 80 µl of 
control HECV cells and treated HECV cells at 1 x 106/ml, p = 0.0007. (B). Caspase-glo 3/7 
apoptosis assay. Relative caspase-glo 3/7 activity obtained from 50 µl control HECV cells and 
treated HECV cells at 1 x 106/ml, p = 0.0012. (C). Trypan blue exclusion.  Percentage of viable 
cells (identified by the intracellular exclusion of trypan blue) in treated HECV and control 
HECV cells (p = 0.02). All samples were analysed in triplicate for the CellTiter96® AQueous 
one solution cell proliferation assay [n = 4] (A), caspase 3/7 assay [n = 4] (B) and trypan blue 
exclusion experiments [n = 4] (C), and the mean was used in further analysis. Data is expressed 
as the group mean ± SEM. p values reflect one-way ANOVA analysis, * and **** reflect post-
hoc analysis (Dunnetts multi-comparisons), p <0.05 and p <0.0001, respectively. RLU, relative 
light units.  
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5.4.5 The effect of metabolic stressors on HUVEC 
microparticle production  
HUVECs were sourced to compare how pathologically relevant stressors affected MP 
production in primary ECs compared to HECV cells. The HUVEC medium recommended by 
the manufacturers contained 5 mM glucose and a proprietary blend of growth nutrients. Thus, 
glucose depleted treatments were not possible. Moreover, the HUVEC medium contained MPs 
(which are likely to be FBS derived-MPs), therefore results are presented as actual MP 
concentration minus MPs in growth medium, normalised to cell count. Hypoxia and H2O2 
appeared to enhance HUVEC MP production, a similar trend observed in HECV cells (figure 
5.11). However, results were obtained from two experiments (n = 2), thus no statistical analysis 
was performed.  
  
Figure 5.11. The effect of metabolic stressors on HUVEC MP production. (A) MPs 
produced per viable cell. (B) Trypan blue exclusion – cell viability (%). Results were obtained 
from two experiments (n = 2). Each sample was analysed in quintuplicate and the mean was 
used in further analysis. Data is expressed as the group mean ± SEM..  
 
5.4.6 Microscopy 
Confocal and electron microscopy was used to visually support the NTA data (figures 5.12 and 
5.13, respectively). For confocal microscopy, prior to exposure to pathologically relevant 
stressors, HECVs were stained with Cell Trace red/orange and visualised 3 hours post exposure. 
Confocal and electron microscopy were also used to confirm the diameter of MPs. Both 
techniques confirmed MP diameters were <1 µm.  
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Figure 5.12. Representative images of microparticle generation following exposure to pathological stressors. (A) Control. (B) Hypoxia (1 % O2). 
(C) H2O2 (10 mM). (D) Testosterone (1 μM). (E) Insulin (2.5 nM). (F) Glucose depleted. White arrows identify select MPs. Scale bar represents 25 μM. 
25µm 
25µm 
25µm 25µm 
25µm 25µm 
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Figure 5.13 Morphology of HECV cells and HECV derived-microparticles. SEM images: MPs budding off non-stimulated (A, D) and H2O2 (10 
mM) treated cells (B, E). MPs appear to be protruding from nanotubes/micro-spikes (B), from H2O2 (10 mM) treated HECV cells. Surface blebs and 
detached vesicles are visualised on non-stimulated and H2O2 treated HECV cells (A, D and B, E, respectively). Scale bars: 25 μm (D, E), 10 μm (B) and 
5 μm (A). TEM images: submicron heterogeneous population of spherical MPs derived from un-stimulated HECV cells (C, F). MPs appear granular 
(C). Scale bars: 0.2 μm (C) and 2 μm (F).  
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5.4.7 Hypoxia mediated microparticle release 
EPR – oximetry was used to confirm the O2 concentration of cell culture medium surrounding 
HECV cells exposed to 1% or 21% O2 (95% air) for 24 hrs (p = 0.003, figure 5.14). To examine 
the role of HIF-1α in the hypoxic enhancement of MP release, HECV cells were transfected 
with a siRNA targeting HIF-1α. Transfected cells (HIF-1α siRNA) failed to show an 
enhancement in MP release following hypoxia exposure compared to cells transfected with 
scrambled siRNA (control, p = 0.003, figure 5.15 A). Western blots confirmed that HIF-1α was 
induced at 1% O2 in non-transfected cells. Cells transfected with HIF-1α siRNA inhibited HIF-
1α expression, whilst the scrambled siRNA had no impact on HIF-1α expression (figure 5.15 
B). 
 
Figure 5.14. Oximetry. (A) Typical EPR spectra. (B) O2 concentration (%) of the cell culture 
medium. Cells were maintained in an incubator at 37 °C and 5% CO2. [Hypoxia: n = 3] and 
[normoxia: n = 1]. Results are expressed as mean ± SEM.  
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Figure 5.15. Hypoxia mediated microparticle release. Experiments were conducted on 
HECV cells at passage 14. Results represent [n = 3] mean ± SEM. * reflects p < 0.05, 
respectively. (A) MPs produced per viable cell. (B). Western blots sections showing relevant 
showing HIF-1α expression. Control refers to cells grown in 95% Air. (B) Lane 1, scrambled 
siRNA at 1% O2. Lane 2: HIF-1α targeted siRNA, 1% O2.  Lane 3: 1% O2. Lane 4: 95% air 
(normoxia). Cells were maintained in an incubator at 37 °C and 5% CO2. 
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5.4.8 Microparticle coagulability  
Annexin V positivity was measured by flow cytometry as described in section 2.23.4 (general 
methods). A greater proportion of MPs were derived from HECV cells exposed to H2O2 (10 
mM), testosterone (1 μM), glucose depletion and insulin (2.5 nM) compared to control MPs. 
Hypoxia had no effect on annexin V MP positivity (p = 0.0002, figure 5.16 A). As an indication 
of MP coagulability, electrical impedance aggregometry was employed to investigate the ability 
of MPs to adhere to an electrode surface. MPs did not show a tendency to adhere to the artificial 
electrode within a 6-minute time scale. All MPs derived from HECV cells exposed to 
pathological stressors did not adhere to the surface apart from MPs derived from HECVs 
stimulated with H2O2 (10 mM, 20 ± 10 au, p < 0.0001). Thus, in order to provoke adhesion, 
MPs were primed with an acute oxidative insult, H2O2 (10 mM). Following this, MPs derived 
from HECV cells post glucose depletion and hypoxia (1% O2) demonstrated enhanced 
adherence to the electrode [glucose-depleted: 711 ± 184, au. p < 0.01 and hypoxia (1 % O2): 
936 ± 339, p < 0.01]. No difference was found with H2O2 (10 mM) [455 ± 189 au], testosterone 
(1 μM) [150 ± 96 au] and insulin (2.5 nM) [142 ± 30 au] (p > 0.05, figure 5.16 B). H2O2 (10 
mM) in saline buffer alone and the supernatant from the last wash step of MP isolation was used 
as controls and did not alter or affect the electrical impedance recordings. 
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Figure 5.16 MP coagulability. (A) The extent of annexin V binding, expressed as a percentage 
(%) of annexin V+ MPs. [n = 4]. Data is expressed as the group mean ± SEM. (B) The ability of 
HECV-derived MPs to adhere to an artificial electrode following acute exposure to H2O2 (10 
mM). [n = 4]. Each sample was analysed in duplicate and the mean was used in further analysis. 
Data is expressed as the group mean ± SEM. The intra-assay coefficient of variation was <5%. 
(C) MP gate (flow cytometry).  A.U: arbitrary units. p values reflect one-way ANOVA analysis, 
** and **** reflect post-hoc analysis (Dunnetts multi-comparisons), p <0.05 and p <0.0001, 
respectively.  
162 
 
Characterisation of surface adhesion molecule profiles 
Cellular activation may promote EC interactions with circulating cells by elevated expression of 
surface adhesion molecules. Antibody enabled flow cytometry was employed to investigate the 
impact of the pathological stressors on the expression of surface adhesion molecules. 
 
Antibody binding may be expressed as median fluorescence intensity (MFI) or percentage of 
immunopositive cells/MPs.  Both MFI and percent of immunopositive cells/MPs have 
biological relevance. In contrast to MFI, percent of antigen presenting cells/MPs is independent 
of signal amplitude. However, it is reasonable to postulate that although a cell/MP may be 
positive for a specific antigen, the amount of antigen present may be considerably different. 
Thus, results are expressed as both MFI and percent of antigen presenting cells/MPs. 
 
The effect of metabolic stressors on HECV surface adhesion expression. MFI and percent of 
immunopositive HECV cells are summarised in table 5.2. Cellular stressors had no effect on 
VCAM-1, ICAM-1, or E-selectin expression. Glucose depletion decreased the percentage of 
PE-CAM-1 positive cells (p < 0.0005), but no difference was observed in MFI for PECAM-1 
expression in HECV cells following exposure to metabolic stressors (p > 0.05). H2O2 (10 mM); 
Testosterone (1 μM); glucose depletion and Hypoxia (1 % O2) decreased P-selectin MFI (p < 
0.001, p < 0.0001, p < 0.05, p < 0.01, respectively). Insulin (2.5 nM) had no effect on P-selectin 
MFI (p > 0.05). The percentage of P-selectin positive cells was not affected by cellular insults 
(p > 0.05). 
 
Treating HECV cells with metabolic stressors: the effect on MP surface adhesion 
expression. Data are summarised in table 5.3. The surface adhesion molecule profiles of MPs 
produced from treated cells were compared to MPs from unstimulated HECV cells. Cellular 
stressors had no effect on MP ICAM-1, PECAM-1, P-selectin or E-selectin expression. Glucose 
depletion resulted in an elevated percentage of VCAM-1 positive MPs (p < 0.05), but H2O2 (10 
mM); testosterone (1 μM); insulin (2.5 nM) and hypoxia (1 % O2) did not affect VCAM-1 
expression (p > 0.05). 
 
The effect of MP treatment (MPs derived from HECV cells treated with stressors) on 
HECV cell surface adhesion expression. Results are summarised in table 5.4. The surface 
adhesion molecule profile of HECVs was assessed after a 24 hr incubation with MPs (1 x 
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109/ml) produced from stimulated cells (including unstimulated cell-derived MPs), and profiles 
were compared to HECV which received no MP treatment. MP treatment had no effect on 
VCAM-1, ICAM-1 or E-selectin expression. HECV cells treated with unstimulated MPs 
decreased the percentage of PE-CAM-1 positive cells (p < 0.0009), but treatment of MPs 
obtained following H2O2 (10 mM); testosterone (1 μM); insulin (2.5 nM), glucose depletion or 
hypoxia (1 % O2) stressors had no effect on PECAM-1 expression (p > 0.05). HECV cells 
treated with MPs, (irrespective of MP origin) decreased P-selectin expression (MFI) in HECV 
cells (p < 0.0001).  
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Results were obtained from four experiments (n = 4). Results are expressed as mean ± SD. p < 0.05 was deemed significant.  * equates to p < 0.05, ** equates 
to p < 0.01, *** equates to p < 0.001.
Table 5.2 The effect of pathologically relevant stressors on HECV cell surface adhesion molecule expression 
 Control H2O2  
(10 mM) 
Testosterone  
(1 μM) 
Glucose  
depleted 
Insulin  
(2.5 nM) 
Hypoxia 
(1% O2) 
p 
VCAM-1 expression 
Immunopositive cells (%) 90 ± 9 67 ± 35 97 ±2 80 ± 15 94 ± 6 85 ± 14 0.12 
Median fluorescence 
intensity 
580 ± 193 486 ± 318 800 ± 156 459 ± 196 791 ± 437 422 ± 135 0.1 
ICAM-1 expression 
Immunopositive cells (%) 99 ± 0.1 100 ± 0 100 ± 0 99 ± 0.1 100 ± 0 99 ± 0.5 0.1 
Median fluorescence 
intensity 
7688  ± 458 8271  ± 424 7247  ± 118 8653  ± 1051 7402  ± 281 8207  ± 591 0.09 
PECAM-1 expression 
Immunopositive cells (%) 84 ± 9 76 ± 26 80 ± 5 33 ± 23 *** 79 ± 6 82 ± 17 0.0005 
Median fluorescence 
intensity 
362 ± 70 440 ± 222 304 ± 6 218 ± 43 340 ± 40 433 ± 171 0.08 
P-Selectin 
Immunopositive cells (%) 99 ± 2 90 ± 18 84 ± 14 92 ± 7 99 ± 2 93 ± 4 0.3 
Median fluorescence 
intensity 
1243 ± 31 380.0 ± 9*** 435.5 ± 159*** 760.2 ± 280* 821 ± 308 560.0 ± 27** 0.0004 
E-Selectin 
Immunopositive cells (%) 74 ± 33 85 ±14 51 ± 45 73 ± 20 86 ± 9 96 ± 14 0.2 
Median fluorescence 
intensity 
369 ± 154 388 ± 73 326 ± 172 257 ± 6 491 ± 114 422 ± 118 0.3 
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Results were obtained from four experiments (n = 4). Results are expressed as mean ± SD. * equates to p < 0.05. 
Table 5.3 The effect of pathologically relevant stressors on microparticle surface adhesion molecule expression 
 Control H2O2  
(10 mM) 
Testosterone  
(1 μM) 
Glucose 
depleted 
Insulin  
(2.5 nM) 
Hypoxia  
(1% O2) 
p 
VCAM-1 expression 
Immunopositive cells (%) 20 ±17 11 ± 13 14 ± 8 46 ± 27* 21 ± 6 23 ± 5 0.02 
Median fluorescence 
intensity 
213 ± 66 208 ± 32 192 ± 0 224 ±37 208 ± 32 195 ± 6 0.49 
ICAM-1 expression 
Immunopositive cells (%) 23 ±18 17 ±13 23 ±14 18 ±14 27 ± 2 33 ± 4 0.49 
Median fluorescence 
intensity 
224 ±35 179 ±29 239 ±27 224 ±83 240 ±32 240 ±32 0.22 
PECAM-1 expression 
Immunopositive cells (%) 15 ±13 14 ±11 11 ± 9 18 ±14 25 ± 25 26 ± 7 0.77 
Median fluorescence 
intensity 
181 ± 48 179 ± 29 192 ±40 191 ± 42 208 ± 32 217 ± 32 0.49 
P-Selectin 
Immunopositive cells (%) 29 ± 13 11 ± 15 16 ± 7 33 ± 11 37 ± 5 34 ± 11 0.04 
Median fluorescence 
intensity 
288 ± 67 208 ± 61 192 ± 64 288 ± 153 320 ± 52 336 ± 160 0.29 
E-Selectin 
Immunopositive cells (%) 23 ± 14 16 ± 16 18 ± 11 17 ± 11 24 ± 9 23 ± 12 0.77 
Median fluorescence 
intensity 
192 ± 52 256 ± 91 203 ± 26 256 ± 45 208 ± 32 256 ± 78 0.29 
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Results were obtained from four experiments (n = 4). Results are expressed as mean ± SD. p < 0.05 was deemed significant. *** equates to p < 0.001, **** 
equates to p < 0.0001. 
 
Table 5.4 The effect of microparticles on HECV cell surface adhesion expression 
 Control Un-
stimulated 
H2O2  
(10 mM) 
Testosterone  
(1 μM) 
Glucose 
depleted 
Insulin  
(2.5 nM) 
Hypoxia 
(1% O2) 
p 
VCAM-1 expression  
Immunopositive cells (%) 90 ± 9 76 ± 14 85 ± 13 81 ± 21 65 ± 14 85 ± 13 81 ± 21 0.3 
Median fluorescence 
intensity 
580 ± 194 375 ± 181 369 ± 107 535 ± 308 293 ± 53 326 ± 66 540 ± 372 0.3 
ICAM-1 expression  
Immunopositive cells (%) 100 ± 0.1 100 ± 0 100 ± 0 100 ± 0 100 ± 0 100 ± 0.5 100 ± 0.01 0.46 
Median fluorescence 
intensity 
7688 ± 484 10915 ± 3462 8438 ± 1071 10415 ± 1628 8894 ± 1150 8970 ± 513 8404 ± 251 0.2 
PECAM-1 expression  
Immunopositive cells (%) 83.74 ± 9 65.48 ± 10* 98.53 ± 2 72.04 ± 18 63.97 ± 20 84.53 ± 8 68.00 ± 0 0.0009 
Median fluorescence 
intensity 
361.8 ±70 298.0 ± 40 4258 ± 5044 339.8 ± 86 289.7 ± 17 389.0 ± 166 326.5 ± 108 0.09 
P-Selectin  
Immunopositive cells (%) 99 ± 1 78 ± 11 80 ± 18 65 ± 33 69 ± 15 68 ± 21 62 ± 34 0.2 
Median fluorescence 
intensity 
1243 ± 310 372 ± 82
***
 359 ± 125 
***
 326 ± 132 
***
 320 ± 97 
****
 313 ± 82 
****
 314 ± 117 
****
 <0.0001 
E-Selectin  
Immunopositive cells (%) 74 ± 33 75 ±26 82 ±13 76 ± 10 80 ± 5 46 ± 17 80 ± 1 0.52 
Median fluorescence 
intensity 
369 ± 154 555 ± 411 387 ± 146 347 ± 69 377 ± 47 241 ± 27 321 ± 32 0.54 
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5.4.9  The effect of microparticles on platelet function 
Eight healthy volunteers (n = 8) were recruited to assess the effect of EMPs on whole blood 
platelet aggregation as described in section 2.21. Briefly, blood was pre-incubated with control 
MPs (2 X 102/ml – 10 X 1010/ml) prior to inducing platelet aggregation by ADP or TRAP 
agonists. Pre-conditioning whole blood with control MPs had no effect on ADP or TRAP 
induced platelet aggregation (figure 5.17 A, B, respectively), nor did MPs alone affect platelet 
aggregation (i.e. No ADP or TRAP p >0.05). MPs derived from metabolic stressors were 
compared to control MPs (normalised to 1 x 109 MPs/ml). MPs derived from different stressors 
did not alter ADP or TRAP induced platelet aggregation, p >0.05 (figure 5.17 C, D). Results 
were compared to control platelet aggregation values (i.e. no MP pre-conditioning), and 
expressed as a fold change. 
 
Multiplate did not account for variability in platelet counts. Thus, antibody enabled flow 
cytometry was used to assess the effect of MPs on platelet activation (in whole blood) where 
blood was diluted in saline to normalise platelet levels (150 x 103 mm3). Blood was collected 
from healthy volunteers (n = 4), as described in section 2.23.5. P-selectin expression was 
normalised to control levels (i.e. P-selectin expression with no MP pre-conditioning). Pre-
conditioning whole blood with MPs had no effect on P-selectin expression induced by ADP or 
TRAP (B, C, respectively, figure 5.18), nor did MPs alone alter P-selectin expression (i.e. No 
ADP or TRAP, p >0.05).  
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Figure 5.17. Multiplate – the effect of MPs on platelet aggregation. The effect of ADP (A) 
or TRAP (B) induced aggregation following pre-conditioning whole blood with control MPs. 
The effect of MP pre-conditioning (1 x 109 MPs/ml) on ADP (C) and TRAP (D) induced whole 
blood platelet aggregometry. X refers to the multiplying factor on the X axis. [n = 8]. Each 
sample was analysed in duplicate. The intra-assay coefficient of variation was <5%. Data 
reflects mean ± SEM.  
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Figure 5.18. The effect of MPs on platelet activation (P-selectin). Whole blood was diluted in saline to normalise platelet levels (150 X 103 mm3). To 
assess the effects of MPs, results are normalised to a whole blood sample control (i.e. No MP pre-conditioning). Results are expressed as a delta (%) in 
P-selectin expression compared to control ([black bar] control refers to whole blood sample not pre-conditioned with MPs). The effect of no-agonist 
(A), ADP (B) or TRAP (C) induced aggregation following pre-conditioning whole blood with MPs (1 x 109 MPs/ml). Results were obtained from four 
experiments (n = 4). Mean ± SEM. 
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5.5 Discussion 
5.5.1 Main Findings 
This study examined the effects of pathologically relevant stressors on MP size, concentration, 
surface adhesion molecule expression and function MPs generated by EC. H2O2 (10 mM), 
glucose depletion and hypoxia (1% O2) increased MP production in ECs. The cellular stress 
condition is reflected in the MP characteristics, whereby each pathological stressor resulted in a 
unique MP phenotype. Notably, the induction of HIF-1α plays a central role in the hypoxic 
enhancement of MP release.  
 
5.5.2 Interpretation 
5.5.2.1 Hypoxia  
During homeostasis or disease states, cellular O2 levels are often insufficient to meet 
physiological demands, a state referred to as hypoxia. Hypoxia is an important feature of IHD, 
PAD, sleep apnoea and is associated with aggressive tumour phenotypes and poor patient 
outcomes (290). In this chapter, HECV cells exposed to hypoxia (1% O2) for 24 hr resulted in 
increased MP production, a trend repeated in primary HUVECs. This increase in MP levels 
appeared to be non-selective, affecting both small MPs in the exosomal range and larger MPs. 
This is in accordance with previous studies which have demonstrated that hypoxia is associated 
with increased EMP production in vitro (291). Vince et al, (292) noted hypoxic breathing (15% 
O2 for 80 minutes), resulted in a significantly elevated level of circulating EMPs, however this 
was measured by flow cytometry where only VCAM-1 expressing MPs were assessed. 
 
Data in this chapter proves that HIF-1α is pivotal in the hypoxia-associated enhancement of MP 
release in HECV cells. To my knowledge, this is the first study to recognise that HIF-1α is 
involved in the hypoxia enhancement of MP release in ECs. This is in good accordance with 
previous reports that found that HIF-1α is central to hypoxia-mediated MP release in breast 
cancer cell lines (193). Thus, hypoxia-mediated MP release may share common cellular 
machinery regardless of the cell type. HIF-1α is a critical regulator of cellular and systemic 
responses to low O2 levels. HIF-1α plays a critical protective role in the pathophysiology of 
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IHD. Future studies should explore potential cardio-protective and therapeutic implications of 
EMPs stimulated by hypoxia. I did not extend my work to identify the bioactive cargo and 
protein content of EMPs. A recent comparison of normoxic versus hypoxic EMPs (MPs derived 
from ECs exposed to 2% O2 for 24 hours) identified that both protein and mRNA cargo is 
affected by hypoxia, although the functional characteristics of these MPs were not assessed 
(197). 
 
The mechanisms by which HIF-1α mediates MP release remains relatively unclear, as does MP 
biogenesis in general. HIF-1α has been shown to induce apoptosis in neonatal rat brain (293). It 
is well established that apoptosis can induce MP formation (157); however there was no 
evidence to suggest that the hypoxic condition applied in this chapter induced apoptosis or 
altered cell viability. In line with this, it is noteworthy that 1% O2 is equivalent to an O2 
concentration of 10 μM which is several orders of magnitude above that required to limit 
mitochondrial electron transport (0.1 μM) and is sufficient to maintain full eNOS function (6 – 9 
μM). Moreover, atmospheric (sea level) oxygen (21% O2) corresponds to a PO2 of ~150 mmHg. 
Although difficult to accurately measure, the human body is exposed to much lower O2 
concentrations than this, ranging from 16% in the pulmonary alveoli, to 6% in exercised muscle 
tissues (290). 
 
Previous reports have suggested that in relatively hypoxic conditions, oxygen-sensitive cells 
may elevate intracellular Ca2+ levels, which is known to initiate MP release. Recently, Zheng et 
al, (294) found that filamin A (FLNA), a large cytoskeletal actin-binding protein, interacts with 
HIF-1α. Moreover, hypoxia induces a calpain-dependent cleavage of FLNA to generate a 
naturally occurring C-terminal fragment that interacts with the N-terminal portion of HIF-1α, 
however MP formation was not assessed in that particular study. Nevertheless the mechanism 
linking HIF-1α to MP formation is still not fully elucidated. 
 
MPs derived from hypoxia-treated HECV cells demonstrated an increased binding affinity to an 
electrode following an acute H2O2 insult compared to MPs derived from unstimulated HECV 
cells. The relevance of this in an in vivo setting is unclear. No difference was found in the 
proportion of annexin V positive MPs. 
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5.5.2.2 H2O2  
H2O2 is less reactive and has a longer T½ in comparison to other ROS (such as ∙OH or ∙O2-), and 
as such is arguably better-suited and more widely applied in in vitro settings. The physiological 
ranges for H2O2 vary amongst cell types/tissue. Reported intracellular H2O2 concentrations 
varies in the literature, ranging from 0.001 – 100 μM (295). Additionally, it is estimated that 
only 1- 15% of the H2O2 applied to the extracellular environment actually becomes biologically 
available in the cytosol, where glutathione peroxidase and catalase limit cytosolic H2O2 
concentration (295, 296). Thus, in vitro, the concentration range of H2O2 is even more varied, 
ranging from nanomolar to millimolar concentrations. Previous studies have found that 
intracellular H2O2 concentration affects the biological activity of ECs, where millimolar 
concentrations induce apoptosis, micromolar concentrations affects cell growth and nanomolar 
concentrations affect cell proliferation (295, 296). Thus it was difficult to ascertain a suitable or 
physiologically pertinent concentration to use in my EC studies. In this chapter H2O2 was used 
to mimic oxidative stress because little is known about how an elevated oxidative burden affects 
MP production in ECs. HECV cells exposed to H2O2 (10 mM) for 24 hr resulted in increased 
MP production, a trend also seen in HUVECs. Specifically this increase was attributed to MPs 
with a diameter range of 50 – 300 nm. H2O2 significantly reduced cell viability based upon 
trypan blue exclusion, but did not alter caspase 3/7 acitivity or cell viability as assessed via the 
MTS assay. This is in accordance with previous reports that noted H2O2 increased MP release in 
ECs in a dose dependent manner, using H2O2 concentrations: 0.05 – 0.8 mM (297). Koga et al, 
(280) demonstrated a similar trend in endothelial progenitor cells treated with H2O2 (0.5 – 1 
mM) for 24 hrs, where MP release was related to apoptosis. Jones and co-workers found that 
H2O2 induced apoptosis in a rat hepatocyte cell line RALA255-10G was associated with 
increased caspase activity (capase, 2, 3 and 7), where caspase inhibitors blocked H2O2-induced 
apoptosis (298). Thus, data in this chapter suggests that H2O2 enhancement of MP release maybe 
associated with cell death. 
 
Several studies have previously shown that H2O2 induces concentration-dependent intracellular 
Ca2+ oscillations in human ECs, which result from the transient leakage of Ca2+ from 
endoplasmic reticulum Ca2+ stores (299). Interestingly, at low concentrations (1 - 10 μM), Hu 
and coworkers found H2O2 did not affect intracellular Ca2+ concentration. However, at higher 
concentrations (1 - 10 mM) intracellular Ca2+ concentration was increased (299). Thus, I 
speculate that the H2O2 enhancement of MP production by high (10 mM) concentrations may be 
related to intracellular Ca2+ concentration.  
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Additionally, an elevated proportion of MPs derived from H2O2 treated cells were annexin V 
positive. This increased exposure of PS may render such MPs more susceptible for target cell 
interaction as previous reports have shown PS exposure on the surface of PMPs, renders them 
50 – 100 times more procoagulant than the surface of an activated platelet (180). However, this 
remains to be confirmed in further studies.  
 
5.5.2.3 Insulin 
As demonstrated in chapter 4, PCOS individuals with an elevated insulin response to a glucose 
challenge have elevated circulating MP levels. Insulin contributes to the metabolic and 
haemodynamic homeostasis of the vascular endothelium, however little is known about the 
direct effects of exogenous insulin on MP production.  
 
In this study, insulin did not affect MP production in HECV or HUVEC cells. MP size, 
concentration and distribution did not alter. Moreover, insulin had no effect on MP annexin V 
positivity or coagulability. There was a modest increase in cell viability (assessed via 
CellTiter96® AQueous one solution cell proliferation assay) following exposure to exogenous 
insulin. This is in accordance with previous studies that found insulin exerts anti-apoptotic 
effects in neuronal and endothelial cells via a mechanism that is believed to involve PKB 
activation (300). The insulin concentration was chosen to reflect normal physiological levels as 
well as hyperinsulinaemic levels observed in PCOS patients described in chapter 3 and 4 (0.5 
nM – 2.5 nM). Interestingly, Wang et al, (301) found the addition of insulin (50 nM) induces 
rapid actin cytoskeletal reorganisation in vascular ECs. This insulin-induced membrane 
cytoskeleton remodeling requires insulin signaling via the PI3K/PKB pathway. Although the 
exact mechanisms involved are unclear, cytoskeletal rearrangement is central to MP biogenesis. 
MP production was not assessed in this particular study, thus the direct effect of ‘supra-
physiological’ insulin concentrations on MP production remains untested. However, my study 
shows that physiological concentrations of insulin do not appear to alter MP production, 
characteristics or function. 
 
5.5.2.4 Glucose 
Uncontrolled blood glucose levels in patients with diabetes may contribute to EC dysfunction. 
In this study, HECV cells were exposed to different glucose concentrations (0 - 20 mM). 
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Glucose depletion resulted in the greatest increase in MP production compared to unstimulated 
controls. Specifically this increase was attributed to MPs with a diameter range of 50 – 150 nm, 
suggesting non-selective MP production via both the exosomal classic pathway as well as 
membrane vesicle shedding In vivo evidence suggests type 2 diabetics (236) and subjects with 
IR have an elevated circulating level of MPs.  
 
Wang and colleagues demonstrated that HUVECs exposed to low glucose conditions (0.2 - 0.4 
μM) resulted in decreased NO bioavailability (assessed by OBC) coupled with a concomitant 
increase in mitochondrial ∙O2- production (302). Moreover, intact human arterioles exposed to 
low glucose demonstrated marked endothelial dysfunction, a state linked to increased MP 
production (302). Paradoxically, high glucose conditions have been associated with increased 
intracellular Ca2+ levels and apoptosis. However, such effects often result from more chronic 
cell treatments, where HUVECs have been treated with 30 mM and 25 mM glucose for 90 and 
75 hrs, respectively (303, 304). In comparison, data presented here reflects 24 hr treatments. No 
difference in caspase activity was noted, however glucose depletion did improve cell viability 
when assessed by the CellTiter96® AQueous one solution cell proliferation assay. This was not 
reflected in trypan blue exclusion. Interestingly, proof of principle confocal images 
demonstrated that HECV derived MPs interact and appear to internalise as intact MPs inside 
target HECV cells. Hempel and co-workers noted that 20 mM glucose medium conditions 
increased EC membrane permeability compared to lower (10 mM) glucose conditions (305). 
Thus, although membrane permeability was not assessed in this study, future studies could 
explore whether glucose depletion directly increases MP production per se rather than altering 
the membrane permeability and altering MP uptake (306). 
 
In addition to enhancing MP production, a significant proportion of MPs produced in glucose 
naive conditions were VCAM-1 and annexin V positive and demonstrated an increased 
tendency to adhere to an electrode. Thus, hypoglycaemia may result in increased EMP 
production. Furthermore, these MPs appear to have increased PS and VCAM-1 exposure, are 
more coaguable and potentially more susceptible to cell interaction. 
 
5.5.2.5 Testosterone 
Previous studies have demonstrated that administration of testosterone increases plaque 
formation in monkeys (307). In vitro studies suggest that androgens may accelerate 
174 
 
atherosclerosis by stimulating the proliferation of VSMCs and increasing EC and monocyte 
VCAM- 1 expression (308). Previous studies have shown that circulating PMP levels are 
positively correlated with free androgen level in patients with PCOS (186), however little is 
known about the direct effect of testosterone on EC MP production. In this study, there was 
little evidence to suggest testosterone directly affected MP production in HECV or HUVEC 
cells. MP size, concentration and distribution did not alter. Testosterone had no effect on MP 
annexin V positivity or coagulability.  
 
5.5.2.6 Surface adhesion molecule profiles 
VCAM-1, ICAM-1, PECAM-1, P-selectin and E-selectin were detected on HECV cells and 
MPs. No difference was found in VCAM-1, ICAM-1, PECAM-1 or E-selectin expression on 
HECV cells treated with pathological stressors. A reduction in surface P-selectin expression 
(MFI) was noted in HECV cells following exposure to H2O2, hypoxia, testosterone and glucose 
depletion stressors but the mechanisms by which this occurs remains unclear. P-selectin is an 
adhesion molecule involved in the initial step of neutrophil recruitment. In contrast, previous 
studies have found that hypoxia (95% N2, 5% CO2) induces an increase in P-selectin expression 
in HUVEC (309). Additionally, other studies have shown that incubation of HUVECs with 25 
mM glucose induced the expression of P-selectin, an effect reversed by the addition of 1 nM 
insulin (310). Numerous studies have shown that such pathological stressors also induce 
VCAM-1 and ICAM-1 expression in ECs (309). Notably, these studies used primary EC 
sources, where the biological relevance may be more apparent.  
 
MPs harbour VCAM-1, ICAM-1, PECAM-1, P-selectin and E-selectin on their surface. Glucose 
depletion was linked to an increased proportion of VCAM-1 bearing MPs. This is in accordance 
with Joy and co-workers who found that hypoglycaemic conditions in patients with diabetes 
resulted in increased circulating VCAM-1 levels (311). Future studies can decipher if this 
increase in circulating VCAM-1 levels is attributed to any potential increase in VCAM-1 
bearing EMPs. The other pathological stressors did not alter MP surface adhesion molecule 
profiles. Interestingly, all MPs (even control MPs isolated from HECV cells grown according to 
manufacturer’s instructions) decreased P-selectin expression on HECV cells but the 
mechanisms by which this occurs remain unclear. Reduced vascular P-selectin expression has 
previously been observed in certain cancers and in patients undergoing immune-suppression. 
Although this is a novel finding with potential anti-thrombotic implications, further studies are 
needed for confirmation. These should include a primary cell model and explore whether MPs 
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interact with HECV cells via P-selectin, subsequently occupying the surface P-selectin antigen 
rendering it undetectable via flow cytometry.  
5.5.2.7 The effect of microparticles on platelet 
function 
Most of the literature focuses on MPs derived from platelets. Previous studies have shown that 
PMPs induce platelet activation and promote platelet aggregates via a glycoprotein IIb/IIIb 
dependent mechanism (312). However, the effects of EMPs on platelet aggregation remain 
untested. This study tested the hypothesis that EMP pre-conditioning would enhance platelet 
activation. There was little evidence to suggest that MPs altered whole blood platelet 
aggregometry or whole blood P-selectin expression.  
 
5.5.3 Limitations  
There are several potential limitations to this study. Firstly, HECV cells were used throughout 
this chapter. HECV is an established cell line. It is well recognised that although cell lines are 
convenient, their biology can become altered with time and may not truly reflect the primary 
cell. Furthermore, HECV cells were grown according to manufacturer’s instructions in medium 
containing 22.5 mM glucose. Admittedly this reflects a hyperglycaemic environment in vivo. 
However, HUVECs were grown in 5 mM glucose (manufacturer’s recommended medium). 
Notably, although similar trends were noted between both cell types, HUVECs produced fewer 
MPs per cell compared to HECV cells (~25 fold less). This may reflect cell culture medium 
conditions as well as possible differences in primary cells versus a cell line. On balance, future 
studies should build upon findings reported in this chapter with applications in primary ECs.  
 
MPs are isolated from culture medium by differential ultra-centrifugation. Although this step-
wise approach allows the removal of possible contaminants such as cells and cell debris, 
collecting MPs in the supernatant is based primarily on the assumption that MP production is 
increased/decreased rather than considering alterations in membrane permeability/MP uptake. 
Additionally, MPs were isolated from the cell culture medium, 24 hrs following exposure to the 
pathological stressors. It remains unclear if the increases in MP production are due to acute or 
chronic exposure. Thus, future studies should isolate MPs from culture medium at several time 
points to decipher the kinetics of MP release following stressor exposure.  
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Flow cytometry was used to determine annexin V positivity and to assess the surface adhesion 
molecule profiles of MPs and HECV cells. Typically, flow cytometry struggles to detect smaller 
MPs (<200 nm) and thus cannot observe the entire spectrum of MPs assessed using NTA. 
Previous studies have shown conflicting results regarding the extent of PS exposure on MPs. 
These studies often employ flow cytometry. Future studies should consider other methods of 
analysis, for example surface PS derivatisation and analysis via HPLC - mass spectroscopy, 
Western blot or ELISA for surface adhesion molecule profiling. 
 
Apoptosis is known to induce MP formation (157). In this study, HECV cells were subjected to 
trypan blue exclusion, a caspase 3/7 assay and a CellTiter96® AQueous one solution cell 
proliferation assay to comprehensively assess the effect of each pathological stressor on cell 
viability. Results were often conflicting, however each method measures different aspects of 
cell viability and is subject to its own limitations and strengths.  
 
In vivo the endothelium is not exposed to a single pathological stressor. Future work should 
explore how different in vitro conditions relevant to PCOS phenotypes might synergistically 
affect the endothelium.  
 
5.5.4 Conclusion 
A summary of the key findings are highlighted in table 6.4. In summary, this study 
demonstrates that H2O2, hypoxia and glucose depletion stressors enhance EC-derived MP 
release. HIF-1α induction plays an important role in the hypoxic enhancement of MP release, 
which was confirmed by manipulation of HIF-1α expression by siRNA interference. Although 
quantitative differences in MP release were not observed after exposure to every stressor 
assessed, several unique characteristics were observed. This would suggest that MP production 
and function reflects their environment/stimuli. Glucose deprived HECV cells produced PS 
exposing, procoagulant MPs. Although further studies are needed to determine the in vivo effect 
of these MPs, this would suggest that blood glucose regulation in patients with diabetes is 
important in perhaps limiting potentially damaging MP release. These MPs may be an appealing 
therapeutic target for future medicines but future work should confirm findings in vivo and 
explore the mechanism governing MP release.  
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Arrow direction indicates an increase (), decrease () or no change (−) in measurement. VCAM-1, vascular cell adhesion molecule-1; MFI, 
median fluorescence intensity. 
 
 
Table 6.4 Summary: microparticle characteristics and function in comparison to the appropriate control(s)  
 H2O2 (10 mM) Testosterone (1 μM) Glucose depleted Insulin (2.5 nM) Hypoxia (1% O2) 
MP production  −  −  
Size distribution  50-300 nm −  50-200 nm − − 
Caspase 3/7 activity − − −  − 
MTS assay −    − 
Trypan blue exclusion  − − − − 
MP annexin V positivity     − 
Multiplate (MP adhesion) − −  −  
HECV surface adhesion 
profile 
 P-selectin (MFI)  P-selectin (MFI)  P-selectin (MFI) −  P-selectin (MFI) 
MP surface adhesion 
profile 
− −  VCAM-1 (%) − − 
Effect of MPs on HECV 
surface adhesion profile 
 P-selectin (MFI)  P-selectin (MFI)  P-selectin (MFI)  P-selectin (MFI)  P-selectin (MFI) 
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5.6 Key findings 
 Twenty-four hour exposure to H2O2 (10 mM), glucose depletion or hypoxia (1% O2) 
enhanced MP production in ECs. 
 Each pathological stressor affected MPs uniquely, suggesting MPs reflect their stimuli. 
 MPs appear to internalise as intact vesicles in target cells. 
 Not all MPs are annexin V positive. 
 MPs possess an array of surface adhesion molecules.  
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6. RESULTS CHAPTER  
 
The effect of lipoprotein-apheresis on circulating microparticles 
in individuals with familial hypercholesterolaemia 
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6.1 Introduction 
Having previously shown that women with PCOS have an elevated concentration of circulating 
MPs, I chose to study an established CVD patient cohort, in which elevated MPs might be 
reduced by an extra-corporal intervention. Familial hypercholesterolaemia (FH) is a common 
genetic disorder that causes increased levels of atherogenic lipoproteins in the plasma, 
particularly LDL. Over 85% of FH cases are caused by mutations in the LDL receptor rendering 
these receptors unable to bind or internalise LDL, consequently leading to atherogenic 
lipoprotein accumulation in plasma (313). The disease follows an autosomal dominant pattern 
of inheritance and can result in heterozygote or homozygote forms (314). In severe forms of FH, 
diet alteration and lipid lowering medications are often insufficient to lower LDL levels enough 
to abate atherosclerotic plaque formation (315). Subsequently, these patients require frequent 
(bi-weekly) lipoprotein-apheresis (herein referred to as apheresis) treatments in combination 
with lifestyle modifications and pharmacological intervention to control LDL levels (316).  
 
Apheresis is a well-established procedure for the extracorporeal removal of LDL. Briefly, blood 
is removed from one arm and passed through a column to remove atherogenic lipoproteins 
before being returned to the body via the other arm. Different apheresis techniques may be 
utilised, but all reduce LDL by approximately 70% immediately following treatment (317-320). 
However, post-treatment these reduced lipoprotein levels are not maintained with levels rising 
to 50% of pre-treatment values within 2-4 days (321). Despite this transiency, apheresis is 
associated with superior long-term cardiovascular benefits compared with alternative therapies 
(322-324). Apart from the physical removal of LDL, other cardio-protective mechanisms 
associated with apheresis remain unclear.  
 
In addition to PCOS, increased numbers of MPs, particularly those derived from platelets, have 
been reported in many CVD entities (325, 326) though their function in both health and disease 
remains poorly understood. Previous studies have found that heterozygous FH patients have 
increased circulating levels of endothelial- and leukocyte-derived MPs compared to non-FH 
hypercholesterolaemia subjects (327). However, in this study MPs were quantified by flow 
cytometry. Cytometric analysis often struggles to detect MPs <200 nm. Little is known about 
the effects of apheresis on circulating MPs in individuals with FH, though other extracorporeal 
methods have been previously shown to remove MPs (328, 329).  
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6.2 Aims 
The aim of this chapter was to characterise size, distribution, concentration, cellular origin, fatty 
acids and thrombin generation of MPs in FH patients undergoing apheresis, hypothesising that 
this treatment would reduce circulating MPs as well as LDL-cholesterol. 
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6.3 Methods 
6.3.1 Ethical approval  
The study was approved by Cardiff University (study sponsors), Cardiff & Vale University 
Health Board and the South East Wales research ethics committee. All subjects gave written 
informed consent before study commencement. Ethical approval was obtained by Prof Julian 
Halcox (Swansea University) as part of a study to assess vascular function in the setting of 
apheresis. 
 
6.3.2 Subjects and protocol 
Twelve patients with clinically significant dyslipidaemia undergoing fortnightly apheresis 
consented to take part in the study. For clinical reasons patients underwent treatment using three 
different techniques: polyacrylate whole blood adsorption (DALI®; n = 8), whole blood- (WB; 
n = 1), or plasma- (n = 3) dextran sulphate adsorption (DSA) as described previously (330). 
Patients attended the Lipid Unit at University Hospital Llandough, Cardiff for apheresis 
treatment as part of their normal clinical care. Patients fasted for at least 4 hours prior to 
attendance and took their prescribed medication for at least 1 hour prior to the study, excluding 
vasoactive medications from which patients were asked to refrain. Routine anthropometric 
measurements were carried out prior to apheresis treatment. After 15 minutes of rest, in a 
temperature controlled room vascular access was gained using 16 gauge 25 mm fistula needles 
into 2 anatomically distinct upper limb veins or by arterio-venous fistula. Blood samples were 
then drawn sequentially prior to and immediately after completion of apheresis, approximately 3 
hours later. Seven healthy volunteers (no overt CVD or medication) were also recruited to 
compare baseline MP concentration, size distribution, cellular origin and fatty acid profiles with 
FH patients.  
 
6.3.3 Biochemical Measurements 
Blood samples were collected into EDTA and citrate vacutainers. Biochemical measurements 
were carried out by the Department of Medical Biochemistry - University Hospital Llandough, 
as described in section 2.4. BP measurements were taken using the Vicorder system (Skidmore 
Medical, UK). 
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6.3.4 Blood sampling, microparticle isolation and 
storage 
Blood sampling is described in section 2.5. Plasma derived MPs were isolated by differential 
ultra-centrifugation as detailed in section 2.10, with modification. Briefly, blood was collected 
in citrate vacutainers and immediately centrifuged (1,509 x g, 10 mins, 4 °C) to obtain PPP. At 
the ISEV conference (2013) I learnt that citrate might prevent residual platelet activation during 
the pre-analytical protocol. Thus, unlike Chapter 3 where blood was collected in EDTA 
vacutainers, I choose to use citrate vacutainers in this chapter. Preliminary data from our 
research group has shown that MP cellular origin is not effected by the anticoagulant (EDTA or 
citrate) used for blood collection, however MPs derived from blood collected in citrate 
vacutainers appeared to have lower levels of MPs than blood collected using EDTA as an 
anticoagulant.  
Citrate PPP was ultracentrifuged (100,000 x g, 1 hour, 4 °C) and the MP pellet was resuspended 
in either PBS or in PBS containing 0.05% (v/v) Tween 20 (for MP size and concentration). The 
latter was then passed through a 1 µm filter (Supelco, Sigma Aldrich, UK) and frozen overnight 
at -80 °C in a Mr Frosty (Nalgene, Thermo Scientific, UK). This forces a slow freeze (1 
°C/minute). In pilot studies conducted in our research group, Connolly et al, (196) found that 
this freezing/storage protocol closely matched fresh MP samples (in regards to MP number and 
size).  
6.3.5 Microparticle size, distribution and concentration  
Two techniques were used to measure MP size and concentration: TRPS and NTA, as described 
in sections 2.12 and 2.11, respectively. Two nanopores (np100 and np200) were used for TRPS 
to detect the entire MP range (30-1000 nm). For NTA, 60-second videos were recorded in 
quintuplicate. Camera sensitivity and detection threshold were set to (14-16) and (5-6), 
respectively.  
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6.3.6 Microparticle cellular origin 
Antibody enabled flow cytometry was used to determine the cellular origin and extent of 
annexin V positivity of plasma derived MPs, as described in section 2.23.3. Results are 
expressed as a percentage of total events (MPs).  
 
6.3.7 Lipid extraction and fatty acid analysis 
MP and plasma lipid extraction details are described in section 2.13. GC-FID was used to 
generate detailed fatty acid profiles of plasma and plasma-derived MPs, as noted in section 2.13.  
 
6.3.8 Microparticle thrombin generation 
Calibrated automated thrombography was used to assess MP thrombin generation, as described 
in section 2.24. 
 
6.3.9 Statistical Analysis 
Data were analysed using GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, 
USA). D'Agostino's K-squared test was used to check data for normality. Results are expressed 
as mean ± SD unless indicated. A paired t-test (two-tailed) or a Wilcoxon matched pairs test 
was used for parametric and non-parametric data, respectively. A p value <0.05 was deemed 
statistically significant. 
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6.4 Results 
6.4.1 Subject characteristics and biochemical data 
Demographic and biochemical measurements are summarised in Table 6.1. Apheresis reduced 
TC, triglycerides, HDL, LDL hsCRP and systolic BP. No changes were observed in glucose 
levels or diastolic BP. 
 
Table 6.1 Demographic and biochemical data 
n 12 (9 male, 3 female) 
Age (years) 57.9 ± 10.3 
BMI kg / m2 30 ± 4 
 Pre-Apheresis Post-Apheresis p value 
TC (mmol/L) 6.1 ± 0.5 2.7 ± 0.2 <0.0001 
HDL (mmol/L) 1.1 (0.4-2.3) 0.9 (0.2-2.1) 0.003 
Triglycerides (mmol/L) 1.8 ± 0.2 0.9 ± 0.1 <0.0001 
LDL (mmol/L) 4.1 ± 0.4 1.4 ± 0.2 <0.0001 
Glucose (mmol/L) 5.7 ± 0.3 6.1 ± 0.3 0.07 
hsCRP (mg/L) 0.8 (0.2-16.9) 0.6 (0.2-13.8) 0.003 
Systolic BP (mmHg) 140 ± 5 148 ± 6 0.02 
Diastolic BP (mmHg) 81.8 ± 2.8 82.8 ± 2.7 0.45 
BP: blood pressure. hsCRP: high sensitivity C-reactive protein. TC: total cholesterol. HDL: high 
density lipoprotein. LDL: low density lipoprotein.  Results reflect mean ± SD or median 
(range).  
 
Additionally, FH patient baseline measurements were compared to non-FH healthy volunteer 
basal measurements (Healthy volunteers: n = 7, 34 ± 8 years and 25 ± 3 kg / m2) (33).  
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6.4.2 Microparticle size and concentration: Pre - versus 
post – apheresis 
Two techniques, TRPS (np100 and np200) and NTA were used to analyse MP size, distribution 
and concentration. TRPS (np100) measured no difference in concentration pre- to post-apheresis 
(4.6 x 1011 ± 1.3 x 1011 to 3.1 x 1011 ± 1.0 x 1011: p =0.18; figure 6.1 A). However, TRPS 
(np200) and NTA both measured a decrease in MPs pre- vs. post-apheresis (4.7 x 1010 ± 8.8 x 
109 to 3.1 x 1010 ± 5.6 x 109, and 1.9 x 1012 ± 2.4 x 1011 to 1.5 x 1012 ± 2.4 x 1011 MPs/ml: p 
=0.013 and p = 0.025; for TRPS (np200) and NTA, respectively, figure 6.1 C and E).  
 
On assessment of MP distribution, TRPS (np100) and NTA showed no preferential reduction 
according to MP size (figure 6.1 B, F) whereas TRPS (np200) demonstrates a reduction in MPs 
between 200-249 nm (figure 6.1 D, p = 0.01). Plasma derived MP levels in FH patients showed 
a trend (non-significant) towards an increase in total concentration compared to healthy 
volunteers however, the size distribution showed subjects with FH had increased concentrations 
of MPs between 50-100 nm (p <0.05, figure 6.2).  
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Figure 6.1. Microparticle concentration and size distributions pre- and post-apheresis. MP 
size and concentration was measured in pre- and post-apheresis samples using TRPS (np100 
and np200) and NTA. Mean concentration of MPs pre- and post-apheresis is shown for TRPS 
np100 (A), np200 (C) and NTA (E). Size/concentration distribution of MPs pre- and post-
apheresis is shown for TRPS np100 (B), TRPS np200 (D) and NTA (F). Concentrations are 
given in particles/mL of plasma. [n = 12, paired-samples, pre versus post apheresis]. Each 
sample was analysed in quintuplicate and the mean was used in further analysis. Data is 
expressed as the group mean ± SEM. * represents p <0.05.  
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Figure 6.2. Comparison of the total microparticle concentration: Healthy volunteer versus 
FH patients. (A) Plasma derived MP concentrations – baseline measurements (B) 
Size/concentration distribution of plasma derived-MPs. NTA was used for comparison 
measurements. . [FH patients (n = 12), healthy volunteers (n = 7)]. Each sample was analysed in 
quintuplicate and the mean was used in further analysis. Data is expressed as the group mean ± 
SEM * represents p <0.05.  
 
Total cholesterol was measured in the MP fraction and was below the detectability of the assay 
(<0.01 mM). Size/concentration distributions of MPs are shown pre- to post-apheresis for each 
technique. In addition to assessing the effect of apheresis on MP populations, I also compared 
each technique pre- and post-apheresis (figure 6.3). The size distribution of MPs was similar for 
TRPS (np100 and np200) and NTA though the measured concentration varied greatly between 
the two techniques. MP size did not change following apheresis by any technique (81.1 ± 19.6 
to 78.4 ± 16.7, p = 0.3 for TRPS (np100), 170.3 ± 40.6 to 163.6 ± 29.2, p =0.18 for TRPS 
(np200) and 93.3 ± 21 to 88.2 ± 14.7 nm, p = 0.32 for NTA). 
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Figure 6.3. Range of microparticle sizes detected by each technique. A comparison of the 
spectrum of MPs measured by TRPS (np100 and np200) and NTA pre- (A) and post-apheresis 
(B). 50 nm bin sizes. Results reflect MPs per ml of plasma. [n = 12, paired-samples, pre versus 
post apheresis]. Each sample was analysed in quintuplicate for NTA measurements and the 
mean was used in further analysis. Data is expressed as the group mean ± SEM.  
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6.4.3 The effect of apheresis on microparticle cellular 
origin 
MP cellular origin was determined by antibody enabled flow cytometry using CD41, CD144, 
CD235a and CD11b. No change in the proportion of annexin V positive MPs was found 
following apheresis (89 ± 12 % vs. 88 ± 17 %, respectively; p = 0.7, figure 6.4 A). Of these 
annexin V positive MPs, there were also no changes in the proportions derived from platelets, 
ECs, monocytes or erythrocytes (figure 6.4 B). MPs positive for both annexin V and CD41 
accounted for the majority (~ 90%) of MPs measured, whilst erythrocyte, EC and monocyte 
derived MPs were infrequent. A similar trend was found for MPs in healthy volunteers. 
However, there was an increase in the proportion of EMPs in individuals with FH compared to 
healthy volunteers (p = 0.03, figure 6.5).  
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Figure 6.4. Microparticle origin. MPs from pre and post-apheresis samples were analyzed by 
flow cytometry to determine cellular origin. Forward and side scatter areas (FSC-A and SSC-A 
respectively) of platelets from fresh plasma were used to determine a sub-micron gate where 
only annexin V positive MPs were analysed. Samples were stained with annexin V (A), CD41, 
CD144, CD235a and CD11b to identify the proportion derived from platelets, endothelial cells, 
erythrocytes and monocytes respectively (B). [n = 12, paired-samples, pre versus post 
apheresis]. Data are presented as mean ± SEM. 
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Figure 6.5. Microparticle: Healthy volunteers versus FH patients. Comparison of the MP 
annexin V positivity (A) and cellular origin (B) of MPs from healthy volunteers compared to 
individuals with FH. [FH patients (n = 12), healthy volunteers (n = 7)]. Data are presented as 
mean ± SEM. * Represents p <0.05. 
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6.4.4 Fatty acid analysis: pre - versus post - apheresis 
Little is known about the lipid concentration of MPs, thus an aim of this chapter was to 
determine the fatty acid concentration and profile of MPs compared with that of the 
corresponding plasma and to observe the effect of apheresis. Total plasma fatty acid 
concentration decreased following apheresis (472 ± 262 to 268 ± 161 mg/200 µl plasma; p = 
0.01) though this was not mirrored in the MP fraction (figure 6.6). Five individual fatty acids 
were altered in the plasma following apheresis (p <0.05): C14:0 (myristic acid); C18:0 (steric 
acid); C18:1n7 (cis-vaccenic acid); C20:5n3 (eicosapentaenoic acid) and C22:3n3 
(docosatrienoic acid), the former three also being altered in the MP fraction (p <0.05, figure 
6.6). Interestingly, comparison of plasma and MP compartments revealed that 10 fatty acids 
differed in composition (p <0.05). This was true in pre- and post-apheresis samples however the 
ten fatty acids were not the same (table 6.2).  
 
Comparing FH subjects to healthy volunteers, both plasma and MP fatty acid levels were 
elevated in FH patients (p = 0.02 and p = 0.01, figure 6.7 A and C). Eight fatty acids were 
different in plasma and nine were different in MPs comparing healthy volunteers and 
individuals with FH (p <0.05, figure 6.7. B and D); apheresis had a similar effect on fatty acids 
in both compartments.  
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Figure 6.6. Fatty acid profiling. Total fatty acid concentration of plasma and MPs (A and C, respectively) followed by fatty acid profiling to determine 
compositional changes pre- to post-apheresis (B and D, respectively). [n = 12, paired-samples, pre versus post apheresis]. Data are presented as mean ± 
SEM. * and ** represents p < 0.05 and p < 0.01, respectively.  
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Table 6.2  Fatty acid composition: Pre versus post apheresis 
 Pre - Apheresis Post - Apheresis 
Fatty acid Plasma (%) MP (%) p value Plasma (%) MP (%) p value 
C14:0 0.6 ± 0.1 1.09  ± 0.1 0.04* 0.9 ± 0.1 0.6 ± 0.07 0.008 
C14:1 0.04 ± 0.01 0.1 ± 0.02 0.006* 0.06 ± 0.1 0.1 ± 0.08 0.4 
C16:0 15.7 ± 3.2 27.3 ± 3.2 0.07 10.5 ± 3.9 25.1 ± 1.2 0.002 
C16:1n7 2.5 ± 0.6 3.4 ± 0.4 0.4 2.0 ± 0.8 4.6 ± 0.7 0.02 
C18:0 5.0 ± 0.8 8.2 ± 0.9 0.07 3.1 ± 1.3 10.6 ± 0.6 <0.001 
C18:1n9 15.0 ± 4.2 6.2 ± 3.3 0.04* 10.1 ± 6.0 17.7 ± 5.4 0.4 
C18:1n7 11.3 ± 4.2 32.5 ± 3.4 0.003* 31.8 ± 7.0 17.4 ± 5.4 0.1 
C18:2n6 22.2 ± 5.8 13.3 ± 1.7 0.03* 14.0 ± 3.6 15.3 ± 1.2 0.7 
C20:1 0.4 ± 0.1 0.3 ± 0.03 0.6 0.4 ± 0.06 0.4 ± 0.07 0.3 
C20:2n6 1.7 ± 1.0 0.6 ± 0.09 0.2 1.5 ± 0.1 0.8 ± 0.09 <0.001 
C20:5n3 0.9 ± 0.2 0.7 ± 0.15 0.03* 2.2 ± 0.4 0.9 ± 0.15 0.002 
C22:0 0.3 ± 0.05 0.14 ± 0.06 0.02* 0.5 ± 0.07 0.14 ± 0.04 0.001 
C22:3n3 0.1 ± 0.03 0.15 ± 0.09 0.7 0.2 ± 0.04 0.02 ± 0.01 <0.001 
C22:3n6 0.4 ± 0.1 0.2 ± 0.1 0.09 0.9 ± 0.4 0.03 ± 0.03 0.004 
C22:5n3 0.2 ± 0.06 0.07 ± 0.04 0.04* 0.2 ± 0.1 0.3 ± 0.3 0.8 
C22:6n3 1.2 ± 0.2 1.1 ± 0.2 0.09 2.4 ± 0.6 1.2 ± 0.2 0.09 
C24:0 0.07 ± 0.03 0.002  0.009* 0.2 ± 0.05 0.02 ± 0.02 0.003 
C24:1n9 0.9 ± 0.2 0.2 ± 0.1 0.006* 1.6 ± 0.7 0.04 ± 0.02 0.08 
MP, microparticle. Data are presented as mean ± SEM, (n = 12, paired-samples).
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Figure 6.7: Plasma and microparticle fatty acid profiles: healthy volunteers versus FH patients (baseline measurements). Total fatty acid 
concentration of MPs (A) and plasma (C) was compared between healthy volunteers and individuals with FH. Individual fatty acid profiles of MPs (B) 
and plasma (D) were also compared between groups. [FH patients (n = 12), healthy volunteers (n = 7)]. Data are presented as mean ± SEM. *p <0.05, 
**p <0.01, ***p <0.001, ****p <0.0001.
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6.4.5 Microparticle thrombin generation 
Thrombin generation of MPs was compared pre- to post-apheresis and was also correlated with 
total MP concentrations. No change was observed in MP peak thrombin generation pre- to post-
apheresis (14.8 ± 2.9 to 16.6 ± 4.1 nM, p = 0.6, figure 6.8). However, MP thrombin generation 
over time (AUC) was positively correlated with MP concentration measured by TRPS (np100) 
and NTA (r = 0.626, p = 0.001 and r = 0.424, p = 0.04 respectively). Thrombin AUC showed no 
correlation with MP concentration measured by TRPS (np200). Furthermore, when TF was 
added to MPs (to exogenously initiate maximum thrombin generation), thrombin AUC no 
longer correlated with MP concentration. 
 
Figure 6.8. MP Thrombin generation: FH patients (pre versus post apheresis). (A) MP 
thrombin generation. (B) MP thrombin generation in the presence of exogenous tissue factor. 
Data are presented as mean ± SEM, (n = 12, paired-samples, pre versus post apheresis). (C) 
Typical calibrated automated thromborgam.  
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6.5 Discussion 
6.5.1 Main findings 
This study details the novel effects of apheresis on MP size, concentration, origin, fatty acid 
concentration and thrombin generation in FH patients. This study demonstrates that apheresis 
reduces circulating MP concentration, the majority of which were annexin V positive and 
derived from platelets. 
 
6.5.2 Interpretation 
There are numerous methods used to detect MPs, each exhibiting its own 
advantages/limitations. Often the technique employed is dictated by the specific research 
question. In this chapter, two well-established methods were used for MP measurement in order 
to capture the full spectrum of MP sizes. Moreover, TRPS and NTA have not previously been 
subjected to a direct comparison in biological samples. The data suggests the range of 
detectability of TRPS (np100 and np200) and NTA are similar, although they differ in reported 
MP concentration.  
 
Both TRPS (np200) and NTA methods showed a decrease in MP concentration pre- versus 
post-apheresis. MPs within the range of 200-250 nm were reduced the most pre- versus post-
apheresis which is much greater than the size of LDL particles (331), providing further evidence 
that the techniques are measuring a reduction in MPs and are not detecting LDL-cholesterol. 
Moreover, MPs were also shown to be elevated in the exosomal range in individuals with FH 
compared to healthy volunteers. This may suggest selective stimulation of the intracellular 
classical exosomal pathway compared to larger MPs formed via cell membrane shedding. Total 
MP concentration also appeared elevated in FH subjects compared to healthy volunteers, though 
overall this did not reach significance. Cytometric measurement of MPs revealed no changes in 
annexin V positivity or cellular origin following apheresis. In keeping with previous data (327, 
332, 333) (and results found in PCOS patients/healthy volunteers detailed in chapter 4) PMPs 
occupied the majority of the MP population (88.9 ± 13%). Taken together with the fall in MP 
concentration this would suggest that apheresis non-selectively removes MPs, the majority of 
which are annexin V positive and derived from platelets. These MPs have not only been shown 
to be elevated in a variety of disease states (209, 237, 334-337) but also to promote coagulation 
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(180), atherosclerotic plaque formation (209) and to be associated with atherothrombotic events 
(336). Non-selective removal of these MPs by apheresis may reduce the risk of thrombus 
formation by slowing the progression of atherosclerotic lesions thereby complementing the 
effect of LDL removal. MPs in healthy volunteers were also found to be mainly annexin V 
positive and of platelet origin. It would appear that individuals with FH have a greater number 
of these circulating annexin V/platelet derived MPs. Interestingly, FH patients had a greater 
proportion of EMPs, perhaps suggesting a greater level of endothelial activation compared to 
healthy volunteers, although the percentage of the total was still low (<2%). This trend is in 
accordance with a recent meta-analysis that demonstrated that FH patients display an increased 
carotid IMT and reduced FMD compared to their non-FH counterparts, and may be indicative of 
endothelial dysfunction in these FH patients. However, the cause of this elevation in EMPs 
remains unclear.  
 
The atheroprotective mechanisms of monousaturated fatty acid (MUFA) and PUFAs are well-
documented (338), as are the data implicating saturated fatty acids in arterial wall lipid 
accumulation and atherosclerotic plaque formation (339). MPs have been shown to carry a 
specific cargo of proteins, genetic material and small molecules, including fatty acids (340) that 
can initiate a pro-inflammatory response in target cells (282). Total fatty acid concentration of 
plasma was decreased following apheresis, however MP fatty acid levels did not change 
following apheresis. Thus, although the overall number of MPs decreases post-apheresis, the 
fatty acid concentration per MP remains the same. Interestingly, apheresis seemed to affect 
individual fatty acids differently in plasma compared with the MP fraction; however the 
physiological relevance of this remains to be elucidated. Furthermore, when plasma was directly 
compared with the MP fraction, the proportion of fatty acids were found to be different between 
compartments. This suggests that the fatty acid composition of MPs is independent to that of 
surrounding plasma, a concept in keeping with the findings in chapter 4 in PCOS patients. 
Several fatty acids were different in individuals with FH compared to healthy volunteers in both 
plasma and MPs, however the affected fatty acids and the trends (i.e. increase or decrease) were 
the same. Similarly to the findings in FH, in healthy volunteers the fatty acid composition of 
MPs did not reflect that of plasma.  
 
Although no change was observed in MP peak thrombin generation pre- versus post-apheresis, 
total MP concentration measured by either TRPS (np100) or NTA was positively correlated 
with thrombin AUC. MP concentration measured by TRPS (np200) showed no correlation. 
Taken together, this suggests that a reduction in MPs is associated with decreased thrombin 
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generation capacity and that smaller MPs, particularly exosomes, are associated with an 
increased total thrombin generation over time. This is on the basis that both TRPS (np100) and 
NTA have an increased sensitivity for MPs in the exosomal range compared to TRPS (np200). 
Additionally, FH patients were shown to have an increased circulating population of smaller 
MPs compared with healthy individuals. Both TRPS (np100) and NTA showed a trend towards 
reduction in exosomal populations of MPs following apheresis, though this did not reach 
significance. This could suggest that the increased circulating population of exosomes in 
individuals with FH makes their MP fraction more procoagulant. Apheresis treatment non-
selectively removes MPs and could potentially reduce the procoagulant potential of exosomes 
and smaller MPs. Also, in accordance with previous studies, these findings confirm MPs have 
endogenous TF activity and can stimulate thrombin generation (341, 342). When exogenous TF 
was added to MPs to stimulate thrombin generation, the correlation between MP concentration 
and AUC was lost reflecting maximum thrombin generation. 
 
6.5.3 Limitations 
There are a number of potential limitations to this study. Patients in this study received 
apheresis based on individual clinical requirements resulting in the use of three different types 
of apheresis treatment. Though there was no observable difference between apheresis technique 
and MP concentration, the current study was not designed to assess this. In vitro studies have 
shown that the surface morphology of the adsorbent polymer may affect MP production (342), 
though this requires conﬁrmation in vivo. FH patients were studied as part of their routine 
clinical outpatient treatment. Clearly, having now established that apheresis directly influences 
MP concentration, longitudinal studies and comparisons of apheresis techniques will help to 
establish whether the reduction in atherogenic MPs is maintained whilst further exploring the 
physiological relevance this reduction in MPs has in regards to CVD pathology.  
 
It is acknowledged that many flow cytometers have a practical lower limit of around 200 nm. 
Therefore smaller MPs (particularly exosomes) are below the detectability of conventional flow 
cytometers. Thus the fluorescence data obtained from a given sample does not completely 
reflect the full range of MP sizes observed by NTA and TRPS. Despite this, antibody enabled 
flow cytometry is arguably the most reliable technique to assess surface antigen expression of 
MPs. Importantly, NTA and TRPS confirm MPs within the range of 200-250 nm were reduced 
the most pre- versus post-apheresis and are likely reflected by the flow cytometric results. The 
use of annexin V positivity to identify MP populations is used widely (332, 343, 344) but has 
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recently been questioned (176). As the majority (~90%) of MPs here were annexin V positive, I 
chose to accept this as the MP population for subsequent staining. This rationale was based on 
the fact that despite not all MPs binding to annexin V, only annexin V positive MPs have been 
shown to possess procoagulant activity (176). 
 
The thrombin generation of patient MP samples was measured in the presence of pooled, 
healthy plasma (PPP) to specifically test the activity of MPs as opposed to whole patient plasma 
(that would likely reflect the total influence of apheresis). Future studies should firstly 
normalise MP thrombin generation to MP number. Secondly, studies should assess the 
procoagulant activity of plasma pre- to post-apheresis to confirm the reduction in MPs is 
associated with a decrease in plasma thrombin generation. 
 
6.5.4 Conclusion 
In summary, apheresis reduces the concentration of circulating MPs in patients with FH, the 
majority of which are annexin V / platelet (CD41) positive. Though MP concentration is 
reduced, apheresis has no effect on the total fatty acid concentration of MPs. Fatty acid 
composition of MPs is unique and does not reflect that of surrounding plasma. MP 
concentration (particularly in the exosomal range) was found to positively correlate with total 
thrombin generation, suggesting that a reduction in MP concentration via apheresis in FH may 
reduce MP-initiated thrombin production. The removal of MPs that are predominantly annexin 
V positive and platelet-derived is a novel finding, supporting the notion that apheresis may have 
beneficial cardiovascular effects beyond lipoprotein removal. Future work should investigate 
whether the reduced MP levels are maintained between apheresis treatments and should aim to 
establish whether MP reduction during apheresis is associated with the longer-term benefits of 
this treatment. 
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6.6 Key findings 
 Apheresis decreases circulating MP levels, the majority of which are annexin V / platelet 
(CD41) positive. 
 Apheresis decreases plasma fatty acid concentration. 
 Plasma and MP fatty acid composition is altered by apheresis. 
 Thrombin generation of MPs correlated with total MP concentrations, suggesting that 
greater numbers of circulating MPs are associated with increased prothrombotic activity 
in FH patients.  
 Apheresis may have beneficial cardiovascular effects beyond lipoprotein removal. 
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7. GENERAL DISCUSSION 
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7.1 Overview and conclusions 
The main aim of this thesis was to provide a clearer understanding of mechanisms that may 
predispose patients to CVD. The initial focus was two-fold; to establish the role of nitro-
oxidative stress early in the disease process and to investigate the occurrence and function of 
circulating MPs in mediating endothelial dysfunction. Women with PCOS were used as a model 
of predisposition to CVD. These patients were compared to healthy controls in an observational 
study, which involved a comprehensive assessment of indices of nitro-oxidative stress and a 
detailed characterisation of circulating MPs. The effect of pathological stressors (akin to those 
found in PCOS), on EC-MP production were assessed in an in vitro model using cultured ECs. 
In order to ascertain whether circulating MP levels could be modulated in a clinical cohort the 
effect of apheresis on circulating MP levels was investigated in patients with established CVD. 
 
Patients with PCOS appear prone to developing numerous cardiovascular health problems 
including obesity (77), hypertension (78), IR (263) and dyslipidaemia (89), which may 
contribute to an increased prevalence of cardiac events in later life (152). Whilst efforts have 
been made to find candidate genes that might influence PCOS expression, the syndrome has an 
unknown aetiology and the mechanisms that govern cardiovascular risk remain unclear.  
 
Uncertainty remains as to whether patients with PCOS are prone to endothelial dysfunction, a 
state associated with nitro-oxidative stress. Previous studies show conflicting results, often 
analysing aspects of this complex biochemistry in isolation (138, 139, 142, 266-269). In contrast 
to my original hypothesis, whereby PCOS patients were predicted to display an elevated 
oxidative burden, a comprehensive biochemical analysis found that there is little evidence to 
suggest that PCOS patients have increased oxidative stress. However, the PCOS patients 
recruited in this thesis were young, carefully matched for age and BMI controls, and were 
diagnosed using the Rotterdam criteria which is associated with a less severe metabolic 
phenotype than other diagnostic criteria (276). The low mean age (29 yrs) is in keeping with 
data from the British Heart Foundation who found that only 798 out of 179,078 CVD associated 
deaths (in the UK in 2013) were in the <35 yr age range (7). Therefore, it is unlikely that this 
mild PCOS phenotype would have established cardiovascular disorders but perhaps may exhibit 
early indices of endothelial dysfunction, a prerequisite to CVD. An additional study from our 
group, using a similar patient cohort found that there was no difference in arterial stiffness 
(assessed by PWV), carotid IMT or myocardial function between PCOS patients and healthy 
controls (96). Nevertheless there is a general view in the literature that women with PCOS are 
prone to developing CVD. 
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Even though there is little biochemical evidence for nitro-oxidative stress in this young PCOS 
cohort, data presented in chapter 4 showed that women with PCOS exhibit elevated levels of 
annexin V positive MPs that were predominantly derived from platelets. The clinical 
significance of this elevated MP population remains unknown. Although MP biogenesis 
represents a physiological phenomenon, multiple pathologies are associated with an increase in 
circulating MPs (157), including inflammatory diseases (210), atherosclerosis (244) and certain 
cancers (226). Interestingly, previous reports have shown that the presence of annexin V 
positive MPs independently predicts cardiovascular events in stable CAD patients (345).  
Young women with PCOS did not display any indices of nitro-oxidative stress, but did present 
with an elevated concentration of circulating MPs. Previous studies have found increased 
markers of nitro-oxidative stress in subjects with established, chronic CVD compared to a 
healthy population. In contrast, the PCOS patients investigated in this thesis were young and 
had no overt CVD. Thus, on reflection it is fair to speculate that these patients would not present 
with vast differences in nitro-oxidative measures, but perhaps may exhibit subtle changes which 
may have not yet be physiologically manifested. To maximise my chance of observing any 
differences in oxidative burden, I undertook a comprehensive set of ‘gold-standard’ biochemical 
measurements (described in chapter 3) to capture lipid-derived radicals in circulation, as well as 
differentiate between plasma NOx.  
 
There are several explanations that may explain why no differences were found in nitro-
oxidative stress indices between PCOS and healthy controls. Firstly, PCOS patients do not 
exhibit nitro-oxidative stress. Secondly, PCOS patients may indeed harbour subtle differences in 
localised nitro-oxidative stress indices, however these are not yet detectable systemically using 
current methods. With an incomplete outer electron shell, ROS including NO are exceptionally 
potent and difficult to detect. Data presented in chapter 5 demonstrates that MP production by 
ECs can be enhanced by metabolic and oxidative stressors, however until current techniques are 
able to accurately detect subtle differences in ROS, it will remain difficult to confirm the role of 
nitro-oxidative stress in MP production in vivo, specifically in disease states where individuals 
may be at a predisposition to CVD and only exhibit subtle redox alterations.  
 
In an exploratory sub-population, novel data presented in chapter 4 found that circulating MPs 
in PCOS patients harbour differentially-expressed miRs. No other study to date has investigated 
the miR content of circulating MPs in PCOS patients. Notably, differentially expressed miRs 
targeted genes that affect insulin sensitivity, androgen and cortisol levels. This finding may be 
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of significant interest to the PCOS community and suggests a novel mechanism by which the 
syndrome may affect cardiometabolic risk and provides an exciting future research theme. If 
these findings are confirmed in a larger PCOS cohort, an elevated annexin V positive MP 
population which harbours differentially expressed (PCOS-specific) miRs could have 
implications for use as biomarkers, in diagnosis and therapeutics. Previous reports have shown 
that MPs can induce ROS formation in ECs and decrease NO production, however, there 
appears to be no association between the nitro-oxidative stress parameters presented in chapter 3 
and MP levels or characteristics presented in chapter 4 in this PCOS cohort.  
 
Some pathological conditions are associated with an increase in circulating MPs; novel data 
presented in chapter 6 provides evidence that reducing circulating MP levels may have potential 
cardio-protective effects. Apheresis decreased circulating levels of MPs and was associated with 
a decreased thrombin generation capacity in patients with established CVD. In addition to 
reducing lipoprotein levels, the non-selective removal of circulating MPs could be another 
beneficial outcome of apheresis. Potentially, similar procedures could be applied to other 
disease states where circulating MPs play a pivotal role in disease pathology. Current 
commercial ventures are investigating the efficacy of the extra-corporeal removal of MPs in 
HIV patients. In order to confirm this, further studies should (i) assess the effect of apheresis on 
MP levels over time and assess if this is associated with acute or long-term cardiovascular 
benefits (ii) determine a means of removing MPs without altering lipoprotein profiles in non-FH 
subjects. Furthermore, the effects of apheresis on circulating MPs in FH patients was 
undertaken as part of a larger clinical study to measure the influence of apheresis on vascular 
flow indices (undertaken by Ms Libby Ellins) and biochemical markers of endothelial function 
(our group). Interestingly, baseline (pre-apheresis) MP concentration was significantly 
associated with CRP levels (p = 0.02), which suggests that this enhancement in circulating MPs 
may in part be related to inflammatory status. However it remains unclear if inflammation is a 
cause or consequence of this elevated MP population. No correlation was found between MP 
concentration and measures of endothelial function.  
 
In PCOS patients, circulating MP concentration was associated with HOMA-IR values, 
suggesting that the increase in MPs may in part be driven by IR. However, I did not find 
evidence of an effect of hyperglycaemia and supra-physiological insulin levels on MP formation 
when tested directly on HECV cells in vitro. Several pathological stressors akin to those found 
in PCOS were used in the in vitro model in an attempt to investigate the possible causes of an 
increased MP formation. HECV cells were exposed to oxidative, hypoxic, hyperandrogenic and 
metabolic stressors. Each pathological stressor affected MP generation uniquely. In accordance 
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with previous studies which have shown that MP protein and mRNA content reflects cellular 
stress conditions, MP characteristics might reflect their particular stimulus. 
 
Cells grown in compliance with the manufacturers recommendations represent cellular 
homeostasis in vitro. However, HECV cells exposed to a glucose-deprived condition resulted in 
an enhanced production of annexin V positive and VCAM-1 expressing MPs, which were more 
procoagulant in vitro. The precise mechanism involved in this enhancement in MP production 
remains unclear. Further studies should attempt to replicate findings in vivo (hypoglycaemia vs. 
normoglycaemia MP production in animal models). Several studies have shown that 
hypoglycaemia is associated with an increased risk of cardiovascular events. In a study 
involving 29 patients with type 2 diabetes, Desouza et al, (346) found that of 54 hypoglycaemic 
episodes, 10 were associated with electrocardiographic evidence or symptoms of ischaemia. In 
contrast, only one episode of chest pain occurred during 59 episodes of hyperglycaemia. The 
data in this thesis suggest that transient hypoglycaemia induces the secretion of prothrombotic 
MPs which might propagate CVD development in patients with diabetes. Furthermore, data 
presented in chapter 5 are the first to show that the enhanced production of hypoxia-mediated 
MP release in ECs is related to HIF-1α. However, further studies are needed to confirm the 
biological effects of these MPs.  
 
Several consistent themes arise from the results of my thesis. Firstly, although the biological 
significance of MPs are increasingly recognised, their isolation and detection has proven 
difficult. For example, with respect to clinical samples, differing pre-analytical protocols not 
only complicate inter-study comparisons but may also co-isolate non-MP plasma fractions. 
Consequently, in chapters 4 and 6, where plasma-derived MPs were isolated, it is probable that 
non-MP plasma fractions were also detected and greater care may be needed in ensuring 
complete removal of contaminating platelets.  
 
The cellular origin of MPs was determined using a custom built BD Aria, whereas MP surface 
adhesion molecule expression was measured using a BD Canto. Different flow cytometers have 
different sensitivity and detection limits (347). For example, Chandler et al, (348) applied a 
gating strategy based upon polystyrene beads (Megamix beads, Biocytex, UK) for the detection 
of PMPs using a Apogee A40 flow cytometer and showed that the gate only detected platelets 
(with a diameter of 2 – 5 µM). In contrast, Mullier et al, (349) and Robert et al, (350) were able 
to distinguish between PMPs and platelets using a similar gating strategy based upon the 
Megamix polystyrene beads using different flow cytometers. The refractive index of 
carboxylated polystyrene beads is different to that of MPs. Refractive index can be described by 
Rayleigh approximation, Faunhofer diffraction or Mie theory. Using Mie calculations, Van der 
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Pol et al, (248) showed that even if 220 nm polystyrene beads are detectable by flow cytometry, 
the same gate equates to MPs with a diameter of 300-500 nm, due to different refractive index 
values. Because MPs have a lower refractive index than polystyrene beads, they scatter light 
approximately 10-fold less efficiently than polystyrene beads. Furthermore, MP detection by a 
regular flow cytometer is limited by swarm detection, whereby multiple MPs are simultaneously 
illuminated by the laser beam and counted as a single event (one MP). This would under-
estimate the FFC and SSC light detection and may account for different fluorescence signals 
corresponding to a single event, where the signal may originate from multiple MPs. Moreover, 
previous reports have shown that the concentration of MPs determined by flow cytometry is 
more than 1000-fold lower than the actual concentration (248). With different instrumentation 
used to determine MP cellular origin and MP surface adhesion molecules, it is likely that the 
flow cytometers would have had different detection parameters, although this was not assessed. 
In spite of these limitations, flow cytometry is often considered the present method of choice for 
MP detection, and is currently the only widely used method for establishing surface 
characteristics/MP parentage. Current on-going experiments in our laboratory are trialling 
enhanced ELISA based methods using time resolved fluorescence for the detection and 
quantification of MP surface makers. This may offer the advantage of high-throughput analysis 
coupled with enhanced sensitivity, especially for smaller MPs.  
 
There are numerous methods used to detect MPs, each exhibiting its own 
advantages/limitations. Often the technique employed is dictated by the specific research 
question. In chapter 6, two well-established methods were used for MP measurement (TRPS 
and NTA). Previous reports have compared different quantitative methods for MP 
measurements such as, TRPS, NTA, TEM, DLS and flow cytometry, however these studies all 
utilised polystyrene beads (which have a greater refractive index compared to biological MPs). 
To the best of my knowledge, the data presented in chapter 6 are the first to compare NTA and 
TRPS directly in the measurement of biological samples. The data suggest that the detection 
ranges of TRPS (np100 and np200) and NTA are similar, although they differ in reported MP 
concentration.  
 
7.2 Future directions 
MPs play an important role in both health and disease. Future research should build upon the 
data presented in this thesis and explore the role of MPs in CVD development. The prospect of 
using circulating MPs as biomarkers or therapeutic agents is an exciting challenge, with 
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potential implications across several disorders. However, standardisation of the pre-analytical 
procedures and overcoming methodological limitations requires addressing and delays the 
implementation of MPs being used as biomarkers in routine clinical practice. 
 
MPs derived from platelets occupied the greatest proportion of plasma-derived MPs. There is 
much variability in the literature regarding the cellular origin of MPs. Often, there are two 
requirements when isolating MPs from blood. Firstly, the venepuncture procedure technique 
itself should minimise platelet activation and secondly, blood must be collected into an anti-
coagulant that will not only prevent coagulation, but preserve the activation status of platelets 
until they have been analysed (or more specifically, until platelets have been removed by 
differential ultra-centrifugation). Interestingly, EDTA, citrate and hirudin anti-coagulants are 
not able to suppress total platelet activation and the extent to which pre-analytical activation 
occurs is markedly dependent on the anticoagulant used. Future efforts should harmonise 
current practices in pre-analytical isolation protocols. Recently, Koshiar et al, (351) used corn-
trypsin inhibitor coupled with tri-sodium citrate as an anti-coagulant medium prior to 
differential ultra-centrifugation. Corn-tripsin inhibitor – trisodium citrate - has been shown to 
inhibit platelet activation until analysis. Although only erythrocyte-derived MPs were assessed 
in their study, future studies should assess and compare such pre-analytical protocols. 
 
Although MP concentration was significantly associated with thrombin generation potential 
(shown in chapter 6), the clinical implications of an elevated annexin V positive MP population 
remain untested. In addition to a prospective follow-up study in these patients, future studies 
could determine the physiological effects of these MPs on isolated vessels (myography).  
 
Additionally, in vitro experiments were predominantly carried out using HECV cells. Future 
studies should use primary cells and compare the effect of pathologically relevant insults to 
established positive controls such as TNFα, which has been shown to induce expression of 
surface adhesion molecules in HUVECs.  
 
Future studies should also study the biological action of MPs on target cells/vessels. This thesis 
showed that MPs interact and appear to internalise as intact MPs. Although it is likely to be MP 
and cell specific, it remains unclear whether MPs fuse with target cells and offload their 
bioactive cargo or whether MPs mediate biological changes via surface/phospholipid 
interaction. Specifically, future studies should test if PS or specific surface adhesion molecules 
(e.g. P-selectin) mediate MP-target cell interactions. The pre-treatment of vessels with MPs 
would provide evidence for their effect on endothelial function as well as an insight into modes 
of action. 
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To a large extent the focus continues to be on the detrimental effects of MPs, whereas in reality 
MP generation may represent a novel homeostatic response or signalling mechanism. In this 
sense MPs do indeed represent a biomarker of stress conditions, but could also be used 
beneficially if their function and role were understood and manipulated in a protective capacity. 
Indeed, this is already the case where mesenchymal stromal cell-derived MPs stimulated under 
hypoxic conditions are currently being trialled for the treatment of pulmonary hypertension 
(personal communication – Professor Stella Kourembanas, Harvard University Medical 
School). 
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